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Avant propos
L'objectif de cette thèse est d'explorer l'inflammation et l'infection au niveau du 
transcriptome, à l'aide de la technologie des puces à ADN. 
Pour cela, nous avons dans un premier temps travaillé sur des données publiques. 
Nous avons construit une base de données de signatures transcriptionnelles annotées, 
et développé un logiciel modulaire d'analyse. Ce logiciel permet d'explorer aisément 
les données publiques en effectuant des recherches par nom de gène ou par mots-clés. 
Nous avons ensuite exploré la modulation temporelle de l'expression des gènes du 
parenchyme pulmonaire dans un modèle murin d'inflammation aiguë par injection 
d'acide oléique. Dans un second modèle murin d'infection par Coxiella burnetii, nous 
avons analysé le rôle du sexe dans la modulation de la réponse transcriptionnelle 
hépatique,  et  identifié  des  voies  métaboliques  impliquées  dans  le  contrôle  de 
l'infection. Dans un troisième modèle  in-vitro d'infection par différentes souches du 
virus de la grippe, nous avons identifié une signature transcriptionnelle commune de 
réponse à l'infection. Par une approche bio-informatique originale, cette signature a 
conduit à l'identification de nouveaux anti-viraux à large spectre, dont l'efficacité a 
été démontrée in-vitro sur les souches utilisées pour l'analyse, et sur la souche H1N1, 
responsable  de  la  dernière  pandémie  grippale.  Enfin,  nous  avons  analysé  les 
modulations  du  transcriptome  lors  de  pneumonies  associées  à  la  ventilation 
mécanique  compliquant  l'évolution  de  sujets  traumatisés  graves  admis  en 
réanimation.
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Introduction
Le sepsis est un syndrome clinique qui décrit une infection grave associée à un 
syndrome  inflammatoire  généralisé  (« SIRS »  pour  « Systemic  Inflammatory 
Response Syndrome » en anglais). Il est caractérisé par une agression aiguë de l'hôte 
par  des  médiateurs  dont  l'expression  est  induite  par  l'infection.  Son  incidence 
augmente avec  le  temps du fait  des progrès de la  médecine (vieillissement  de la 
population), mais la mortalité reste aux alentours de 35 %  [1]. D'un point de vue 
clinique, le patient a généralement des signes aspécifiques comme une fièvre ou une 
hypothermie,  une  tachypnée,  une  tachycardie  et  une  hyperleucocytose  ou  une 
leucopénie.  Le  SIRS  ainsi  défini  recouvre  des  situations  pathologiques  variées, 
souvent sans relation avec une infection. 
Le sepsis se complique souvent d'une ou plusieurs défaillances d'organe incluant 
une hypotension, une insuffisance cardiaque, un coma, une insuffisance rénale ou une 
coagulation intravasculaire disséminée. Il est alors désigné sous le terme de sepsis 
grave.  Lorsque  la  défaillance  cardio-vasculaire  prédomine  et  qu'il  existe  une 
hypotension qui ne répond pas au remplissage vasculaire, le terme de choc septique 
est employé. Il existe un continuum nosologique entre le SIRS, le sepsis, le sepsis 
grave et le choc septique (Figure 1). Les formes graves sont associées à une mortalité 
d’environ 50 % dans le choc septique [2]. 
D'un point de vue physiopathologique, le sepsis est un phénomène complexe, où 
l'infection  initiale  active  une  réponse  systémique  de  l'organisme,  responsable  des 
défaillances  d'organe  et  de  la  mortalité.  C'est  un  phénomène  dynamique  où  des 
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molécules du micro-organisme (endotoxine par exemple) entraînent la synthèse de 
diverses cytokines, chemokines, radicaux libres, etc … La réponse de l'organisme 
met  en  jeu  l'immunité  innée  et  adaptative  (figure  2),  en  étroite  relation  avec  les 
réponses de l'endothélium vasculaire et du système hormonal [3,4].
Pour comprendre cette physiopathologie complexe, un modèle constitué de deux 
phases  de  réponse  a  été  proposé.  Le  sepsis  consisterait  en  une  phase  pro-
inflammatoire  initiale  suivie  d'une  phase  de  réponse  compensatrice  anti-
inflammatoire [5] (figure 3). La recherche pharmaceutique s’est longtemps focalisée 
sur  la  seule  réponse  pro-inflammatoire  excessive.  Malheureusement,  en  dépit  de 
résultats  positifs  dans  des  modèles  animaux  [6-8],  les  essais  cliniques  n'ont  pas 
démontré l’efficacité de cette approche. Ce modèle a donc été progressivement remis 
en cause.
Pour comprendre la complexité de ce syndrome au lit du patient, des cliniciens 
ont cherché à déterminer des biomarqueurs spécifiques du sepsis. Les biomarqueurs 
évalués  sont  le  plus  souvent  des  molécules  de  la  réponse  pro-inflammatoire.  Le 
dosage  de  diverses  cytokines  chez  les  patients  septiques,  a  permis  de  mieux 
appréhender la physiopathologie du sepsis. Toutefois, ceci ne s'est pas concrétisé par 
des  progrès  significatifs  en  termes  de  prise  en  charge  des  patients.  De  plus,  de 
nombreuses  études  soulignent  le  caractère  contradictoire  de  ces  résultats  [9-11]. 
Enfin,  malgré  des  travaux  relativement  homogènes  dans  des  modèles  animaux 
stéréotypés, il est souvent difficile de déterminer en clinique le statut pro- ou anti-
inflammatoire  d'un  patient  sur  le  seul  dosage de  quelques  cytokines.  En effet,  le 
résultat dépend souvent du choix des cytokines et du moment du prélèvement.
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En réanimation, une des complexités de prise en charge des patients est liée à 
l’incapacité  de prédire la nature infectieuse ou non d’un état  inflammatoire.  Pour 
évaluer l’état des patients, les réanimateurs disposent de nombreux outils intégrant 
des  variables  cliniques  et  biologiques  à  l'admission,  comme  l’indice  de  gravité 
simplifié  (IGS) II  [12] ou le score APACHE II  [13]. Toutefois,  si  ces outils sont 
adaptés pour traiter des données collectives, leur performance est moindre à l’échelon 
individuel. Depuis une vingtaine d'années, de nombreuses études ont été conduites 
afin de pouvoir : (1) mesurer une susceptibilité individuelle d'origine héréditaire ; (2) 
identifier  un  profil  complexe  de  réponse  biologique  permettant  d'affiner  le 
diagnostic ;  (3) utiliser  la  modulation  de  cette  réponse  biologique  pour  suivre  la 
réponse au traitement. Les hypothèses biologiques qui soutiennent ces approches sont 
que : (1) la susceptibilité à une maladie est en partie déterminée par notre patrimoine 
génétique ; (2) la réponse de l'hôte à l'agression et aux traitements mis en œuvre peut 
être  prédite  au  niveau  moléculaire.  Ainsi,  le  clinicien  espère  utiliser  l'outil 
moléculaire  pour  affiner  son  diagnostic,  classer  les  patients  en  fonction  de  leur 
gravité et de leur pronostic, et suivre la réponse aux traitements mis en œuvre.
Les  progrès  technologiques  permettent  d’envisager  l'analyse  globale  de 
l'expression  du  génome  au  niveau  du  transcriptome  [14]. En  effet,  cette  analyse 
globale permet de s'affranchir du biais de sélection a priori des études de dosage de 
cytokines, où seuls certains gènes pré-sélectionnés sont explorés.
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Qu'est-ce que le transcriptome ?
Le transcriptome est un terme générique représentant un ensemble de molécules 
d'acide  ribonucléique  (ARN).  Ces  ARN  sont  transcrits  à  partir  du  génome.  Les 
transcriptomes  diffèrent  selon  le  type  cellulaire,  le  moment  du  recueil  et  les 
stimulations  reçues  par  la  cellule.  Le  génome,  qui  est  composé  d'acide 
désoxyribonucléique  (ADN),  est  identique  dans  l'ensemble  des  cellules  d'un 
organisme. Par contre, son expression varie au cours du temps. Par conséquent, le 
transcriptome est une photographie « instantanée » de l'expression du génome. Par 
extension, le terme transcriptome est utilisé pour les ARN extraits à partir d'un type 
cellulaire ou d'un tissu.
Le transcriptome regroupe l'ensemble des molécules d'ARN transcrites à partir du 
génome [15]. Cela comprend les ARN messagers (ARNm), qui sont traduits par les 
ribosomes en protéines, et les ARN ribosomiques, les ARN de transfert, et tous les 
autres ARN non codant  [16] qui assurent diverses fonctions au sein de la cellule. 
L'expression  du  génome  met  en  jeu  un  grand  nombre  de  mécanismes  de 
modifications post-transcriptionnelles des ARN. Par conséquent, l'ensemble théorique 
des ARN synthétisés à partir du génome est plus vaste que le génome lui-même. Une 
des caractéristiques du transcriptome est donc de varier en fonction des conditions et 
au cours du temps. 
Méthodes d'analyse du transcriptome
Il existe de nombreuses méthodes d'analyse du transcriptome : analyse basée sur 
le  type  d'ARN étudiés,  analyse  d’un  ou  de  quelques  ARN messagers  (par  PCR, 
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« Polymerase Chain Reaction » en anglais), ou analyse d’un ensemble d'ARN. 
Historiquement,  la  comparaison  de  deux  transcriptomes  faisait  appel  à  la 
construction d'une banque soustractive (figure 4) [17]. Cette méthode est basée sur la 
propriété d'hybridation complémentaire des acides nucléiques. Elle est qualitative et 
non exhaustive.  Elle  identifie  un certain nombre de gènes dont l'expression varie 
entre les deux transcriptomes étudiés (par exemple TA et TB, figure 4). Pour cela, les 
ARNm sont rétro-transcrits en ADN complémentaires (ADNc) à double-brin. L'un 
des deux transcriptomes est  rétro-transcrit  en incorporant des nucléotides marqués 
(TB, par exemple par de la biotine). Les ADNc des deux transcriptomes sont alors 
mélangés  afin  de  permettre  l'hybridation  des  ADNc  identiques  dans  les  deux 
transcriptomes.  Les  ADNc  du  transcriptome  marqué  (TB),  ainsi  que  les  ADNc 
hybrides  entre  les  deux  transcriptomes  sont  alors  éliminés  en  utilisant  un  ligand 
(streptavidine si les nucléotides sont marqués à la biotine). Il ne reste donc que les 
ADNc des  gènes  exprimés  uniquement  dans  le  transcriptome A.  Ces  ADNc sont 
clonés  dans  des  vecteurs  d'expression,  puis  isolés  après  transformation  dans  une 
bactérie.  Les  clones  d'intérêts  sont  alors  cultivés.  Le  gène  d'intérêt  est  purifié  et 
séquencé pour identification.
Les techniques plus récentes d'analyse du transcriptome permettent une analyse 
quantitative de l'expression des gènes. La technique SAGE (pour « Serial Analysis of  
Gene Expression ») est basée sur le séquençage (figure 5) [18]. Les ARNm sont rétro-
transcrits en ADNc, puis ces derniers sont soumis à une digestion par un enzyme de 
restriction. Les fragments obtenus sont ligaturés les uns aux autres et clonés dans un 
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vecteur de séquençage. On obtient des fragments d'ADNc juxtaposés et séparés par 
un motif  connu (le  site de l'enzyme de restriction).  Le long fragment hybride est 
séquencé, puis, par analyse bioinformatique, les séquences de chaque fragment sont 
extraites. Les fragments identiques sont comptabilisés. L'analyse nécessite une étape 
d'annotation pour identifier le gène dont les fragments sont issus, par alignement sur 
un génome de référence.  Cette technique permet d'obtenir pour chacun des gènes 
identifiés un compte du nombre de fragments clonés et séquencés. [19]
Les  puces  à  ADN (DNA microarrays)  sont  un  outil  d'analyse  quantitative  de 
l'expression des gènes (figure 6)  permettant  l’analyse de l'expression de plusieurs 
milliers de gènes en une seule expérience [20]. La puce à ADN est généralement une 
membrane de nylon ou une lame de verre sur laquelle sont attachés des morceaux 
d'ADN (sondes) dont la séquence est spécifique d'un gène donné. Les sondes sont soit 
synthétisées in-situ soit déposées par un robot selon un motif régulier et connu. Les 
sondes  sont  soit  des  oligonucléotides  (d'une  longueur  de  quelques  dizaines  de 
nucléotides), soit des ADNc (d'une longueur de quelques centaines de nucléotides). 
Les ARNm de l'échantillon étudié sont marqués à l'aide de nucléotides associés à une 
molécule radioactive ou un fluorochrome au cours d'une étape de rétro-transcription. 
La sensibilité de l'outil évite normalement une étape d'amplification des ADNc. Selon 
le même principe d'hybridation spécifique des séquences complémentaires, les ADNc 
marqués s'hybrident aux sondes complémentaires fixées sur le support. Une fois le 
support lavé, une image de la puce est réalisée. La fluorescence ou la radioactivité de 
chaque point de la puce est détectée et convertie en une intensité lumineuse par un 
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scanner  approprié.  Une  analyse  bioinformatique  permet  alors  de  comparer  les 
quantités relatives de chaque espèce d'ARNm au sein des échantillons.
Le  séquençage  de  l'ADN  a  été  mis  au  point  dans  les  années  1970 
indépendamment par Frederick Sanger (Royaume-Uni) et Walter Gilbert (Etats-Unis). 
Ces deux scientifiques ont reçu en 1980 le prix Nobel de chimie. La méthode de 
Gilbert  ayant  recours  à  des  réactifs  très  toxiques,  elle  a  été  progressivement 
abandonnée au profit de la méthode de Sanger. Cette méthode a connu d'énormes 
progrès technologiques afin de permettre le séquençage de manière parallèle et à bas 
coût de génomes eucaryotes entier en peu de temps. La possibilité d'obtenir pour un 
coût  modéré  et  dans  un  temps  raisonnable  les  séquences  d'un  ensemble  d'acides 
nucléiques  de  grande  taille  a  conduit  à  transposer  cette  technique  à  l'analyse  du 
transcriptome (RNA-seq,  figure  7)  [21]. La  première  étape,  commune  aux autres 
techniques, est l'extraction de l'ARN. Une des difficultés est d'éliminer les espèces 
trop  abondantes  qui  risquent  de  saturer  l'analyse,  comme  par  exemple  les  ARN 
ribosomiques.  Les  ARNm  sont  alors  convertis  en  ADNc.  Différents  procédés 
spécifiques [22-27] ont été développés pour retrouver le brin à partir duquel l'ARN a 
été transcrit, comme par exemple la synthèse d’ADNc mono-brin (Illumina [28]). Le 
tableau 1 présente les trois principaux systèmes de séquençage haut-débit avec leurs 
caractéristiques. La phase d'hybridation est virtuelle, par alignement des séquences 
obtenues  avec  un  génome  de  référence.  Une  fois  les  séquences  alignées  sur  le 
génome, elles sont dénombrées, ce qui permet une analyse quantitative au niveau de 
chaque gène.  [29]
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Réponse à l'infection : données expérimentales
Réponse cellulaire à l'infection
Les  puces  à  ADN  permettent  (1)  d'identifier  des  signatures  moléculaires 
spécifiques en fonction du stimulus (cellules en culture stimulées par de l'interféron 
(IFN) α, β ou γ) [30] ; (2) de décrire la réponse de l'hôte à l'infection [31]. En utilisant 
des cellules dendritiques, impliquées dans l'initiation des réponses immunes innée et 
acquise, des profils de réponse spécifique et commune à différents micro-organismes 
ont  été  caractérisés  [32].  Ce  résultat  a  été  confirmé  par  l'analyse  de  la  réponse 
transcriptionnelle  de macrophages humains stimulés  ex-vivo  par diverses bactéries 
(E.  coli,  Salmonella  sp.,  Staphylococcus  aureus,  Listeria  monocytogenes,  
Mycobacterium tuberculosis,  et le bacille de Calmette et Guerrin) [33], et sur sang 
total,  mélangé  ex-vivo  à  du  lipopolysaccharide  (LPS)  ou  des  fragments  de 
Staphylococcus  aureus [34].  La réponse  de l'hôte  au niveau cellulaire  a  donc été 
caractérisée  au  sein  de  plus  de  25  types  cellulaires,  après  stimulation  par  des 
bactéries,  virus,  levures  ou  parasites  [35].  Ainsi,  l'analyse  de  la  réponse 
transcriptionnelle de l'hôte est un outil de diagnostic moléculaire caractérisant au sein 
de diverses cellules un profil de réponse temporel précis, sensible et spécifique pour 
divers micro-organismes. 
Spécificité de la réponse (selon le tissu ou le micro-organisme)
Plusieurs équipes ont essayé de confirmer ces résultats in-vivo, dans des modèles 
animaux de sepsis. L'analyse in-vivo introduit un degré supplémentaire de complexité 
puisque la réponse de l'hôte peut être observée au sein d'un ou plusieurs tissus. Dans 
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un modèle de sepsis intra-abdominal plurimicrobien (secondaire à une perforation et 
ligature caecale [CLP]),  la réponse tissulaire (analysée au niveau du cerveau,  des 
reins, du foie, des poumons, de la rate et du thymus) était majoritairement spécifique 
de  l’organe,  parfois  commune  à  plusieurs  organes,  ou  nettement  opposée  entre 
différents organes [36]. L’analyse de la littérature montre que les profils d’expression 
des gènes diffèrent dans  le sang, le tissu hépatique et le tissu splénique [37,38]. La 
réponse de chaque organe a ainsi été analysée de façon spécifique : cœur  [39-42], 
cerveau  [36,43,44], foie [36,37,45-49], rate [36-38,46,47,50,51], poumon [36,47], et 
sang [38,52,53]. La variabilité des modèles utilisés rend difficile la synthèse de ces 
résultats. Il apparaît simplement qu'il existe une réponse tissulaire spécifique.
L’utilisation d’un stimulus différent (CLP (polymicrobien) ou LPS) est également 
à l’origine d’une variation de la réponse [38]. L'analyse du transcriptome aux niveaux 
sanguin et splénique identifie des signatures spécifiques de chaque stimulus (CLP ou 
LPS).  Dans  une  autre  étude,  l'analyse  du  transcriptome  hépatique  montre  que 
l'expression  de  17  gènes  diffère  après  infection  par  Escherichia  coli ou 
Staphylococcus aureus [49]. La réponse est donc spécifique, selon l’organe analysé 
ou la nature de la stimulation. 
Pronostic
L’analyse du transcriptome est une aide pour classer les états septiques selon leur 
gravité. Peu d’études ont exploré cette question chez l'animal. Expérimentalement, 
les profils d’expression discriminent avec précision des groupes de souris exposées à 
(1) une injection de sérum physiologique (contrôles), (2) l’administration de LPS, (3) 
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une laparotomie blanche,  (4) une laparotomie associée à une CLP, et  (5) une CLP 
associée à un traitement antibiotique  [38]. Les différents groupes de souris avaient 
des taux de mortalités variant de 0 % à 100 %. En pathologie humaine, on envisage 
donc que l’analyse du transcriptome soit une aide pour identifier les patients à risque 
de décès.
Distinction SIRS/Sepsis
Au lit du malade, déterminer l’origine infectieuse ou non des états inflammatoires 
reste  difficile.  L’implication  thérapeutique  est  directe  puisque  la  prescription 
d’antibiotiques  repose  sur  le  résultat  de  cette  analyse.  Demain,  des  traitements 
immunomodulateurs  pourraient  être  prescrits  en  fonction  de  cette  différence.  Des 
signatures  spécifiques  ont  été  mises  en  évidence  en  comparant  le  transcriptome 
exprimé par des PBMC prélevés chez des rats « contrôles » (sérum physiologique), 
des  rats  ayant  une  infection  intra-abdominale  (CLP)  et  des  rats  présentant  une 
réponse  inflammatoire  systématisée  (pancréatite)  (Figure  8)  [53].  Seuls  15  (5 %) 
gènes modulés sont communs aux groupes CLP et pancréatite. De la même manière, 
il  existe  une  signature  spécifique  selon  que  des  souris  sont  soumises  à  une 
laparotomie  blanche  ou  associée  à  une  CLP  [38].  Ces  résultats  soutiennent 
l'hypothèse selon laquelle l'analyse du transcriptome permet de distinguer SIRS et 
sepsis.
Intégration du facteur temps
L'analyse  du transcriptome a  permis  de caractériser  l'évolution temporelle  des 
profils d'expression génique durant un épisode septique. Dans un modèle murin, le 
14 / 192
transcriptome hépatique a été analysé à 2 h, 8 h, 24 h 48 h et 72 h après injection 
intraveineuse d'Escherichia coli ou de Staphylococcus aureus [49]. Sur cette période, 
300  (5 %)  gènes  étaient  modulés  par  un  facteur  2  ou  plus.  Ces  gènes  étaient 
regroupés en quatre groupes fonctionnels, (1) des gènes de la réponse inflammatoire 
et de la réponse au stress, (2) des gènes codant des protéines de structure, et des gènes 
impliqués dans la motilité cellulaire ainsi que dans le trafic vésiculaire au sein de la 
cellule,  (3) des  gènes  codant  des  récepteurs  membranaires,  des  molécules  de 
transduction  du  signal  et  des  facteurs  de  transcription,  (4) des  gènes  codant  des 
enzymes du métabolisme cellulaire, ainsi que des gènes impliqués dans la synthèse 
protéique. L'expression des gènes au cours du temps évoluait selon quatre profils : 
(1) augmentation ou (2) diminution de l'expression, suivie d'un retour à l'état basal ; 
(3) augmentation ou (4) inhibition persistante de l'expression.
Dissection du modèle physiopathologique chez l'animal
Un  des  attraits  des  modèles  animaux  est  de  comparer  la  modulation  de 
l'expression des gènes chez des animaux sauvages ou génétiquement modifiés (KO 
pour « Knock-Out » en anglais). Le rôle de certains gènes dans la réponse au sepsis 
peut ainsi être précisé. En étudiant un modèle de CLP au sein de souris sauvages ou 
ayant une délétion du gène codant MyD88 (MyD88-/-), on observe une diminution du 
nombre de gènes modulés au niveau hépatique chez les souris KO MyD88-/-.  Ce 
résultat  n’est  pas  retrouvé au niveau splénique.  Cela  confirme le rôle  de certains 
gènes dans la réponse tissulaire spécifique. L’analyse du transcriptome hépatique de 
souris IL6ST KO montre qu’IL6ST (également nommée GP130) est impliqué dans la 
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transduction du signal de cytokines comme l'IL-6 vers STAT3. Surtout, ce gène est 
essentiel pour la survie des souris, via l'activation de la réponse inflammatoire et le 
recrutement de cellules immunitaires au niveau hépatique  [48]. Il a également été 
montré que la NO synthase inductible est essentielle pour moduler un certain nombre 
de gènes associés à la dysfonction myocardique dans le sepsis [41].
Intégration de la variabilité inter-individuelle
L'outil  d'analyse  du  transcriptome  permet  d'explorer  la  variabilité  inter-
individuelle  en  réponse  à  l'infection.  Celle-ci  peut  être  d'origine  génétique  ou 
environnementale. En analysant les réponses hépatique, splénique et pulmonaire de 
différentes  lignées  de  souris  à  l'injection  de  LPS,  de  nouveaux  facteurs  de 
transcription impliqués dans le contrôle de l'expression des gènes induits par le LPS 
ont été identifiés [47]. Par rapport aux souris sauvages, les souris ayant une délétion 
du  gène  codant  pour  le  facteur  de  transcription  E2F1  avaient  une  réponse 
inflammatoire  réduite  après  l’administration  systémique  de  LPS.  Les  souris 
hétérozygotes pour le gène PTCH, impliqué dans la voie d’Hedgehog, avaient au 
contraire une réponse exacerbée au LPS. Enfin,  des facteurs intrinsèques,  comme 
l’âge  ou  l’obésité,  modifient  également  les  profils  de  réponse 
transcriptionnels [40,43,54].
L'ensemble de ces études répond à différentes questions : (1) la description de la 
réponse  transcriptionnelle  à  un  micro-organisme  au  cours  du  temps ;  (2) la 
description des réponses commmunes et  spécifiques de l'hôte selon le tissu ou le 
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stimulus ; (3) l'altération de cette réponse lors de l'utilisation d'un hôte mutant (pour 
décrire  le  rôle  de  certains  gènes  dans  la  réponse,  et  ainsi  identifier  des  cibles 
thérapeutiques potentielles). Ces différents travaux chez l'animal ont posé les bases 
de  l'analyse  du  transcriptome  en  pathologie  humaine.  Ils  permettent  également 
d'affiner la compréhension des mécanismes physiopathologique du sepsis.
Réponse à l'infection : données humaines
L'ensemble des résultats obtenus in vitro et in vivo ont conduit à utiliser les puces 
à ADN comme un outil d'analyse du transcriptome chez les patients septiques. Les 
objectifs étaient  (1) d'identifier une réponse transcriptionnelle liée à l'infection ;  (2) 
de déterminer si comme chez l'animal, la réponse est spécifique de chaque organe 
tissus ;  (3) de déterminer si cette réponse distingue les états inflammatoires (SIRS) 
d'origine infectieuse ou non ;  (4) de déterminer si  chaque micro-organisme a une 
signature spécifique; (5) de déterminer si une signature temporelle permet de suivre 
l'évolution de la maladie ; et (6) de déterminer si des profils spécifiques sont liés au 
pronostic.
Réponse à l'infection
L'analyse du transcriptome à partir de PBMC ou de sang total identifie les sujets 
septiques. A l'aide d'une puce à ADN (testant 340 gènes humains impliqués dans la 
réponse inflammatoire), le transcriptome sanguin (sang total) a  été comparé chez huit 
patients  en  sepsis  grave  et  quatre  patients  en  surveillance  post-opératoire  d'une 
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chirurgie  du rachis,  sans signe de SIRS  [55].  Cette  analyse différenciait  les  deux 
groupes de patients. A l'aide d'une puce Affymetrix (GeneChip, 54 000 sondes), une 
signature  distinguant  des  patients  septiques  de  sujets  contrôles  a  également  été 
identifiée en réanimation pédiatrique [56]. Elle comprenait des gènes impliqués dans 
la  réponse  immunitaire  et  dans  l'homéostasie  du  zinc.  Dans  une  étude  de 
confirmation,  95  à  100 %  des  enfants  étaient  classés  dans  la  bonne  catégorie 
diagnostique [57].
Réponse tissulaire à l'infection
Une  seule  étude  humaine  a  analysé  le  transcriptome  de  cellules  musculaires 
striées dans le sepsis. L’objectif était de décortiquer les phénomènes de myopathie 
liée  aux  états  septiques  graves  [58].  Toutefois,  il  n'existe  pas  de  données  chez 
l'homme  comparant  les  réponses  transcriptionnelles  des  différents  tissus  dans  le 
sepsis.
Distinction des états inflammatoires d'origine infectieuse ou non
Du point de vue du clinicien, un des enjeux est de distinguer l'origine infectieuse 
ou  non  d’un  syndrome  inflammatoire.  En  réanimation  pédiatrique,  il  existe  des 
différences entre le transcriptome de cellules mononuclées d'enfants en SIRS, sepsis, 
et  choc septique  [59].  Une partie  de la  modulation de  l'expression des  gènes  est 
commune  à  l'ensemble  des  patients.  Les  auteurs  l'attribuent  à  la  réponse 
inflammatoire. Ils identifient également une réponse spécifique des patients septiques 
par  rapport  aux  patients  inflammatoires.  L'analyse  temporelle  montre  que  la 
modulation des gènes persiste trois jours seulement chez les enfants en choc septique. 
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Cette modulation est majoritairement une sous-expression de gènes liés à la réponse 
immunitaire acquise et à l'homéostasie du zinc. 
Des  résultats  similaires  ont  été  retrouvés  chez  l'adulte.  Le  transcriptome  de 
cellules  mononuclées  a  été  étudié  chez  46  patients  en  sepsis  et  24  patients  de 
réanimation avec un diagnostic de syndrome de réponse inflammatoire systémique 
non liée à l’infection  [60]. La sensibilité et la spécificité de cette signature ont été 
testées  sur  un  second  groupe  de  patients.  Elles  étaient  de  81 %  et  de  79 %, 
respectivement  [60].  L'évolution  de  l'expression  des  gènes  sur  trois  jours  a  été 
comparée chez des patients en SIRS évoluant ou non vers un sepsis. L'expression de 
4 559 gènes discrimine les deux groupes de patients  [61]. Globalement,  les gènes 
identifiés sont impliqués dans la réponse immune innée, la transduction du signal des 
cytokines,  la  différentiation  des  lymphocytes  T  et  la  régulation  de  la  synthèse 
protéique.  Alors  que  les  gènes  impliqués  dans  la  réponse  inflammatoire  sont 
fortement  activés  dans  les  états  de  SIRS,  ils  sont  sous-exprimés  dans  les  états 
septiques graves. Par contre, les gènes impliqués dans l'apoptose sont activés. Ces 
résultats soutiennent la vision actuelle de la physiopathologie du sepsis grave avec 
une réponse anti-inflammatoire exagérée et un état d'anergie.
Identifier une réponse spécifique d'un micro-organisme
Une seule étude animale a montré des différences au sein du transcriptome selon 
le  micro-organisme en cause  [49].  Les tentatives pour  reproduire  ces  résultats  en 
pathologie humaine sont infructueuses.  Ceci est  bien corrélé à une étude clinique 
montrant une absence d’association entre la nature de la bactérie et l’évolution du 
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patient [62]. Le transcriptome de 131 enfants atteints d’infection aiguë a été analysé 
en  fonction  de  la  nature  virale  ou  bactérienne  de  l’infection.  Trente-cinq  gènes 
distinguaient avec précision l’infection en fonction de la nature de l’agent microbien 
[63]. Toutefois, aucune différence n’était notée entre les différentes bactéries. Deux 
études conduites sur des populations d'adultes hospitalisés en réanimation n’ont pas 
eu la capacité de discriminer une infection par une bactérie à Gram positif ou négatif  
[60,64]. La contradiction entre les résultats animaux et humains est probablement liée 
à un manque de puissance de l'analyse. En effet, dans le modèle expérimental, les 
animaux ont un fonds génétique commun, et les prélèvements sont réalisés dans un 
même délai  par  rapport  à  l'inoculation.  De  plus,  seules  deux  bactéries  distinctes 
étaient utilisées et un faible nombre de gènes identifiés (n = 17) [49]. Chez l'homme, 
il existe une variabilité du « fonds génétique », une variabilité en terme de délai de 
prélèvement  par  rapport  au  début  de  l'infection,  et  une  variabilité  de  micro-
organismes en cause, avec parfois des infections polymicrobiennes. Enfin, la majeure 
partie  de  la  réponse  transcriptionnelle  est  probablement  commune.  Il  est  donc 
possible  de  caractériser  les  mécanismes  moléculaires  spécifiques  mis  en  jeu  par 
divers agents pathogènes dans les modèles animaux, mais il est actuellement difficile 
d'utiliser les données de transcriptome pour affiner le diagnostic microbiologique, en 
dehors de la distinction entre infections virale et bactérienne.
Evolution  naturelle  ou  en  réponse  aux  traitements  de  la  réponse 
transcriptionnelle
Plusieurs  études  ont  décrit  une  signature  chez  des  sujets  sains  exposés  à  une 
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injection  intraveineuse  de  LPS.  Le  LPS  est  un  des  composants  de  la  membrane 
externe  des  bactéries  à  Gram  négatif.  Il  joue  un  rôle  prépondérant  dans  le 
déclenchement  de  la  réponse  immunitaire  lors  de  l'infection  [65-67].  Après 
administration  de  LPS,  l’expression  d’environ  3 700  gènes  est  modulée  avec  un 
retour à l'expression basale dans les 24 h. La plupart des gènes sont activés entre 4 et 
6 h après l’agression. La transcription de gènes impliqués dans le rétrocontrôle de 
l'activation de la réponse immunitaire s'articule durant cette période. Parmi les gènes 
modulés,  on  note  une  sur-expression  des  gènes  impliqués  dans  le  système  de 
phagocytose  NADPH-oxydase.  Ce  composant  est  important  dans  le  système  de 
défense  de  l'hôte.  On  note  également  une  diminution  de  l'expression  des  gènes 
impliqués dans le complexe majeur d'histocompatibilité de type II et une réduction de 
la synthèse des intégrines, impliquées dans l'adhésion intercellulaire (figure 9).
Une  analyse  longitudinale  du  transcriptome  permettrait  de  suivre  l’évolution 
naturelle  de  la  maladie  et  la  réponse  au  traitement.  L'expression  de  certains 
biomarqueurs  impliqués  dans  la  réponse  pro-inflammatoire  (S100A8,  S100A12, 
ALOX5AP)  diminue  au  cours  de  la  rémission  du  choc  septique,  alors  que 
l'expression  de  gènes  impliqués  dans  la  présentation  de  l'antigène  (par  exemple 
CD74) augmente [68]. L'évolution du transcriptome a été comparée chez 90 patients 
en SIRS pendant les 72 h précédant ou non l'apparition du sepsis  [69]. L’analyse, 
conduite a posteriori,  s'est focalisée sur les gènes impliqués dans la transduction du 
signal  par  les  récepteurs de type Toll.  L'expression de plusieurs de ces gènes est 
discriminante un à deux jours avant la survenue des signes cliniques. McDunn et al. 
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ont proposé à partir  de données de transcriptome le concept  de riboleukogramme 
(figure 10)  [70]. Une signature transcriptionnelle a été déterminée par l’analyse des 
modifications du transcriptome obtenues dans un modèle murin de pneumonie. Cette 
signature a ensuite  été analysée chez des patients  dont les poumons sont ventilés 
mécaniquement.  L'expression  des  85  gènes  de  la  signature  permet  de  suivre 
l'évolution d’un épisode de pneumonie, avec un diagnostic moléculaire précédant le 
diagnostic  clinique,  et  une  seconde  modulation  du  riboleukogramme  lors  de  la 
rémission.  Malheureusement,  ce  riboleukogramme  n’a  pas  été  validé  dans  une 
population de 158 patients  traumatisés graves  [71].  La sensibilité et  la  spécificité 
diagnostique du test étaient respectivement de 57 % et 69 %. Toutefois, en dépit de ce 
résultat, un tel modèle d'analyse reste probablement pertinent pour le diagnostic et le 
suivi de la réponse au traitement.
Identification de signatures pronostiques
En clinique, il existe enfin un grand intérêt pour la recherche de biomarqueurs 
pronostiques. L'analyse du transcriptome s’intègre totalement dans cette démarche. 
Des  signatures  spécifiques  ont  été  associées  à  un  mauvais  pronostic.  Chez  des 
patients en choc septique, une signature de 28 gènes classe les patients selon leur 
survie avec une sensibilité de 100 % et une spécificité de 86 %  [72]. De la même 
manière,  Wong  et  al.  ont  identifié  34  gènes  dont  l'expression  prédit  la  mortalité 
d'enfants  en  choc  septique  [73].  De  façon  surprenante,  la  comparaison  des  deux 
signatures ne retrouve aucun gène commun. Il est probable que les résultats obtenus 
ne  soient  valides  qu'au  sein  de  la  population  étudiée  (enfants  vs.  adultes).  Les 
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signatures  identifiées  sur  ces  analyses  pronostiques  diffèrent  également  de  celles 
identifiées pour la détection du sepsis [74]. 
L'ensemble  de  ces  travaux souligne la  variabilité  importante  de la réponse de 
l'hôte à l'infection. Parmi les variables qui influencent la réponse de l'hôte, le sexe a 
été  particulièrement  étudié  dans  le  sepsis.  Plusieurs  travaux  montre  que  le  sexe 
modifie la réponse à l'infection et le pronostic des patients en sepsis [75,76]. Pourtant, 
bien qu'il semble évident que le sexe joue un rôle dans la réponse transcriptionnelle, 
les divers travaux d'analyse globale du transcriptome par puces à ADN n'ont pas pris 
en compte cette variable dans leur analyse. 
Au total, l'analyse du transcriptome par la technologie des puces à ADN permet 
de  décrire  la  réponse  de  différents  tissus  à  l'agression,  et  d'affiner  notre 
compréhension des mécanismes physiopathologique de l'inflammation et du sepsis. 
C'est  donc  un  outil  d'analyse  de  la  réponse  de  l'hôte  à  l'agression,  notamment  à 
l'infection. 
23 / 192
Objectifs
L'objectif de cette thèse est d'explorer l'inflammation et l'infection au niveau du 
transcriptome, à l'aide de la technologie des puces à ADN. 
Dans  ce  but,  nous  avons  mis  au  point  un  logiciel  permettant  d'explorer  et 
d'analyser les données publiques de transcriptome. Ce travail a été initié devant le 
constat d'une croissance exponentielle des données publiques de transcriptome, et la 
pauvreté  d'outils  adaptés  pour  comparer  et  analyser  de  manière  intégrative  ces 
données et les autres bases de données publiques d'annotation.
Ensuite,  nous avons essayé de différencier  la  réponse inflammatoire de l'hôte, 
associée  ou  non  à  un  sepsis.   La  volonté  de  distinguer  une  réponse  infectieuse 
spécifique au sein de la réponse inflammatoire nous a conduit à mettre en place un 
schéma expérimental permettant de comparer une réponse inflammatoire liée ou non 
à  l'infection.  Pour  cela,  nous  avons  mis  au  point  un  modèle  murin  d'atteinte 
inflammatoire pure du poumon par injection d'acide oléique et étudié dans un premier 
temps la réponse du parenchyme pulmonaire, et des cellules sanguines mononuclées. 
Ainsi, il sera possible de comparer dans un second temps la réponse de ce modèle 
d'atteinte  inflammatoire,  à  un  modèle  murin  d'infection  pulmonaire.  Nous  avons 
ensuite imaginé un modèle clinique similaire, analysant des traumatisés graves dont 
l'évolution  est  compliquée  d'une  pneumonie  associée  à  la  ventilation  mécanique 
(projet SepsiChip). Chez un même patient, le syndrome inflammatoire déclenché par 
le traumatisme grave sert ainsi de témoin à la réponse infectieuse de la pneumonie. 
Le second objectif de la thèse est d'utiliser l'analyse globale du transcriptome pour 
explorer les mécanismes physiopathologiques du sepsis, et notamment les variables 
qui influencent la relation hôte-pathogène, et la réponse de l'hôte à l'agression. Les 
deux premiers modèles d'analyse (projet SepsiChip chez l'homme, et le modèle murin 
d'atteinte  inflammatoire  pulmonaire)  permettent  de  souligner  le  rôle  du  temps. 
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Comme le sexe est une des principales caractéristiques de l'hôte et que de nombreux 
travaux  soutiennent  son  rôle  dans  la  réponse  à  l'agression,  nous  avons  choisit 
d'intégrer  ce  facteur  dans  l'analyse.  Le  choix  d'un  modèle  murin  d'infection  par 
Coxiella  burnetii repose  sur  l'existence  de  travaux  antérieurs  du  laboratoire/de 
l'équipe sur le rôle du sexe dans la fièvre Q, et l'existence d'un dimorphisme sexuel 
connu en clinique. Enfin, pour intégrer dans l'analyse une variable liée au pathogène, 
le dernier modèle analysé (infection par le virus  Influenza) examine l'influence de 
l'infection par différentes souches plus ou moins virulentes d'un même virus sur la 
réponse de l'hôte (dans un modèle de cellules en culture).
Le dernier objectif de ce travail est d'évaluer si l'analyse globale de la réponse de 
l'hôte peut conduire à l'identification de nouvelles cibles thérapeutiques, au sein d'un 
modèle  in-vitro d'infection virale par différentes souches du virus de la grippe. Au 
cours de ce travail,  nous avons mis au point une méthodologie originale  in silico 
d'identification  de  molécules  candidates.  Huit  antiviraux  potentiels  ont  ainsi  été 
évalués in-vitro  dans le même modèle d'analyse.
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Résultats
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TranscriptomeBrowser:  A  Powerful  and  Flexible  Toolbox  to  Explore 
Productively the Transcriptional Landscape of the Gene Expression Omnibus 
Database
Julien Textoris, Fabrice Lopez, Aurélie Bergon, Gilles Didier, Elisabeth Remy, Samuel Granjeaud, Jean 
Imbert, Catherine Nguyen, Denis Puthier
PLoS ONE 3(12): e4001
L'utilisation de technologies à haut-débit comme par exemple les puces à ADN génère une quantité 
importante  de  données.  Ces  données  sont  aujourd'hui  accessibles  publiquement  dans  des  bases  de 
données en ligne. La taille de ces bases grandit rapidement, et nécessite la mise au point de stratégies  
d'analyse pour traiter ces données de manière efficace.
Nous avons utilisé une version modifiée de l'algorithme MCL (pour Markov CLustering) pour extraire 
de manière systématique et automatisée des clusters de gènes co-régulés à partir de centaines de jeux de  
données (n = 1 484) stockés dans la base de donnée GEO (pour « Gene Expression Omnibus », NCBI). 
Cette stratégie a conduit à l'identification de 18 250 signatures transcriptionnelles. Ces signatures ont dans 
un  second  temps  été  annotées  à  partir  de  la  suite  logicielle  DAVID  (pour  « Database  for  Annotation, 
Visualization and Integrated Discovery »). Un enrichissement fonctionnel a été retrouvé pour la plupart de 
ces signatures transcriptionnelles (84 %). Nous avons développé une application java modulaire et évolutive, 
TBrowser qui est composée d'une interface graphique et d'une série de greffons. L'architecture open source 
autorise  le  développement  de  nouveaux  greffons  d'analyse  par  la  communauté  scientifique.  L'interface 
graphique  est  muni  d'un  module  de  recherche  sophistiqué  supportant  les  opérations  booléennes 
(http://tagc.univ-mrs.fr/tbrowser/).  L'utilisateur  peut  interroger  la  base  de  données  de  signatures 
transcriptionnelles à partir de divers identifiants (noms de gènes, identifiants de sondes, …) et/ou des mots-
clés d'annotation fonctionnelle.
Comme preuve de concept, TBrowser a été utilisé pour identifier des gènes spécifiques de tumeur 
maligne du sein, ainsi que pour détecter des anomalies chromosomiques associées à ces tumeurs. Enfin, à 
partir de cette vaste collection de signatures transcriptionnellles, nous avons construit une carte résumant 
les co-régulations gène/gène observées à travers l'ensemble des expériences réalisées sur une puce à ADN 
Affymetrix  HGU133A.  Nous  montrons  ainsi  que  l'analyse  de  cette  carte  permet  de  compléter  nos 
connaissances sur diverses voies métaboliques. Enfin, dans l'analyse de la réponse à l'infection par Coxiella 
burnetii en fonction du sexe, l'utilisation de TBrowser nous a permis de mettre en évidence des différences 
de localisation sub-cellulaire.
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Abstract
Background: As public microarray repositories are constantly growing, we are facing the challenge of designing strategies
to provide productive access to the available data.
Methodology: We used a modified version of the Markov clustering algorithm to systematically extract clusters of co-
regulated genes from hundreds of microarray datasets stored in the Gene Expression Omnibus database (n = 1,484). This
approach led to the definition of 18,250 transcriptional signatures (TS) that were tested for functional enrichment using the
DAVID knowledgebase. Over-representation of functional terms was found in a large proportion of these TS (84%). We
developed a JAVA application, TBrowser that comes with an open plug-in architecture and whose interface implements a
highly sophisticated search engine supporting several Boolean operators (http://tagc.univ-mrs.fr/tbrowser/). User can search
and analyze TS containing a list of identifiers (gene symbols or AffyIDs) or associated with a set of functional terms.
Conclusions/Significance: As proof of principle, TBrowser was used to define breast cancer cell specific genes and to detect
chromosomal abnormalities in tumors. Finally, taking advantage of our large collection of transcriptional signatures, we
constructed a comprehensive map that summarizes gene-gene co-regulations observed through all the experiments
performed on HGU133A Affymetrix platform. We provide evidences that this map can extend our knowledge of cellular
signaling pathways.
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Introduction
Microarray technology provides biologists with a powerful
approach for comprehensive analyzes of cells or tissues at the
transcriptional level. DNA chips are now widely used to assess the
expression levels from all genes of a given organism. These data,
most generally deposited in MIAME-compliant public databases,
constitute an unprecedented source of knowledge for biologists [1].
As an example, until now, the Gene Expression Omnibus
repository (GEO) host approximately 8,000 experiments encom-
passing about 200,000 biological samples analyzed using various
high through-put technologies [2]. Consequently, this represents
billions of measurements that reflect the biological states of cells or
tissues recorded in physiological or pathological conditions or in
response to various chemical compounds and/or natural mole-
cules. As public repositories are continually expanding, we are
facing the new challenge of designing new strategies to provide
efficient and productive access to the available data.
To date, at least two major solutions have emerged. The first
one applies a ‘‘gene-centered perspective’’, as developed in the ‘‘GEO
profile‘‘ or ‘‘SOURCE’’ web interfaces [3]. This approach allows
users to retrieve the expression profiles of a given gene in
numerous curated experiments. Once a profile is selected, a list of
similar profiles (i.e. neighbors) can be retrieved. Although GEO
proposes several tools to refine the queries, cross-analysis through
multiple experiments can not be performed. The second solution
involves an ‘‘experiment-centered perspective’’ as developed in the
‘‘GEO DataSets’’ and ‘‘ArrayExpress’’ web interfaces [4]. This
approach provides to biologists a set of classification tools to re-
analyze selected experiments. Depending on the interface,
supervised or unsupervised analysis (see below) can be pre-
calculated or computed on demand. Again, as no meta-analysis
tool is available, mining and compiling even few GEO Serie
Experiments (GSE) remains a difficult and time-consuming task.
We therefore lack efficient tools allowing productive data
mining of microarray databases. For example, querying whole
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public microarray data using a single gene identifier is an
ambiguous procedure to extract relevant co-regulated genes.
Indeed, depending of the biological context, genes can be involved
in different signaling pathways and may be associated with
different neighbors. As a consequence, combined queries should
be more appropriate to build relevant gene networks. Moreover,
numerous uninformative genes exist in microarray experiments.
They correspond most generally to those with low standard
deviation that are outside any natural gene cluster. These genes
should be discarded from analysis as they are inevitably associated
with false positive neighbors. These considerations motivated the
present work and the development of a new approach that follows
a ‘‘transcriptional signature centered perspective’’. The goal was to build
an application that would interact with a large database of
transcriptional signatures and would implement efficient tools to
analyze and visualize the results.
The first issue resided in the construction of a database containing
high quality transcriptional signatures obtained in an automated
fashion. Both supervised and unsupervised classification algorithms
can be used in microarray data analysis [5]. Supervised methods
aim at finding a set of genes whose expression profiles best correlate
with a known phenotype. They provide a way to select informative
genes by choosing the top k genes according to the results of a
statistical test (e.g. Student’s t-test, Significance Analysis of Micro-
arrays, Signal to Noise Ratio, ANOVA) and by controlling the false
discovery rate (FDR). In contrast, unsupervised classification
approaches, achieve clustering of genes based on their respective
expression profiles but are not intended to filter out uninformative
genes. Some popular approaches in microarray analysis use either
agglomerative methods (hierarchical clustering), partitioning meth-
ods (k-medoids, k-means, PAM, SOM, etc.) or methods aimed at
capturing informative dimensions (PCA). A filtering step is most
generally applied prior to unsupervised classification. One can select
genes with high standard deviations, those displaying a proportion
of values above a user-defined threshold or those having a given
maximum (or minimum) value. However this procedure is
extremely subjective and the number of selected genes may be
over or under estimated. Finally, another limit of classical
unsupervised methods also resides in their inability to accurately
identify the actual number of clusters if no further argument is
provided to the algorithm. As a consequence, additional algorithms
for unsupervised classification have been proposed such as Quality
Cluster algorithm (QT_Clust) [6], CHAMELEON [7] or Markov
CLustering (MCL) [8]. However, none of them address both the
filtering and partitioning issues. MCL is a graph partitioning
algorithm whose ability to solve complex classification problems has
been underlined in many applications including protein-protein
interaction networks [9], sequence analysis (TRIBE-MCL) [10] or
microarray analysis (geneMCL) [11]. In a graph representation of
microarray data, nodes stand for genes and edges represent profile
similarities between genes. As processing the full graph for
partitioning is time-consuming and computer-intensive the gen-
eMCL algorithm has to be run on a subset of genes that are selected
using classical filters (e.g. high standard deviation or fold-change). As
such a filtering procedure is not well suited for automated analysis of
numerous experiments; we developed an adaptive density-based
filter (DBF) whose goal is to isolate automatically informative genes
from a dataset. Selected genes are next used to construct a graph
that is subsequently partitioned using MCL. This modified version
of MCL algorithm was termed DBF-MCL for ‘‘Density Based
Filtering and Markov CLustering’’.
In the present paper, we show that DBF-MCL provides very
good results both on simulated and real datasets. The algorithm
was run on 1,484 microarrays datasets (46,564 biological samples)
performed on various Affymetrix platforms (human, mouse and
rat). This led to the identification of 18,250 transcriptional
signatures (TS) whose corresponding gene lists were tested for an
enrichment in terms derived from numerous ontologies or curated
databases using the DAVID knowledgebase [12] (Gene Ontology,
KEGG, BioCarta, Swiss-Prot, BBID, SMART, NIH Genetic
Association DB, COG/KOG, etc.) (see Figure S1 for an overview
of the data processing pipeline). Informations related to biological
samples, experiments, TS composition, TS associated expression
values and TS keyword enrichment scores were stored in a
relational database. A Java application, TBrowser (Transcripto-
meBrowser), was developed and deployed using Java Web Start
technology. Combined queries that can be done with an extended
set of Boolean operators allow user to rapidly select sets of TS
containing (or not) a given list of gene symbols. Based on these TS,
a list of frequently observed neighbors can be created. As each TS
is linked to a set of biological keywords (derived from ontologies),
user can also search for those enriched in genes involved in specific
biological processes. We show that TBrowser can be used to mine
productively hundreds of experiments and to reveal underlying
gene networks. Furthermore, using this unprecedented collection
of TS we built the first synthetic transcriptional map of all human
microarray data performed on Affymetrix HG-U133A platform
and currently available in the GEO database.
Results
DBF-MCL algorithm
Conventional algorithms used for unsupervised classifications of
gene expression profiles suffer from two main limitations. First, they
do not filter out uninformative profiles and second, they are not able
to find out the actual number of natural clusters in a microarray
dataset. We can considerer genes as points located in a hyperspace
whose number of axes would be equal to the number of biological
samples. As it is difficult to perceive high-dimensional spaces, a
common way to illustrate classification methods is to use a 2D
representation. In Supplemental Figure S2, each point represents a
gene and we are interested in isolating dense regions as they are
populated with genes that display weak distances to their nearest
neighbors (i.e. strong profile similarities). To isolate these regions we
can compute, for each gene, the distance with its kth nearest
neighbor (DKNN). If k is relatively small, DKNN should be smaller
for all genes falling in a dense area. Thus, the filtering procedure
used in DBF-MCL starts by computing a gene-gene distance matrix
D. Then, for each gene, DBF-MCL computes its associated DKNN
value (with k being set typically to 100 for microarrays containing 10
to 50k elements). Distributions of DKNN values observed with both
an artificial and a real dataset (Complex9RN200 and GSE1456
respectively, see thereafter for a description) are shown in Figure
S3A and S3B (solid curve). The asymmetrical shape of the
distribution observed in Figure S3B suggests the presence of a
particular structure within the GSE1456 microarray dataset.
Indeed, the long tail that corresponds to low DKNN values could
indicate the existence of dense regions. The fact that regions of
heterogeneous densities exist in the Complex9RN200 artificial
dataset is even clearer as a bimodal distribution is observed. Next,
we would like to define a critical DKNN value below which a gene
can be considered as belonging to a dense area and that would
depend on the intrinsic structure of the dataset. To this end, DBF-
MCL computes simulated DKNN values by using an empirical
randomization procedure. Given a dataset containing n genes and p
samples, a simulated DKNN value is obtained by sampling n
distance values from the gene-gene distance matrix D and by
extracting the kth-smallest value. This procedure is repeated n times
GEO Datamining with TBrowser
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to obtain a set of simulated DKNN values Si. As shown in Figure S3
(dotted line), the variance of the simulated DKNN values is very low
compare to that observed using the real dataset. Indeed, we can
think of simulated DKNN values as the distances to the kth element
if no structure existed in the associated space. In this case, we would
expect elements to be uniformly spread throughout the space and
the variance of DKNN value to be low. In practice several sets S1..q
are computed and thus several distributions of simulated DKNN
values are obtained. For each observed DKNN value d, a false
discovery rate (FDR) value is estimated by dividing the mean
number of simulated DKNN below d by the number of observed
value below d. The critical value of DKNN is the one for which a
user-defined FDR value (typically 10%) is observed. Given a set of
selected genes, the next issue is to partition them into homogeneous
clusters. This step is achieved through a graph partitioning
procedure. In the created graph, edges are constructed between
two genes (nodes) if one of them belongs to the k nearest neighbor of
the other. Edges are weighted based on the respective coefficient of
correlation (i.e.; similarity) and the graph obtained is partitioned
using the Markov CLustering Algorithm (MCL).
Performances of DBF-MCL on Complex9RN200 dataset
To test the performances of DBF-MCL algorithm we used a
modified version of the complex9 dataset which was used earlier
by Karypis et al. [7]. Since DBF-MCL is designed to handle noisy
datasets, 200% of normally distributed random noise was added to
the original data. The resulting dataset (which will be referred as
Complex9RN200 thereafter, see Figure S4A and S4B) shows some
difficulties for partitioning since it is composed of a noisy
environment in which arbitrary geometric entities with various
spacing have been placed. The two main parameters of DBF-
MCL are k that controls the size of the neighborhood and the
inflation I (range 1.1 to 5) which controls the way the underlying
graph is partitioned. The effect of k on the selection of informative
elements is shown in Figure S5A (Euclidean distance was used for
this dataset). A steep ascending phase and a slow increasing phase
(starting from a k values close to 40) were observed. This confirms
the existence of areas with heterogeneous densities. In fact, the
transition between the two phases reflects the transition from
dense to sparse regions. Indeed, datasets produced with k values
above 40 contain noisy elements (Fig S4C). In contrast, choosing k
values in the ascending phase ensure the achievement of noise-free
datasets. In the case of artificial data, satisfying partitioning results
were obtained with inflation values close to 1.2 (Fig S4D–G)
although in some cases some of the shapes were merged in a
manner that appears to be meaningful (Fig S4E and S4G). We
then compared DBF-MCL to several algorithms commonly used
in microarray analysis. All of them were run multiple times with
various parameters and the best solution was kept. In all cases, the
Euclidean distance was used as a distance measure between
elements. As these algorithms are not well-suited for noisy data,
they were run on the 3,108 points extracted using DBF-MCL
(k = 20). Also it is difficult to compare those algorithms to one
another, some of them obviously failed to identify the shapes.
Indeed, although k-means was run 10 times with random initial
starts (and the right number of centers) it led to a very poor
partitioning result (Fig S4J). Cluster Affinity Search Technique
(CAST, Fig S4K) and Quality Cluster algorithm QT_CLUST (Fig
S4I), gave also poor results as did the Self-Organizing Map (SOM)
(data not shown). Hierarchical clustering was run with single
linkage as arguments and the obtained dendrogram was then split
into 9 clusters (Fig S4H). Patterns were well recognized using this
method but prior knowledge of the number of clusters is a
prerequisite. Thus both DBF-MCL and hierarchical clustering are
able to properly identify complex shapes in a 2D space. The main
benefit of using DBF-MCL resides in its ability to extract relevant
informations from a noisy environment. However, a range of
optimal values for inflation parameter needs to be defined to get
the best results.
Performances of DBF-MCL on GSE1456 dataset
Next, DBF-MCL was tested with microarray data to explore its
effectiveness in finding clusters of co-regulated genes. To this end,
we used the microarray data from Pawitan et al. [13], who studied
gene expression profiles in a large cohort of Swedish patients
affected by breast cancer. This experiment is recorded as GSE1456
in the GEO database. All sample (n= 159) have been hybridized
onto the GPL96 platform (Affymetrix GeneChip Human Genome
U133 Array Set, HG-U133A). The complete dataset (22,283 genes)
was used for analysis. Figure S5B, shows the number of informative
genes obtained with various k values. Again, two phases were
observed suggesting that regions with heterogeneous densities exist
in the GSE1456 dataset. As expected, the transition from dense to
sparse regions was less marked than in the artificial dataset. A k
value of 100 was chosen to allow the extraction of a large part of
data that can be considered as noise-free. This value led to the
selection of 4,470 elements out of the whole dataset (Fig. 1A–B). The
graph partitioning procedure, using default MCL parameters
(I = 2), generated 11 highly homogeneous clusters (Fig. 1C–F). As
with the Complex9RN200 dataset, the results were very consistent
with those obtained using hierarchical clustering although for some
genes the clustering results differed (Fig. 1E). Importantly, partition
results were not very sensitive to inflation values. Indeed, 10 and 12
clusters were observed with I set to 1.5 and 2.5 respectively (data not
shown). All signatures were then submitted to functional enrichment
analysis. A summary of the results is given in Figure 1G. As expected
for a breast cancer dataset, TS were found to be related to (i)
immune response (T-lymphocyte activation, B-lymphocyte activa-
tion and interferon alpha), (ii) primary metabolism (cell cycle,
ribosome biogenesis, nuclear phosphorylation and transcription)
which is probably reminiscent of tumor aggressiveness (iii),
modification of local environment (extracellular matrix and cell
adhesion) which could sign metastasis potential of each sample, (iv)
and estrogen receptor status of breast tumors (estrogen response
pathway). Altogether, these results underline the ability of DBF-
MCL algorithm to find natural gene clusters within a randomly
selected dataset. Indeed, for numerous additional microarray
datasets hierarchical clustering results and DBF-MCL results were
compared. As illustrated in Figure S5B for a representative set of
experiments, setting k to 100 allows in all cases to delete noisy
elements and to select only informative genes in a microarray
dataset. Interestingly, in all cases meaningful partitioning results
were obtained using inflation parameter set to 2.
Systematic extraction of TS
We next applied DBF-MCL algorithm to all experiments
performed on human, mouse and rat Affymetrix microarrays and
available in the GEO database (33 platforms, Supplementary
Table S1 and S2). Only experiments containing more than 10
biological samples were kept for analysis. Overall, this dataset
includes 46,564 biological samples hybridized in the context of
1,484 experiments. Each experiment was analyzed independently
and subjected to TS discovery process (k = 100, FDR=10%, S1..3,
Inflation = 2). As mentioned in the Material and Methods section,
we rank-transformed data from each biological sample to get a
common input for DBF-MCL algorithm and to allow analysis of a
large broad of experiments whose normalization status is
frequently unknown. Furthermore, a distance based on Spear-
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man’s rank correlation coefficient was used for kth-nearest
neighbor computation. This rank-based distance is known to be
clearly more resistant to outlying data points than Pearson-based
distance and thus ensured the selection of genes belonging to
unmistakable clusters. The full pipeline was run on a server
equipped with 6 CPUs and took about 4 days to complete. For the
sake of clarity, only results obtained with GPL96 which is the most
widely used Affymetrix microarray platform will be presented in
this section (311 experiments related to GPL96 were analyzed,
12,752 hybridized samples). On average, 4,341 probes (min= 832,
max= 5,849) per expression matrix were declared as informative
by DBF-MCL suggesting that routinely 20% of the 22,283 probes
measured on the HG-U133A array belong to a natural cluster.
Graph partitioning generated on average 10.8 clusters (min= 2,
max= 29) for each experiment and each cluster contained
approximately 400 probes corresponding in average to 370
distinct gene symbols. Figure 2 shows a summary of these results.
As expected no clear correlation was observed between the
number of selected genes and the number of samples in the
experiments which demonstrates the robustness of the filtering
process. In contrast, a trend to produce more clusters in
experiments containing few samples was observed. This was
notably marked in experiments containing 10 to 15 samples. Such
a bias is classical in data analysis. Indeed, if numerous values (i.e.
samples) are used to estimate the expression profile of a given gene,
outliers will have weak impact on distance calculation and the
gene will be assign to the expected cluster. In contrast, when only
few values are available, each of them has a greater impact on
distance calculation. This results in producing more clusters with
some of them having centers close to one another. This bias is also
presumably amplified by the fact that small sample sets contain
most generally a greater biological diversity compared to large
sample sets as they contain fewer replicates. Overall, our analysis
of GPL96 related experiments gave rise to 3,377 TS. The full
analysis on the 33 Affymetrix platforms produced 18,250 TS
which correspond to 220 millions of expression values. Partitioning
results where manually checked for a large panel of experiments.
Although, results seemed perfectible in few cases, they always
appeared to be rational.
The TBrowser interface
Comprehensive information on samples, experiments, probes
and genes were stored in a mySQL relational database. A flat file
indexed on TS IDs was used to store TS expression data. This
solution was preferred because it turned out to be an excellent
alternative to database for retrieving rapidly expression values for
the selected TS. We next developed TBrowser, a Multitier
architecture system composed of (i) a ‘‘heavy client’’ written in
JAVA (presentation Tier), (ii) a servlet container (logic tier) and (iii)
a back-end database (data tier). The client application allows user
Figure 1. Results obtained with the GSE1456 dataset. DBF-MCL was run with GSE1456 as input (k = 100, FDR= 10%, S1..3, Inflation= 2). (A)
Hierarchical clustering of the GSE1456 dataset. (B) Same as (A) but only informative genes are displayed. (C) The graph constructed with the 4,470
selected genes. (D) The graph after MCL partitioning. Each point is colored according to its associated class. (E) Correspondence between
hierarchical clustering and DBF-MCL results. (F) TS obtained for GSE1456 (G) Functional enrichment associated with these TS.
doi:10.1371/journal.pone.0004001.g001
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to query TBrowser database using six methods: by gene symbols,
by probe IDs, by experiments, by microarray platform, by
ontology terms (annotation) or by TS. Three of them (gene
symbols, probe IDs, and annotation methods) accept a list of
operators that control the way a query is to be processed. One may
take advantage of these operators to create complex queries using
the AND operator (&), the OR operator (|), the NOT operator (!)
or using additional characters such as the quote or parenthesis
(reader may refer to the user guide for additional explanations and
informations). The main window of TBrowser is made of five
panels (Fig. 3). The search panel is the main entry as it is used (i) to
define the search method, (ii) to write the queries, (iii) to launch
database interrogation and (iv) eventually to filter out some of the
TS. Filters can be applied to select species of interest and to
control the sizes (number of samples and number of genes) of the
TS that one wants to analyze. The results area can display two
panels: the list of queries the user launched during his session and
the list of TS that correspond to the currently selected query.
Double-clicking on one (or several) TS send it (them) to the
selected plugin. The information area is used to display various
informations about the selected TS whereas the plugin area is used
to select one of the currently installed plugins. Finally, the plugin
display panel manages the display of the currently selected plugin.
To date, eight plugins have been developed (three of them are
presented in this article). The Heatmap plugin is composed of two
main panels: the heatmap on the left and the annotation panel on
the right (Fig. 3). The Heatmap panel displays a color-coded
image of TS expression values. In this representation, each row
corresponds to a probe and each column to a sample. Additional
informations, such as external links, can be retrieved by single-
click on genes or samples. Functional enrichment informations are
available on the right. The TBCommonGenes plugin was
developed to compare gene composition of several TS and will
be presented in the next section. Finally the TBMap plugin that
can be used to visualize a summary of transcriptional regulation
events observed in a given microarray platform will be presented
in the last paragraph of the results section.
Meta-analysis of public microarray data using TBrowser: a
case study
TBrowser can be used in many biological contexts to point out
relevant experiments and construct robust gene networks. Several
peer-reviewed publications have highlighted the joint regulation of
the estrogen receptor-a (ESR1/ER-a), GATA3 and FOXA1 in
breast cancer cells [14]. Although some of these reports have
associated entry in the GEO database, retrieving neighbors of
GATA3, FOXA1 and ESR1 remains a time consuming and
difficult task using existing tools. As a consequence, these
informations are reserved to those with strong bioinformatics skills
although they are of primary interest to the biologist. Using the
TBrowser search engine, this task can be translated into a very
simple Boolean query, ‘‘ESR1 & GATA3 & FOXA1’’, which will
Figure 2. Large scale TS extraction from GPL96 experiments. DBF-MCL was run with default parameters (k = 100, FDR=10%, S1..3,
Inflation= 2). X axis corresponds to the number of samples in the experiment and Y axis to the number of informative genes. For each experiment,
the number of associated TS is represented by the size of the dot. For clarity purpose only experiments with less than 100 samples are represented.
Furthermore, the name of only some of them is displayed.
doi:10.1371/journal.pone.0004001.g002
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be almost instantaneously proceeded by the server. With the
current database release, this produces a list of 16 TS (see Table 1)
containing on average 508 probes (range: 82–1,572) and which
were obtained using various microarray platforms (GPL96,
GPL570, GPL91). Interestingly, all these TS are related to
experiments performed on breast cancer cells underlying the high
specificity of this gene list (Table 1). The TBCommonGenes plugin
indicates that in addition to ESR1, GATA3 and FOXA1 two
genes (ANXA9 and ERBB4) are found in all 16 TS. Importantly,
63 genes are found in at least 10 out of the 16 selected TS (63%).
As expected, this list contains numerous markers of breast cancer
cells whose expression specificity was previously reported by other
(notably ERBB3, XBP1, KRT18, IL6ST, CREB1, TFF1, TFF3;
see Supplementary Table S3). Thus TBrowser can be used to
perform meta-analysis of microarray data in a platform-indepen-
dent manner providing high confidence gene lists. However, one
can also focus the analysis on a unique platform. Indeed, the
transcriptional signatures 3DE64836D, B79B1C0B9 and
E2E620F40 that were derived from the GPL570 platform (which
measures over 47,000 transcripts) share a list of 68 genes. Many of
them correspond to poorly characterized genes (for example,
C17orf28 C1orf64, KIAA1370, KIAA1467, LOC143381,
LOC400451, LOC92497 and ZNF703). This example clearly
demonstrates the superiority of TBrowser over conventional
approaches as it can be used, easily and productively, to create
robust sets of transcriptionally related genes whose subsequent
analysis may be crucial in defining new therapeutic targets.
Using annotation terms to mine public microarray data
Based on the systematic functional enrichment analysis, the vast
majority of TS (84%) have a set of associated biological terms (only
functional enrichment with q-value,0.01 are stored in the
database). One can search for TS related to functional terms of
the DAVID knowledgebase (e.g. ‘‘nervous system development’’).
More interestingly, multiple terms can be combined with Boolean
operators. Searching for TS which contain genes located in the
6p21.3 and 14q32.33 chromosomal regions (major histocompat-
ibility complex and human immunoglobulin heavy-chain locus
respectively) and which contain T-cell specific genes, can be
translated as: 6p21.3[4] & 14q32.33[4] & ‘‘T CELL ACTIVA-
TION’’[5,12] ([4] = cytoband term, [5] =GO term, [12] = Pan-
ther pathways term). As chromosomal aberrations do occur
frequently in cancer our approach can also be used to perform
systematic cytogenetic analysis. Indeed, throughout our analysis,
2,208 functional enrichments related to 360 human cytobands
were observed and stored in the database. As an example, TS with
very strong enrichment (q-value,1.10220) for any of the human
cytobands stored in the database are presented in Table 2. The
first one is related to atopic dermatis analysis (skin biopsies) and
contained 24% of genes located in 17q12-q21. They correspond to
genes encoding for the keratin and keratin-associated protein
families (KRT17, KRT27, KRTAP1-5, KRTAP17-1, KRTAP3-
1, KRTAP3-3, KRTAP4-10, KRTAP4-12, KRTAP4-13,
KRTAP4-15, KRTAP4-2, KRTAP4-3, KRTAP4-5, KRTAP4-
8, KRTAP4-9, KRTAP9-2, KRTAP9-3, KRTAP9-4 and
Figure 3. The TBrowser 2.0 interface. The main window of TBrowser is made of five panels (highlighted in red): the search panel (1), the results
panel (2), the information panel (3), the plugins panel (4) and the plugin display panel (5). This example shows the expression profiles of genes
contained in the TS CBE3881EB derived from GSE469 (‘‘Temporal profiling in muscle regeneration’’). Annotation panel shows that this TS is highly
enriched in genes related to ATP synthesis.
doi:10.1371/journal.pone.0004001.g003
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KRTAP9-8). This signature is notably annotated as being
enriched in genes related to PMID 11279113 (‘‘Characterization
of a cluster of human high/ultrahigh sulfur keratin-associated
protein genes embedded in the type I keratin gene domain on
chromosome 17q12-21’’) [15] and in genes related to the PIR
keyword ‘‘multigene family’’. Furthermore, several signatures, of
Table 2 are related to melanoma and six of them were observed in
the GSE7127 experiment [16]. Although data from Table 2 would
deserve further analysis they are most likely related to gain or loss
of genetic material in tumors. Indeed, gain of 8q is frequently
observed in a number of tumor types (including melanoma and
ovarian tumors) and this region is known to contain the c-myc
oncogene at 8q24.21. Interestingly, in several cases, contiguous
cytobands were significantly enriched suggesting a large deletion
or amplification of genetic material in these tumors (TS
60E29DA83 is enriched in genes from 8q13, 8q21.11, 8q22.1,
8q22.3, 8q24.13 and 8q24.3 cytobands). In the same way, loss of
genetic material of the long arm of chromosome 11 occurs in
primary melanoma but is even more frequent in metastatic tumors
(TS A93ED7519 is enriched in genes from 11q21, 11q23.3 and
11q24.2 cytobands). Altogether, these results underline the
versatility of TBrowser and its ability to extract hidden and
meaningful informations from published or unpublished micro-
array data. Indeed, the cytogenetic results presented in Table 2
were not discussed by the authors in the corresponding articles.
A synthetic view of all GPL96 related experiments
The paradigm that genes from a TS share functional
relationships is now widely accepted and constitutes the basis of
transcriptome analysis [17]. However, each of these TS is rather
Table 1. Transcriptional signatures containing Affymetrix probes for ESR1, GATA3 and FOXA1.
TS ID1 Genes2 Probes2 Samples2 Sample type GSE ID GPL ID Author PubMed IDs
0F2635383 1190 1572 23 Cell lines GSE6569 GPL96 Huang F et al 2007 17332353
3DE64836D 102 143 62 Tissue GSE7904 GPL570 unpublished 2007 -
59A18E225 690 893 121 Both GSE2603 GPL96 Minn AJ et al 2005 16049480
6C975B20B 88 96 26 Tissue GSE6772 GPL96 Klein A et al 2007 17410534
6C975B290 88 96 26 Tissue GSE6596 GPL96 Klein A et al 2007 17410534
7150E17F6 868 1032 34 Cell lines GSE4668 GPL96 Coser KR et al 2003 14610279
8059848B4 200 250 251 Tissue GSE3494 GPL96 Miller LD et al 2005 16141321
84E5E1077 694 883 198 Tissue GSE7390 GPL96 Desmedt C et al 2007 17545524
8F69864F9 68 82 95 Tissue GSE5847 GPL96 Boersma BJ et al 2007 17999412
A151D5695 297 361 58 Tissue GSE5327 GPL96 Minn AJ et al 2007 17420468
B79B1C0B9 270 380 47 Tissue GSE3744 GPL570 Richardson AL et al 2006 16473279
BDB6D8700 550 679 104 Tissue GSE3726 GPL96 Chowdary D et al 2006 16436632
D8F0B528C 125 152 159 Tissue GSE1456 GPL96 Pawitan Y et al 2005 16280042
E2E620F40 448 616 129 Tissue GSE5460 GPL570 unpublished 2007 -
EA9669A21 219 251 158 Tissue GSE3143 GPL91 Bild AH et al 2006 16273092
F310ACC36 519 646 49 Tissue GSE1561 GPL96 Farmer P et al 2005 15897907
1Transcriptional signature ID.
2Total number.
doi:10.1371/journal.pone.0004001.t001
Table 2. Transcriptionnal signatures displaying high enrichment (q value,1.10220 ) for any of the human cytoband tested.
TS ID1 Enrich.2 Cytoband q.value Sample type GSE ID GPL ID Authors PubMed ID
3DA3C8345 24% 17q12-q21 1.7.10239 Skin GSE5667 GPL97 Plager DA et al 2007 17181634
43CC3EF57 9% 8q24.3 7.0.10232 Melanoma GSE7153 GPL570 Unpublished 2007 -
60E29DA83 16% 8q24.3 6.8.10224 Melanoma GSE7127 GPL570 Johansson P et al 2007 17516929
60E581184 26% 17q25.1 5.5.10223 Melanoma GSE7127 GPL570 Johansson P et al 2007 17516929
60E6B4129 35% 20p13 1.6.10226 Melanoma GSE7127 GPL570 Johansson P et al 2007 17516929
60E96FF1E 28% 6p21.3 1.2.10228 Melanoma GSE7127 GPL570 Johansson P et al 2007 17516929
60EC95F6A 17% 7q22.1 6.3.10231 Melanoma GSE7127 GPL570 Johansson P et al 2007 17516929
60EEBD669 32% 11q23.3 1.4.10226 Melanoma GSE7127 GPL570 Johansson P et al 2007 17516929
B4C95CF18 42% 8q24.3 1.1.10236 Ovary GSE6008 GPL96 Hendrix ND et al 2006 16452189
A93ED6519 16% 11q23.3 6.9.10223 Melanoma GSE7152 GPL570 Packer LM et al 2007 17450523
A93DB01ED 11% 7q22.1 9.5.10230 Melanoma GSE7152 GPL570 Packer LM et al 2007 17450523
1Transcriptional signature ID.
2Enrichment: Proportion of non redondant genes from the TS that are located in the corresponding cytoband.
doi:10.1371/journal.pone.0004001.t002
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associated to multiple underlying pathways whose components
and limits are unclear. Our difficulty in depicting comprehensive
maps for pathways is illustrated by existing discrepancies, for
instance, between those proposed by BioCarta, KEGG and
GeneMAPP. We reasoned that the more frequently two genes fall
in the same TS, the more likely these genes belong to the same
core functional network. To test this hypothesis, we produced a
Boolean matrix with 22,215 probes from GPL96 platform as rows
and 3,114 GPL96 specific TS as columns (only TS containing 30
to 1500 probes were included). This matrix was filled with zero
and elements were set to 1 if a given gene was observed in the
corresponding TS. Hierarchical clustering with uncentered
Pearson’s correlation coefficient was used to reveal genes
frequently associated to the same TS. Given the order of the
resulting matrix, it could not be visualized on a desktop computer
using conventional software (i.e.; Treeview, MeV). We thus
developed the TBMap plugin which allows one to visualize the
map but also to superimpose a user-defined or a KEGG-related
gene list. As expected, most of the clusters where obviously
enriched in genes involved in similar biological processes (Protein
biosynthesis/Ribosome function, oxidative phosphorylation, cell
cycle, fatty acid metabolism, valine leucine and isoleucine
degradation, extracellular matrix, breast cancer cells, structural
constituent of muscles, neuronal processes, etc.). This was
particularly clear when KEGG pathway informations were
superimposed (see Figure S6). The Figure 4 presents some of the
clusters that were identified as related to immune system functions.
We could find a signature defining T cells that contained
numerous cell-surface markers (e.g. TCA@, CD2, CD3G, CD6,
IL2RB, IL2RG, IL7R, IL21R and ICOS), signaling genes
(ZAP70, LAT, LCK, ITK) and cytotoxicity-related genes (GZMA,
GZMB, GZMH, GZMK and PRF1). Concerning B-cells, three
clusters were observed. A large signature contains mature B-cell
markers (CD19, CD22, CD72 and CD79B) and transcription
factors important in B-cell development such as PAX5 and
TCL1A. A second signature contains POU2AF1/OBF-1, together
with its described targets: genes coding for immunoglobulin
(IGHG1, IGHG3, IGHA1, IGHM, IGJ, IGKC and IGL) and the
B-cell maturation factor, TNFRSF17/BCMA [18,19]. The third
B-cell signature contains cell surface markers found in immature
B-cells (CD24, VPREB1, IGLL1/CD179B and CR2/CD21) in
addition to transcription factors known to play a crucial role
during early B-cell development (TCF3, SPIB and CUTL1). The
NK signature contains eight genes of the Killer cell immunoglob-
ulin-like receptors (KIR) family, 3 genes of the killer cell lectin-like
receptor family in addition to other markers whose expression has
Figure 4. The transcriptional MAP associated with GPL96 related experiments. (A) A low resolution image made of 22,215 probes from
GPL96 platform as rows and 3,114 GPL96 specific TS as columns. Red color indicates the presence of a gene in the corresponding TS (default to black).
(B) Zooms of the corresponding areas showing some immune system related meta-signatures. (C) Representative genes that fall into these clusters.
doi:10.1371/journal.pone.0004001.g004
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been reported on the surface of NK cells (CD160, CD244/2B4
and CD226) [20,21,22]. It also contains TBX21/T-bet together
with IL18R1, IL18RAP, IL12RB2 and IFNG. Importantly, the
IL12/IL18 combination has been shown to be potent inducers of
both TBX21/T-bet and IFNG in NK cells[23,24]. In addition to
MHC-Class I, MHC-Class II and macrophage related signatures,
two pathways related to immune function are presented in
Figure 4. The AP1 pathway is made of the prototypical immediate
early genes and contains numerous transcription factors (EGR1,
EGR2, FOS, FOSB, IER2, JUN, JUNB, KLF6, KLF4, KLF10,
ATF3, BTG2 and BTG3) whose complex interplay has been
reported earlier. Finally, a NFKB signature was also observed
which, again, contains prototypical regulators (NFKIA, NFKIE,
RELB, BCL-3 and MAP3K8/TPL2) and known targets (CCL20,
CXCL3, IL1B, IL8 and SOD2). Altogether, these results
underline the high relevance of the signatures obtained using this
compilation of TS derived from GPL96 related GEO experiments.
Discussion
In the present paper, we present the construction of a unique
collection of TS that summarize almost all human, mouse and rat
Affymetrix microarray data stored in the GEO database.
TBrowser constitutes a highly powerful search engine that makes
it possible to perform easily platform independent meta-analysis of
microarray data. This can be considered as a real improvement
over classical approaches and softwares as it provides easy and
productive access to data without the need of any programming
skills. Indeed the simple use of an extended set of operators proved
to be sufficient to construct robust gene networks and assign poorly
characterized genes to relevant biological pathways. As a
consequence, it is particularly well suited to compare results
obtained through microarray, ChIP-on-chip, ChIP-seq, CGH or
protein-protein interaction experiments to those previously stored
in the GEO database.
In all tested experiments, we found that DBF-MCL gives very
good results both on simulated datasets and real microarray
datasets. Although Lattimore et al proposed another MCL-based
algorithm (geneMCL) we were unable to compare our results with
their implementation as the software is no longer available nor
maintained. However, DBF-MCL was run on the full van’t Veer
DataSet [25] (117 biological samples) that was used by Lattimore
and collaborators in the original paper. In their report, the authors
used a subset of genes (5,730 out of 24,482) that were selected
based on their associated variance. Our procedure run on the full
dataset led to the selection of 5,932 genes that fall into 22 clusters
(in contrast to 154 clusters using geneMCL). This discrepancy is
likely to be due to the filtering step applied to the dataset. Indeed,
a strong associated variance can also be reminiscent of punctual
random artifacts. Thus, selecting those genes will generate small or
singleton clusters. In this context, the MDNN statistic better
handle these artifacts as its purpose is to conserve genes that
belong to dense region in the hyperspace.
To date, TBrowser provides user with only one partitioning
solution for a dataset. However as density is heterogeneous inside a
dataset, several partitioning solutions exist. For instance, if one
observes a cluster containing cells of the immune system this will
also frequently contain several sub-clusters that will be reminiscent
of cell types (B- or T-cells for example) or activation status.
Increasing MCL granularity (‘‘Inflation’’ parameter) will most
generally split the parent clusters and provided user with another
partitioning result. However, both results can be considered as
optimal and we should consider all of them. To this end we plan to
propose multiple partitioning solutions for each dataset to provide
a more exhaustive view of underlying biological pathways.
Although, such an approach could appear computer-intensive it
should be practicable, taking into account that DBF-MCL is much
faster than hierarchical clustering or MCL run on a whole dataset.
In addition, although we routinely obtained very relevant results
with DBF-MCL, we expect that even more accurate methods will
be proposed in the future.
The present work focus on human, mouse and rat Affymetrix
microarray data but TBrowser can handle any type of microarrays
and organism. The current release of the database already
contains data obtained using other commercial (e.g. Agilent,
Illumina Inc., GE Healthcare, Applied Biosystems, Panomics,
CapitalBio Corporation, TeleChem ArrayIt, Mergen-LTD, Ep-
pendorf Array Technologies) and non commercial platforms (e.g.
National Cancer Institute, Vanderbilt Microarray Shared Re-
source, Genome Institute of Singapore), several of them being
related to the MicroArray Quality Control (MAQC) project
(GSE5350) [26]. However, to date, systematic analysis of all
experiments performed on these platforms has not been done. The
flexibility of our approach also makes it possible to integrate and
compare data obtained through any kind of large scale analysis
technologies providing that the experiment can be represented by
a single numerical matrix (ChIP-on-chip, Protein array, large scale
Real-time PCR, ChIP-seq, etc.). Three plugins (Heatmap,
TBCommonGenes and TBMap) have been presented in this
article but seven new plugins have been recently developed
(manuscript in preparation). In the near future, the ease of plugin
development will makes it possible to look for TS enriched in
genes sharing transcription factor and miRNA specific motifs in
their non-coding regions.
As raw data are only available for some of the microarray
datasets, we used the ‘‘normalized’’ data provided by submitters.
These data were subsequently rank-transformed and used for
classification. This procedure allowed us to re-analyze a very large
number of datasets. However, the drawback is that quality status
of individual samples or experiments could not be determined
(computing the so-called ‘‘39/59 ratio’’ requires raw data). We plan
to provide extensive quality control informations through a
dedicated plugin. However, we think that scientists should comply
better with the MIAME guidelines and that they should provide
systematically raw data when submitting a new experiment.
Finally, we would like to acknowledge the GEO database team
whose efforts in providing high quality repository service made this
work possible.
Materials and Methods
Microarray data retrieval
Human mouse and rat microarray data derived from 30
Affymetrix microarray platforms (Supplementary Table S1) were
downloaded from the GEO ftp site and retrieved in seriesMatrix file
format (ftp://ftp.ncbi.nih.gov/pub/geo/DATA/SeriesMatrix/).
SeriesMatrix are summary text files related to a GEO series
Experiment (GSE) that include sample and experiment metadata
together with a tab-delimited matrix that corresponds to normalized
expression data. Each file (n= 2,869) was parsed using a Perl script
to extract gene expression matrix and metadata. Probes with
missing expression values were excluded from analysis. Only
expression matrix with at least ten columns/samples were kept for
subsequent analysis (n= 1,484, Supplementary Table S2).
DBF-MCL algorithm
The filtering step of DBF-MCL was implemented in C. The
latest Markov Clustering algorithm version (1.006, 06-058) was
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obtained from http://micans.org/mcl/src/. The full pipeline of
DBF-MCL (that integrates normalization, filtering and partition-
ing) was implemented in Bash Shell Scripting language. This script
supports different metrics for distance calculation (Euclidean
distance, Pearson’s correlation coefficient-based distance, Spear-
man’s rank correlation-based distance).
Data normalization and processing
Given the huge amount of data processed by GEO curators it is
impractical to determine the quality and efficiency of the
normalization methods used [27]. Although seriesMatrix files
should ideally contain log-transformed data, expression matrices in
linear scale were also observed in several cases. To circumvent this
problem each column of the expression matrix was rank-transform
(using R software). This normalization procedure is insensitive to
data distribution and provided us with a standard input for the
DBF-MCL algorithm. In the case of microarray data, DBF-MCL
was run using Spearman’s rank correlation-based distance (1-r).
However, although rank-based methods are well suited for
normalization and distance calculation purposes they are not
appropriate to display gene expression profiles. To this end, a
normal score transformation was applied to each column of the
datasets after DBF-MCL classification. The transformation
ensures that whatever the data a standard format is available for
heatmap visualization. Finally, for each experiment, this dataset
was used (1) to classify samples using hierarchical clustering (2) to
build the expression matrix for the corresponding TS.
Data storage
Expression matrix for each TS were stored in an indexed flat file
with a TS ID as a key. This flat file is used by the TBrowser client
to retrieve expression data for the requested TS. Experiment
metadata, corresponding to sample and experiment informations
were stored in a mySQL relational database. Probe meta-
information (gene symbol, gene name, GenBank accession ID,
chromosomal location, Entrez ID) were obtained from Biocon-
ductor [28] annotation packages and stored in the database. In
some cases, as no annotation packages were available (especially
for GeneChipH CustomExpressH Array) a script was used to
obtain gene symbols and gene names from GenBank files based on
the provided GenBank accession ID. Both flat file and database
information will be periodically updated to give access to novel
experiments stored in GEO repository.
Complex9 dataset
The complexe9 dataset was obtained from the UH Data Mining
and Machine Learning Group (UH-DMML, http://www2.cs.uh.
edu/,ml_kdd/). Cluster Affinity Search Technique (CAST) was
run using the TMEV software. QT_CLUST and k-means were
run using the flexclust and fpc R package. For k-means, the
algorithm was run 10 times with random initial centers.
Hierarchical clustering was performed using the amap library
from the R/Bioconductor project. The Euclidean distance was
used in all cases.
Functional enrichment analysis
We used the DAVID knowledgebase [12] for functional
enrichment analysis as it provided a practical mean to gain access
to a wide range of heterogeneous sources of gene annotation
(152,543 annotation terms were used for human, 105,207 for
mouse and 39,787 for rat). DAVID ID mapping was obtained for
218,727 AffyID. A Perl script that integrates call to the R software
was run to load probe list and calculate iteratively Fisher’s exact
test p-values on 262 contingency tables. Bonferroni adjusted p-
values were calculated using the multtest Bioconductor library for
all TS. Overall, 5.106 Fisher’s exact test were performed.
User interface
TBrowser is accessible through a web browser at TAGC web
site (http://tagc.univ-mrs.fr/tbrowser/). Of note, the TBrowser
client is extensible through a plug-in architecture that allows rapid
development of additional features. A developer’s guide will be
available soon on our website.
Supporting Information
Figure S1 A schematic overview of the pipeline used in
TBrowser.
Found at: doi:10.1371/journal.pone.0004001.s001 (10.16 MB
TIF)
Figure S2 An illustration in two dimensions of the motivation
behind DBF-MCL filtering step. Arrows point out the 20th nearest
neighbor for selected points. Length of each segment corresponds
to a given DKNN value.
Found at: doi:10.1371/journal.pone.0004001.s002 (8.22 MB TIF)
Figure S3 Distributions of DKNN values. Observed DKNN
values (solid line) and of a set of simulated DKNN values S (dotted
line) are shown for (A) the Complex9RN200 artificial dataset and
(B) the GSE1456 microarray dataset.
Found at: doi:10.1371/journal.pone.0004001.s003 (9.01 MB TIF)
Figure S4 Colors correspond to the clusters found using the
corresponding algorithm (A) The whole dataset (9,112 points). (B)
A zoom-in of Complex9RN200 dataset that displays the various
shapes to be found. (C) DBF filtering step without partitioning.
With k set to 60, noisy elements remain around the shapes. (D–G)
The filtering and partitioning results obtained using DBF-MCL
run with a range of k values and I values. Other arguments are
unchanged (FDR=10%, S1..3). The set of points (n = 3,108)
obtained using DBF-MCL (k = 20) was used to test the other
algorithms (H) Results obtained with hierarchical clustering (single
linkage). The obtained dendrogram was cut to produce 9 clusters.
(I) Results obtained with the QT_CLUST algorithm (radius = 0.8).
(J) Results obtained for k-means (9 centers, 100 initializations). (K)
Results obtained with cst(threshold = 0.81).
Found at: doi:10.1371/journal.pone.0004001.s004 (9.41 MB TIF)
Figure S5 Impact of various k values on DBF-MCL results. The
x-axis correspond to k values. The y-axis correspond to the
number of elements considered as informative. (A) DBF-MCL was
run with the Complex9RN200 as input using a range of k values
(FDR=10%, S1..3, Inflation = 1.2). (B) DBF-MCL was run with
several microarray datasets as input (including GSE1456) using a
range of k values (FDR=10%, S1..3, Inflation = 2).
Found at: doi:10.1371/journal.pone.0004001.s005 (8.72 MB TIF)
Figure S6 The TBMap plugin. These pictures are derived from
the GPL96 map (22,215 probes as rows and 3,114 GPL96 specific
TS as columns). Red indicates the presence of a gene in the
corresponding TS (default to black). Only small parts of the map
are displayed. (A) A cluster enriched in genes from the
‘‘Aminoacyl-tRNA biosynthesis’’ KEGG pathway (hsa00970).
Genes (rows) from this KEGG pathway are displayed as blue
lines (CARS, SARS, AARS, GARS, MARS, IARS, YARS).
Genes from a manually entered gene list are shown in yellow
(TRIB3, MOCOS, MPZL1, CBS, PPCDC). (B) A cluster enriched
in genes related to oxydative phosphorylation (KEGG pathway
hsa00190, ‘‘Oxidative phosphorylation’’). (C) A cluster containing
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genes related to ribosome biogenesis (KEGG pathway hsa03010
‘‘Ribosome’’). (D) A cluster enriched in genes involved in cell
proliferation (KEGG pathway hsa04110 ‘‘Cell cycle’’).
Found at: doi:10.1371/journal.pone.0004001.s006 (9.66 MB TIF)
Table S1 Informations related to Affymetrix platforms (n= 33)
used in the present work.
Found at: doi:10.1371/journal.pone.0004001.s007 (0.12 MB
XLS)
Table S2 Informations related to experiments (n = 1,484) that
were analyzed using the DBF-MCL algorithm. All Informations
were obtained from the GEO website.
Found at: doi:10.1371/journal.pone.0004001.s008 (1.38 MB
XLS)
Table S3 This matrix summarizes the results obtained using the
‘‘ESR1 & GATA3 & FOXA1’’ query. Rows correspond to genes
and columns to TS. The presence of a given gene in a given TS is
indicated by 1 (default 0).
Found at: doi:10.1371/journal.pone.0004001.s009 (0.66 MB
XLS)
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GPL91 12651
GPL92 12620
GPL93 12646
GPL570 54681
GPL571 22277
GPL80 7129
GPL97 22645
GPL98 8934
GPL99 8924
GPL94 12644
GPL95 12639
GPL201 8793
GPL101 8928
GPL100 17856
GPL96 22283
GPL3921 22277
GPL75 6584
GPL32 12654
GPL339 22690
GPL340 22575
GPL76 6595
GPL1261 45101
GPL5722 4019
GPL83 11934
GPL82 12477
GPL81 12488
GPL1355 31099
GPL342 15333
GPL85 8799
GPL341 15923
GPL88 1322
GPL86 8791
GPL87 8789
Plateform ID Plateform Manufacturer Organism Number of Probes Title
Affymetrix Homo sapiens Affymetrix GeneChip Human Genome U95 Version [1 or 2] Set HG-U95A
Affymetrix Homo sapiens Affymetrix GeneChip Human Genome U95 Set HG-U95B
Affymetrix Homo sapiens Affymetrix GeneChip Human Genome U95 Set HG-U95C
Affymetrix Homo sapiens Affymetrix GeneChip Human Genome U133 Plus 2.0 Array
Affymetrix Homo sapiens Affymetrix GeneChip Human Genome U133A 2.0 Array
Affymetrix Homo sapiens Affymetrix GeneChip Human Full Length Array HuGeneFL
Affymetrix Homo sapiens Affymetrix GeneChip Human Genome U133 Array Set HG-U133B
Affymetrix Homo sapiens Affymetrix GeneChip Human 35K SubA Array Hu35k-A
Affymetrix Homo sapiens Affymetrix GeneChip Human 35K SubB Array Hu35k-B
Affymetrix Homo sapiens Affymetrix GeneChip Human Genome U95 Set HG-U95D
Affymetrix Homo sapiens Affymetrix GeneChip Human Genome U95 Set HG-U95E
Affymetrix Homo sapiens Affymetrix GeneChip Human HG-Focus Target Array
Affymetrix Homo sapiens Affymetrix GeneChip Human 35K SubD Array Hu35k-D
Affymetrix Homo sapiens Affymetrix GeneChip Human 35K SubC Array Hu35k-C
Affymetrix Homo sapiens Affymetrix GeneChip Human Genome U133 Array Set HG-U133A
Affymetrix Homo sapiens Affymetrix GeneChip HT-HG_U133A Array
Affymetrix Mus musculus Affymetrix GeneChip Murine 11K SubA Array Mu11K-A
Affymetrix Mus musculus Affymetrix GeneChip Murine Genome U74A Version 1
Affymetrix Mus musculus Affymetrix GeneChip Mouse Expression Array 430A and Mouse Genome 430A 2.0 Array
Affymetrix Mus musculus Affymetrix GeneChip Mouse Expression Array 430B
Affymetrix Mus musculus Affymetrix GeneChip Murine 11K SubB Array Mu11K-B
Affymetrix Mus musculus Affymetrix GeneChip Mouse Genome 430 2.0 Array
Affymetrix Mus musculus Affymetrix Mus musculus 4K chromosome 11 and 16 CustomExpress Array
Affymetrix Mus musculus Affymetrix GeneChip Murine Genome U74 Version 2 Set MG-U74C
Affymetrix Mus musculus Affymetrix GeneChip Murine Genome U74 Version 2 Set MG-U74B
Affymetrix Mus musculus Affymetrix GeneChip Murine Genome U74 Version 2 Set MG-U74A
Affymetrix Rattus norvegicus Affymetrix GeneChip Rat Genome 230 2.0 Array
Affymetrix Rattus norvegicus Affymetrix GeneChip Rat Expression Set 230 Array RAE230B
Affymetrix Rattus norvegicus Affymetrix GeneChip Rat Genome U34 Array Set RG-U34A
Affymetrix Rattus norvegicus Affymetrix GeneChip Rat Expression Set 230 Array RAE230A
Affymetrix Rattus norvegicus Affymetrix GeneChip Rat Neurobiology U34 Array RN-U34
Affymetrix Rattus norvegicus Affymetrix GeneChip Rat Genome U34 Array Set RG-U34B
Affymetrix Rattus norvegicus Affymetrix GeneChip Rat Genome U34 Array Set RG-U34C
Table S2. 
Informations related to experiments (n = 1,484) that were analyzed using the DBF-MCL algorithm. 
All Informations were obtained from the GEO website.
Ce fichier n'est pas reproduit compte tenu du nombre important de pages qu'il 
représente.
Table S3. 
This matrix summarizes the results obtained using the “ESR1 & GATA3 & FOXA1” query. Rows 
correspond to genes and columns to TS. The presence of a given gene in a given TS is indicated by 
1 (default 0).
Ce fichier n'est pas reproduit compte tenu du nombre important de pages qu'il 
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Gene Expression Profiles Characterize Inflammation Stages in the Acute 
Lung Injury in Mice
Isabelle Lesur, Julien Textoris, Béatrice Loriod, Cécile Courbon, Stéphane Garcia, Marc Leone, Catherine 
Nguyen
PLoS ONE 5(7): e11485
L'atteinte  inflammatoire  aiguë  du  parenchyme  pulmonaire  est  une  complication  grave  de  diverses 
pathologies, notamment infectieuses. Malgré la ventilation mécanique, la mortalité des patients est élevée. La 
distinction entre une atteinte inflammatoire d'origine infectieuse ou non est difficile, d'autant que l'inflammation  
du  parenchyme  pulmonaire  favorise  la  survenue  de  surinfections  et  d'un  syndrome  de  défaillance  multi-
viscérale.
Nous proposons dans cette étude de décrire la modulation du transcriptome pulmonaire en réponse à une 
agression  d'origine  non  infectieuse.  Pour  cela,  nous  avons  mis  au  point  un  modèle  murin  d'agression 
inflammatoire pure du poumon par injection d'acide oléique dans la veine caudale. Les souris ont été sacrifiées 
à différents temps dans les 24 h après l'injection d'acide oléique. Le choix des temps d'analyse est issu d'une 
analyse  préliminaire  de  l'expression  de  certains  marqueurs  pro-  ou  anti-inflammatoires  par  RT-PCR  (pics 
d'expression du TNF, de l'IL4, l'IL6 et l'IL10). L'expression du transcriptome pulmonaire a été analysée par une 
puce cDNA/nylon de 9 900 sondes. Les gènes modulés de manière précoce (1 h – 1 h 30) sont impliqués dans 
la réponse immune pro-inflammatoire. Les gènes modulés entre 3 h et 4 h sont impliqués dans l'adhésion inter-
cellulaire et le remodelage du cytosquelette. Les gènes modulés plus tardivement (18 h – 24 h) révèlent une 
modulation de la transcription, de la synthèse des protéines et du métabolisme des lipides. L'évolution au cours 
du temps de l'expression des cytokines pro- et anti-inflammatoires au sein du parenchyme pulmonaire a été  
confirmée par RT-PCR. 
Ce travail décrit l'évolution de l'expression des gènes au sein du parenchyme pulmonaire dans les 24 h qui 
suivent une agression inflammatoire. Ces résultats préliminaires posent les bases de l'analyse du transcriptome 
pulmonaire lors d'une inflammation d'origine infectieuse ou non. Cette étude est suivie d'une seconde analyse 
réalisée à partir des prélèvements sanguins et analysant la réponse des cellules mononuclées dans le même 
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modèle d'injection d'acide oléique. Plusieurs voies métaboliques sont activées de manière concomitantes dans 
le sang et le poumon (réponse immune et inflammatoire, perturbation du métabolisme des lipides). D'autres 
comme la réparation de l'ADN ou l'autophagie ne sont activées que dans le sang. Enfin, les gènes impliqués 
dans le contrôle de la transcription sont activés plus précocement dans le sang que dans le poumon. Ces  
résultats montrent que la réponse inflammatoire à l'injection d'acide oléique est partiellement compartimentalisé. 
(Cette étude est en cours de révision (R2) à PlosOne et est présentée en annexe 1).
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Abstract
Acute Lung Injury (ALI) carries about 50 percent mortality and is frequently associated with an infection (sepsis). Life-
support treatment with mechanical ventilation rescues many patients, although superimposed infection or multiple organ
failure can result in death. The outcome of a patient developing sepsis depends on two factors: the infection and the pre-
existing inflammation. In this study, we described each stage of the inflammation process using a transcriptional approach
and an animal model. Female C57BL6/J mice received an intravenous oleic acid injection to induce an acute lung injury
(ALI). Lung expression patterns were analyzed using a 9900 cDNA mouse microarray (MUSV29K). Our gene-expression
analysis revealed marked changes in the immune and inflammatory response metabolic pathways, notably lipid metabolism
and transcription. The early stage (1 hour–1.5 hours) is characterized by a pro-inflammatory immune response. Later
(3 hours–4 hours), the immune cells migrate into inflamed tissues through interaction with vascular endothelial cells.
Finally, at late stages of lung inflammation (18 hours–24 hours), metabolism is deeply disturbed. Highly expressed pro-
inflammatory cytokines activate transcription of many genes and lipid metabolism. In this study, we described a global
overview of critical events occurring during lung inflammation which is essential to understand infectious pathologies such
as sepsis where inflammation and infection are intertwined. Based on these data, it becomes possible to isolate the impact
of a pathogen at the transcriptional level from the global gene expression modifications resulting from the infection
associated with the inflammation.
Citation: Lesur I, Textoris J, Loriod B, Courbon C, Garcia S, et al. (2010) Gene Expression Profiles Characterize Inflammation Stages in the Acute Lung Injury in
Mice. PLoS ONE 5(7): e11485. doi:10.1371/journal.pone.0011485
Editor: Carol Feghali-Bostwick, University of Pittsburgh, United States of America
Received December 9, 2009; Accepted June 8, 2010; Published July 8, 2010
Copyright:  2010 Lesur et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from Conseil Re´gional Provence Alpes Coˆte d’Azur, Socie´te´ Franc¸aise d’Anesthe´sie et de Re´animation, and le
Ministere de la sante´ (Programme Hospitalier de Recherche Clinique, PHRC 2005). The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: nguyen@tagc.univ-mrs.fr
Introduction
Acute lung injury (ALI) is a diffuse lung injury which is
characterized by a widespread capillary leakage leading to
hypoxemia and low lung compliance. ALI is caused by either a
direct (e.g. pneumonia) or indirect (e.g. pancreatitis) injury of the
lung. Any local (e.g. pneumonia) or systemic inflammation (e.g.
pancreatitis) can lead to a critical alteration of the lung function.
The Acute Respiratory Distress Syndrome (ARDS) is the last stage
of this acute inflammatory process and still carries a high mortality
rate (40–50%) [1]. Sepsis is a major cause of ARDS either by
direct alteration of the lung or indirectly through the Systemic
Inflammatory Response Syndrome (SIRS) associated with severe
sepsis. Inflammation is part of the defense mechanisms of innate
immunity, occurring after tissue injury. At the site of inflamma-
tion, a cascade of mediators such as cytokines initiates activation of
inflammatory cells (early-inflammatory phase). Then, white blood
cells migrate through the wall of blood vessels and infiltrate the
surrounding tissues. ARDS frequently occurs in a context of severe
sepsis in which inflammation and infection interplay. Then, it is
unclear to delineate the pathways related to inflammation or
infection. In sepsis, the production of both pro- and anti-
inflammatory cytokines in sepsis has been widely studied [2].
While pro-inflammatory cytokines are necessary for initiating an
effective inflammatory process against infection, anti-inflammatory
cytokines seem to be a prerequisite for controlling and down-
regulating the inflammatory response leading to a depression of
the immune system of patients [3]. Human immune responses to
sepsis are mediated mainly by the primary pro-inflammatory
cytokines. The timing of cytokine release and the balance between
pro- and anti-inflammatory mediators seems to be associated with
the severity of sepsis [4–5]. An excessive production may induce
deleterious effects [5]. To this purpose, deciphering gene
expression profiles of either infection or inflammation alone seems
crucial.
One way to do so consists on studying transcriptional genes
expression profiles at several inflammation stages (with or without
sepsis). Genome-wide gene expression profiling using microarray
technology has been applied successfully to the study of human
disease pathogenesis. Examples include the discovery of new
cancer subtypes with different prognosis and response to therapies
[6], or new hypotheses of disease pathogenesis in ARDS [7]. Gene
expression analysis by microarray studies of genes clusters that
have similar expression changes over time allows the definition of
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functionally meaningful expression patterns. This approach has
been successfully used to study either ARDS, using either a whole
organ or cultured cells or in severe sepsis studies where
inflammation was associated with infection [8].
In humans with ARDS, time-course studies using blood samples
made it possible to obtain successful results using a transcriptional
approach. Wang et al. studied global gene expression profiling in 8
human blood samples and identified potential candidate genes that
can be used as biomarkers for ARDS [9]. They reported for
instance the role of peptidase inhibitor 3 (Serpina1c/PI3) encoding
Elafin which has antimicrobial and anti-inflammatory activities.
One limitation in using human samples is the heterogeneity of the
samples with patients from different gender, age, injury, ethnic
origin and genetic backgrounds.
Previous transcriptional studies performed to study ARDS used
various experimental techniques, various species and various types
of infection. The common point between these studies is the
sequence of events: first, an infection is associated with an
inflammation and then, samples are studied using a transcriptional
approach. At this point, since gene expression patterns depend on
both inflammation and infection, it is not possible to identify the
impact of either inflammation or infection on gene expression. A
similar infective agent leads to different outcomes depending on
the pre-existent inflammation stage of each patient [4]. For this
reason, we decided to set up a mouse model to study ALI without
any infection. Inflammation induced by intravenous administra-
tion of Oleic Acid (OA) resembles ARDS in many morphological,
histological, and physiological respects [10]. OA-induced ALI is
consistently associated with acute respiratory failure characterized
by hypoxemia and reduced lung compliance due to alveolar
damage, intra-alveolar hemorrhage, and leakage of proteinaceous
fluid into the air space [11]. The progression of OA-induced injury
is much shorter than that of human ARDS. The acute phase of
human ARDS develops over 1–7 days. However, it is also
characterized by extensive damage to the alveolar epithelium,
hemorrhage, and pulmonary edema. Despite some limitations, the
OA-ALI remains a relevant model for investigating the effects of
ALI. Indeed, no other model has been used as extensively to
evaluate the risks and benefits of various treatment strategies
before applying them to patients with ARDS [10].
Our objective was to identify some biologically relevant process
important in ALI by studying the molecular interactions between
OA and inflammation in a mouse model. The modest success of
microarray approaches to identify novel potential therapeutic
targets may be due to a lack of comprehension to how changes in
gene expression occur through time. For this reason, we decided to
investigate lung gene expression patterns in female mice
developing inflammation without any infection using a 9900
cDNA mouse microarray over a 24 hours time-course. By looking
at changes in gene expression over time, we developed a global
strategy to identify novel pathways that could represent novel
targets for therapy.
Results
Outcome of mice and definition of pro- and anti-
inflammatory phases by real-time PCR
Following the injection of OA, we noticed a transitional
prostration of the mice which started 1.5 hours after injection
and lasted for several hours. All mice recovered; the survival rate
was 100% after 24 hours incubation. To evaluate for the
incubation period necessary to induce lung inflammation, we
considered a wide time-course ranging from 1 hour to 24 hours
after OA injection even if previously published studies considered
much shorter incubation times [12–13]. Prior to large-scale gene
expression analysis, we quantified expression level of one pro-
inflammatory cytokine (Tnfa), one cytokine with pro- and anti-
inflammatory activities (Il6), and two anti-inflammatory cytokines
(Il10 and Il4) at 1 hour, 1.5 hours, 3 hours, 4 hours, 18 hours and
24 hours after OA and physiological serum injection (figure 1 A).
Expression levels of Tnfa, Il6, Il10 and Il4 peaked respectively at
1.5 hours, 3 hours, 4 hours and 3 hours-4 hours after OA
injection. Thus, inflammatory response ranged from 60 minutes
to several hours following OA injection. Real-time PCR allowed
us to identify a pro-inflammatory expression peak 1.5 hours after
OA injection (figure 1 B), a transition phase 3 hours to 4 hours
after OA injection (figure 1 C) and an anti-inflammatory phase
4 hours after OA injection (figure 1 D, E).
Identification of the inflammation timing following OA
injection using lung histology
Compared with physiological serum controls, OA induced a
transient increase in histological lung damage 1.5 hours after
injection (figure 2). Histologically, 1.5 hours after OA injection, we
found a neutrophil accumulation in the alveolar wall associated
with edema. Lung histological modifications are thus correlated
with the transcriptional up-regulation of pro-inflammatory
mediators (both by microarray and RT-PCR). These results
strengthened our real-time PCR data. There were no more
histological lung lesions 3 hours after OA injection.
Microarray analysis discriminated between early- and
late-inflammatory stages according to the time-course
after injection
To focus on transcriptional changes associated with the
inflammatory process in lung, we searched for a set of genes that
discriminated between mice at different incubation times. To this
purpose, we used the multi-class SAM procedure [14], and we
applied a false discovery rate of 5% (figure 3 and see
supplementary data file S1). The analysis yielded a set of 1000
genes (see supplementary data file S2). By performing a
hierarchical clustering of the samples (microarrays), we identified
3 clusters (see supplementary data file S3). Samples at 1 hour and
1.5 hours clustered together. The same way, samples at 3 hours
and 4 hours were grouped together. Finally, samples at 18 hours
and 24 hours clustered together with the exception of three
18 hours samples which have been grouped with the 3 hours–
4 hours cluster as an out-group.
We also performed unsupervised hierarchical clustering on the
1000 genes (figure 4). Interestingly, the expression level of numerous
genes was induced specifically either early or late after OA injection
while other genes were specifically up-regulated during the
transition phase between the early- and late-inflammatory stages
(see supplementary data file S4). The Cluster software [15] classified
the 1000 significantly differentially expressed genes into 3 main
clusters. Genes of cluster Early (365 genes) were over-expressed at
early stage of inflammation (1 hour–1.5 hours); their expression
level decreased at 3–4 hours and then these genes were under-
expressed at late time-points (18 hours–24 hours). Genes of the
Intermediate cluster (269 genes) were over-expressed between
1.5 hours and 4 hours compared to the earliest time-point (1 hour)
and the late measurements (18 hours –24 hours), which correspond
to the transition between early- and late-inflammatory responses. At
the latest stage of inflammation, genes from the Late cluster (366
genes) were highly over-expressed. Expression level of these genes
increased at 3 hours to 4 hours after OA injection and reached a
peak at 18 hours–24 hours.
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To analyze functional annotations related to the pulmonary
inflammation, we considered biological process Gene Ontology
(GO) terms, Kegg pathways and the Biocarta database using
DAVID for the 365 genes belonging to the cluster Early, the 269
genes belonging to the cluster Intermediate, and the 366 genes
belonging to the cluster Late.
GO terms related to the «Defense response» (p= 9.961023)
such as «Inflammatory response» (p = 6.961023), ‘‘cytokine
activity’’ (p = 1.161022) and «Immune response» (p= 6.561023)
were strongly represented in cluster Early (table 1). Similarly,
several genes grouped in the cluster Early were found to be
involved in Kegg pathways related to immune responses such as
Figure 2. Histological quantification of lung injury following OA injection. Sections are representative of all animals examined per group. A-
Section of lung 1H30 after OA injection showing interstitial neutrophils (n) and edema (e). There was no significant fibrin formation within the
alveolar spaces – B- Section of lung 3H00 after OA injection showing absence of edema or fibrin. There was no more significant neutrophil infiltrate -
(tb) Terminal bronchiole. (H&E x100, cartridges X400).
doi:10.1371/journal.pone.0011485.g002
Figure 1. Variation of expression of pro-inflammatory and anti-inflammatory cytokines determined by real-time RT-PCR in lung
samples. The X-axis corresponds to the incubation time after OA injection. The Y-axis corresponds to the ratio between the expression level of a
cytokine measured after OA injection and the expression level of this same cytokine measured after the same incubation time following physiological
serum injection. Measurements are normalized using the bactin housekeeping gene. A- Variations of expression level of Tnfa, Il6, Il10 and Il4 across
OA incubation time allowed us to identify pro- and anti-inflammatory phases. B- We identified the pro-inflammatory peak 1H30 after injection of OA
which corresponds to the maximum expression level of Tnfa. C- Il6 which is both a pro- and anti-inflammatory cytokine is highly expressed 3H after
OA injection. D- The expression level of Il10, an anti-inflammatory cytokine is maximal 4H after injection of OA. E- Il4 is highly expressed 3H to 4H after
injection of OA. We observe that the anti-inflammatory response occurs approximately 4H after OA injection and follows the pro-inflammatory
response which occurs approximately 1H30 after OA injection.
doi:10.1371/journal.pone.0011485.g001
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«MAPK signaling pathway» (p = 1.461022). The Functional
Annotation Clustering tool from DAVID grouped these terms in
a single annotation cluster with the best enrichment score (1.36).
Nine genes belonging to the «Hematopoietic cell lineage» pathway
(p = 6.561022) were present in this cluster. As expected in
inflammation response, immune and pro-inflammatory responses
are activated. These results validate our experimental strategy,
particularly the use of OA to induce a reliable inflammation
without any infection.
Most of the genes grouped in the cluster Intermediate were found
to be involved in Kegg pathways related to the immune response,
notably the spreading of immune cells into inflamed tissues through
interaction with vascular endothelial cells, such as «Leukocyte
Transendothelial migration» (p=7.861023) or «Adherens junction»
(p=3.561022) (table 2). This was further supported by the analysis
of Biocarta Pathway, which pointed out several pathways such as
«Adhesion Molecules on Lymphocyte» (p=8.561023) and «Mono-
cyte and its Surface Molecules» (p=1.861022). These pathways
were clustered together by the Functional Annotation Clustering tool
Figure 3. Schematic outline of data analysis. a We compared gene
expression between three groups: 1H-1H30/3H-4H/18H-24H. b HCL:
Hierarchical Clustering. We considered the full dataset (n = 6622 genes)
to identify genes significantly differentially expressed between the
three classes previously described. The 1000 genes identified with SAM
have been clustered using the Cluster software and each cluster was
independently functionally annotated using DAVID.
doi:10.1371/journal.pone.0011485.g003
Figure 4. Hierarchical classification of 1000 significant genes
differentially expressed at early and late stages of inflamma-
tion. This set of genes was extracted from the full dataset (n = 9984) by
use of a SAM procedure and a false discovery rate of 5%. Each row
represents a gene and each column represents a sample. Red and green
indicate expression levels respectively above and below the median.
Dendrogram of genes, to the left of the matrix represents overall
similarities in gene expression profiles. 3 clusters have been identified:
Early, Intermediate and Late.
doi:10.1371/journal.pone.0011485.g004
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Table 1. Functional annotation and enrichment of the 365 genes belonging to cluster Early.
Functional classification
Database Term Count P-Value
Gene Ontology Immune response 23 6.50E-03
Gene Ontology Inflammatory response 14 6.90E-03
Gene Ontology Defense response 18 9.90E-03
Gene Ontology Cytokine activity 13 1.10E-02
Kegg pathway MAPK signaling pathway 16 1.40E-02
Gene Ontology Response to wounding 16 1.90E-02
Gene Ontology Immune system process 30 2.30E-02
Gene Ontology Protein kinase cascade 14 3.10E-02
Gene Ontology Positive regulation of kinase activity 8 3.30E-02
Gene Ontology Chemokine activity 6 5.00E-02
Gene Ontology MAP kinase tyrosine/serine/threonine phosphatase activity 3 5.10E-02
Gene Ontology MAP kinase phosphatase activity 3 5.10E-02
Gene Ontology Chemokine receptor binding 6 5.60E-02
Kegg pathway Hematopoietic cell lineage 9 6.50E-02
Gene Ontology Interleukin-1 receptor binding 3 6.90E-02
Gene Ontology MAPKKK cascade 7 7.40E-02
Annotation Cluster 1 Enrichment score: 1.36
Database Term Count P-Value
Gene ontology Immune response 23 6.50E-03
Gene ontology Inflammatory response 14 6.90E-03
Gene ontology Defense response 18 9.90E-03
Gene ontology Cytokine activity 13 1.10E-02
Gene ontology Response to wounding 16 1.90E-02
Gene ontology Immune system process 30 2.30E-02
Gene ontology Response to external stimulus 19 3.30E-02
Gene ontology Chemokine activity 6 5.00E-02
Gene ontology Chemokine receptor binding 6 5.60E-02
doi:10.1371/journal.pone.0011485.t001
Table 2. Functional annotation and enrichment of the 269 genes belonging to cluster Intermediate.
Functional classification
Database Term Count P-Value
Kegg pathway Leukocyte transendothelial migration 8 7.80E-03
Biocarta Adhesion molecules on lymphocyte 4 8.50E-03
Biocarta Neutrophil and its surface molecules 4 8.50E-03
Biocarta Monocyte and its surface molecules 4 1.80E-02
Kegg pathway Adherens junction 6 3.50E-02
Kegg pathway Hematopoietic cell lineage 7 4.20E-02
Annotation Cluster 1 Enrichment score: 1.16
Database Term Count P-Value
Biocarta Adhesion molecules on lymphocyte 4 8.50E-03
Biocarta Neutrophil and its surface molecules 4 8.50E-03
Biocarta Monocyte and its surface molecules 4 1.80E-02
Gene Ontology Wound healing 5 9.40E-02
doi:10.1371/journal.pone.0011485.t002
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from DAVID in a single cluster with an enrichment score of 1.16. In
addition, 5 genes involved in differentiation of T and B lymphocytes
cells were found to be involved in the «Hematopoietic cell lineage»
pathway (p= 4.261022). Surprisingly, genes involved in the
spreading of inflammation were grouped together. Usually, this
process can not be clearly visualized because of the very short period
of time between activation of the inflammatory and immune and
anti-inflammatory response.
Functional annotation analysis of genes belonging to the cluster
Late showed an over-representation of GO terms related to
transcription, metabolism and in particular lipid metabolism
(figure 5 and supplementary table S1). The Functional Annotation
Clustering tool from DAVID identified 3 groups of genes with the
highest enrichment scores. The first one (enrichment score = 2.07)
showed an over-representation of GO terms related to «Transcrip-
tion» (p=1.461023), such as «Regulation of transcription»
(p=1.161023) or «Regulation of nucleobase, nucleoside, nucleotide
and nucleic acid metabolic process» (p=7.761024). Most of the GO
terms grouped in the second annotation cluster (enrichment
score =1.96) were found to be involved in metabolism, such as
«Metabolic process» (p=2.261023) or «Cellular metabolic process»
(p=2.361023). The third annotation cluster (enrichment score =
1.44) included GO terms related to lipid metabolism such as
«Cholesterol metabolic process» (p=9.361023) or «Cellular lipid
metabolic process» (p=5.261022). Increased expression level of
genes involved in transcription is a consequence of the metabolism
which is highly perturbed. Multiple alterations in lipid and
lipoprotein metabolism have been previously described associated
with infection and inflammation [16]. Here, we observed that
disturbance of genes expression levels related to lipid metabolism is
associated only with inflammation.
We also considered genes of interest for clinical studies such as
Smad7 [17]. In our study, Smad7 belongs to the set of significantly
differentially expressed genes across time and it belongs to cluster
Late. Its expression level increased between 3 hours and 4 hours
after OA injection to reach a maximum expression level 24 hours
after injection. We also considered the angiotensin-converting
enzyme gene (Ace) [18–19]. In our study, Ace expression level did
not significantly change over time. Finally, we considered
transcription of genes involved in surfactant lipid biosynthesis
and surfactant-associated proteins. In a previous study, authors
quantified expression levels of 5 genes involved in the surfactant
lipid biosynthesis and 5 genes involved in the surfactant-associated
protein biosynthesis [20]. Expression levels of these genes
decreased significantly in mice developing ALI. Out of these 10
genes, 4 are present on MUSV29K: Slc34a, Fasn, Sftpd and
Napsa. In our study, Slc34a, involved in surfactant lipid
biosynthesis, is the only gene whose expression level changed
significantly over time. It belongs to the cluster Late and its
expression level increased over time after OA injection to reach a
peak at 24 hours incubation.
Overall, our gene expression analysis revealed marked changes
in pathways involved in the immune and inflammatory responses,
and also lipid metabolism and transcription. First, the pro-
inflammatory phase is activated with high expression level of genes
involved in inflammation and immune response. Then, inflam-
mation is spreading into inflamed tissues. And, later, transcription
is activated and lipid metabolism seems highly disturbed.
Discussion
Data summary
In this study, we have searched for genes and physiological
pathways potentially involved in ALI. To this purpose, we
analyzed differentially expressed genes in lung from C57BL/6J
mice at different stages of inflammation. We found that injection
of OA deeply alters gene expression. In particular, we identified 3
clusters of genes specifically highly expressed either at early time-
points (early-inflammatory stage), at late time-points (late-inflam-
matory stage), or at the time-points when the shift between early-
and late-inflammatory stages occurs. In order to identify genes
whose changes in expression levels are associated with lung
inflammation, we performed a three class SAM procedure with a
stringent false discovery rate of 5%. The procedure was conducted
on the whole dataset. Because the technical procedure may affect
the gene expression level, we adjusted the measurements of mice
treated with OA to that treated with physiological serum. Thus,
we identified 1000 genes differentially expressed between OA mice
and physiological serum mice.
Limits of the OA model
In this study, our first aim was to define a model of lung
inflammation in mouse using OA. Despite its widespread use, the
OA-induced ALI model has not been standardized. One to 2 ml
of OA generates ALI when injected as a single bolus directly into
the pulmonary circulation to an animal weighing 25 Kg [10].
However, both smaller and larger doses have also been used. At
other times, the injection has been given in fractions, after
sonication in saline, after OA dissolution in ethanol, or as
continuous infusion. Each of these variations may alter the severity
or extensiveness of the injury, resulting in different physiopatho-
logic consequences. For example, Zhou et al. determined that an
intravenous dose of 0.15 mL/g body weight OA in mice resulted in
an approximate 24-hour survival rate of 75% [12]. Sixty minutes
after OA injection, they observed severe alveolar damage with the
development of alveolar edema, increased-permeability and
abnormalities in oxygenation. Using doses of OA that were up
to approximately 1.5 times the dose used by Zhou et al., Ulrich
et al. reported similar histopathological findings 1 hour after OA
injection in mice [13]. A dose-related difference in mortality was
observed in animals treated with 0.2 and 0.4 mL/g of OA
administered through the tail vein, respectively. The higher dose
was associated with 100% mortality, 30 to 40 minutes following
OA administration.
Previous studies showed that a time-course ranging from 40 to
90 minutes was required to detect an inflammatory response [12].
The length of the incubation period required to detect a pro-
inflammatory profile (expression levels of pro- and anti-inflamma-
tory cytokine or lung histology) depended on the OA dosage. As
mechanical ventilation induces by itself an inflammation [21], one
can hypothesize that models using mechanical ventilation
increased the inflammatory response. Given the contradictory
results previously published regarding the kinetics of inflammation
in mice, we quantified mRNA levels of pro- and anti-inflammatory
cytokines before performing high-throughput gene expression
analysis. Cytokines play a critical role as signaling molecules that
initiate, amplify, and perpetuate inflammatory responses on a local
and systemic basis.
Timing of inflammation
We quantified expression levels of 4 cytokines 1 hour,
1.5 hours, 3 hours, 4 hours, 18 hours and 24 hours after OA
incubation. Tnfa, Il6, Il10 and Il4 are commonly used to
specifically study pro- and anti-inflammatory phases (figure 1)
[22].
Tnfa is an early response cytokine. It plays an important role in
immunity and inflammation, in the control of cell proliferation,
differentiation and programmed cell death [23]. We found that, in
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Figure 5. Functional annotation enrichment of the 366 genes belonging to cluster Late. Expression levels of genes belonging to cluster
Late increases 3H-4H after OA injection and reach a peak after 18H to 24H incubation. A- Distribution of the 366 genes belonging to Cluster Late into
the 3 main annotation clusters identified by the functional annotation clustering tool from DAVID: Transcription, Metabolic process and Lipid
metabolic process. B- 21 genes in cluster Late belong to the lipid metabolic process. These genes can be assigned to one or several of 7 GO
categories related to Lipid metabolism. Three of them also belong to 3 PIR categories (Protein Information resources) related to lipid metabolism. Red
means the gene belong to the pathway and Blue means that the gene does not belong to the pathway.
doi:10.1371/journal.pone.0011485.g005
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our model without infection, Tnfa is temporarily highly expressed
60 to 90 minutes after OA injection (figure 1 B). This corresponds
to the pro-inflammatory response.
Il6 is produced by a wide range of cells including monocytes/
macrophages, endothelial cells, fibroblasts, and smooth muscle
cells in response to stimulation by endotoxin [24]. Raised levels of
Il6 have been described in a number of acute conditions such as
burns, major surgery and sepsis [25]. Il6 is a ubiquitous cytokine
playing a role on pro- and anti-inflammation. Several experimen-
tal models suggest a protective role for Il6 against inflammation
[26]. Pro-inflammatory effects of Il6 have been shown in several
tumor cell lines [27]. Il6 is also involved in the spreading of pro-
inflammatory cells [28]. In our study, expression level of Il6 is
maximum 3 hours after OA injection, interconnecting the pro-
and anti-inflammatory phases (figure 1 C).
Il10, an anti-inflammatory cytokine [29], inhibits the release of
pro-inflammatory cytokines such as Tnfa from monocytes/
macrophages, thus preventing subsequent tissue damage [30].
The role of Il10 is essential to counter balance the pro-
inflammatory response. In a previous study, Park et al. found a
disproportionate anti-inflammatory response to the early pro-
inflammatory response, which leads to ARDS [31]. In our study,
Il10 expression increased from 3 hours and peaked 4 hours after
OA injection which corresponds to the anti-inflammatory response
to Tnfa (figure 1 D).
Il4 is also an anti-inflammatory cytokine which down-regulates
local levels of pro-inflammatory cytokines and chemokines [32].
We found that its production was simultaneous with Il10
expression peak. This finding confirms the timing of the anti-
inflammatory phase (figure 1 E).
The quantification of expression levels of 4 pro- and anti-
inflammatory cytokines by real-time PCR allowed us to identify
two phases during inflammation. We identified the pro-inflam-
matory phase based on the high expression level of Tnfa 1.5 hours
after OA injection. Later, 3 to 4 hours after OA injection, anti-
inflammatory cytokines Il10 and Il4 are highly expressed.
Meantime, Il6, which has pro- and anti-inflammatory activities,
is highly transcribed 3 hours after OA injection. Given the
contradictory results previously published, this preliminary step
was essential to timely identify pro- and anti-inflammatory phases
in our model and then perform large-scale transcriptional study
considering each phase of inflammation described.
An early inflammatory and immune response
Once our mouse model of lung inflammation settled, we
identified molecular pathways associated with lung injury.
Injection of OA rapidly affects the expression of genes involved
in the defense response such as inflammatory and immune
responses. Expression level of numerous chemokines such as
Cxcl5, Ccl22, Ccl4, Ccl3, Ccl6 or Ccl25 increased rapidly and
allowed recruitment of specific leukocyte subpopulations to sites of
tissue damage (see supplementary data file S4) [33]. The
expression of pro-inflammatory cytokines and chemokines has
been previously observed in transcriptional studies of infection in
model organisms. Calvano et al. showed, in human blood
leukocytes, an over-expression of pro-inflammatory chemokines
2 hours to 4 hours after endotoxin administration [34]. The
activation of cytokines following inflammation has also been
observed in lung by Chinnaiyan et al. in a transcriptional study of
systemic inflammation in a cecal ligation/puncture model of sepsis
in rat [35]. Also, the MAPK signaling pathway, involved in cell
proliferation, differentiation and inflammation is activated (see
supplementary data file S4) (figure 6). Three regulated groups of
MAPK are activated: the extracellular signal-related kinases
(ERK) with genes such as Fgf1, Rasa2, Ras, Dusp1, Mknk1,
Mknk2 or Rps6ka3; the Jun amino-terminal kinases (Mapk8,
Mapk9, Mapk10) with Il1, Map4k1, Pak1, Pak2 and Dusp1; and
the p38 proteins with Il1, Map3k7ip1, Map3k7ip2, Dusp1 and
Map3k6. Il1b is known to participate in ARDS pathogenesis [36].
The MAPK cascade pathways are critical for the transmission of
activated cell surface receptor signals to invoke multiple regulated
intracellular processes. We also noticed over-expression of Il15ra
which blocks Il15, an inhibitor of Tnfa [37]. Activation of
inflammatory and immune responses early after OA injection
validates our inflammation model in mouse [23].
An intermediate spreading of inflammation
The transition phase at 3 hours –4 hours which followed the
pro-inflammatory phase corresponds to the spreading of inflam-
mation. Among genes whose expression level reaches a maximum
at this time-point, we found transmembrane adhesion molecules
(Cd44, Pecam1 and Icam1) as well as endothelial cell adhesion
molecule (CAM) (Cd34, Icam1, Glycam1 and Pecam1) (see
supplementary data file S4) [37–38]. It has been previously shown
that CAM adhesion molecules are strongly involved in the
inflammatory process by modulating the leukocyte trafficking
[38–39]. B and T cell lymphocytes interact with a variety of cells
as part of their immune function allowing inflammatory signals to
circulate between organs. The interaction of lymphocytes with
other cell types like vascular endothelial cells requires transmem-
brane adhesion molecules. Each of these lymphocyte adhesion
molecules interacts with specific ligands expressed on cells like
endothelial cells to moderate adhesion between cells. Cd44 is an
adhesion molecule with several roles, including interaction of
leukocytes with endothelial cells in response to inflammation [40].
Pecam1 mediates the spreading of monocytes and other immune
cells into inflamed tissues through interaction with vascular
endothelial cells [41]. Expression of intercellular adhesion
molecule-1 (Icam1) is increased by inflammatory signals, leading
to higher adhesion and permeation of lymphocytes into inflamed
tissues. Icam1 is an inducible protein expressed on the surface of
endothelial cells. Under physiological conditions, Icam1 is not
constitutively expressed, or is expressed at low levels in most
tissues. In inflammatory states, it has been shown that expression
level of Icam1 is up-regulated by Tnfa [42]. It has been shown that
increased expression of Icam1 protects lung against injury by
neutralizing antibodies or targeted gene deletion during bacterial
sepsis, acute pancreatitis and trauma [43]. As Icam1 deficiency
interferes with neutrophil recruitment, these results support the
concept of a therapeutic strategy directed against neutrophil
migration and activation. During inflammation, leukocytes bind
to endothelial CAM and then migrate across the vascular
endothelium.
There is a clear link between blood and inflammation as blood
carries the inflammation throughout the entire organism. We
found, in cluster Intermediate, 9 genes such as Cd34, Cd44, Il7r,
Csf1 and Cd38 leading to differentiation of blood cells (see
supplementary data file S4). Blood-cell development progresses
from an hematopoietic stem cell which can differentiate into
several lineages such as T lymphocytes, B lymphocytes, NK cells,
erythrocytes or platelets. Cells undergoing this differentiation
process express a stage- and lineage-specific set of surface markers.
Therefore cellular stages are identified by the specific expression
patterns of these genes. Cd34 is an adhesion molecule with a role
in early hematopoiesis by mediating the attachment of stem cells to
the bone marrow extracellular matrix or directly to stromal cells
[44]. Cd44 is involved in lymphocyte activation [40]. Il7r is the
receptor of Il7 which is involved in the regulation of lymphopoi-
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esis. Response of cells to Il7 is dependent on the presence of the
Il7r [45]. Csf1 induces cells of the monocyte/macrophage lineage
[46].
We were able to visualize the spreading of inflammation as
many genes involved in leukocyte transendothelial migration and
CAM clustered together. Spreading of inflammation is part of the
pro-inflammatory response to inflammation. We observed that
high expression level of genes involved in the spreading of
inflammation signal follows the high expression level of genes
involved in inflammation and immune processes. This is probably
due to the fact that vascular endothelium is the target of pro-
inflammatory cytokines. Once the vascular endothelium activated,
genes involved in cell adhesion are expressed and leukocytes are
transferred from circulating blood to the site of inflammation.
A late disruption of lipid metabolism
In our study, we found a late disruption of gene expression level
related to lipid metabolism. Indeed, among numerous genes whose
expression level increases at 3 to 4 hours and reach a peak at
18 hours–24 hours, 21 belong to the lipid metabolic process
(figure 5 and see supplementary data file S4). Previous studies
showed lipid metabolism disturbance soon after inflammation
started. Hardardottir et al. have proposed that the changes in lipid
and lipoprotein metabolism that occur during the host response to
infection/inflammation include anti-infective and anti-inflamma-
tory effects that contribute to the host defense [47]. Infection and
inflammation are accompanied by cytokine-induced alterations in
lipid and lipoprotein metabolism [48]. As expression level of
numerous genes involved in lipid metabolism increased 3 to
4 hours after OA injection and are highly over-expressed 24 hours
after OA injection, we believe that lipid metabolism disruption is
related to the highly transcribed pro-inflammatory cytokines such
as Tnfa and Il1. Indeed, we observed that expression level of Tnfa
is maximum 1.5 hours after OA administration (figure 1 B) and
Il1, which belongs to cluster Early, is highly expressed 1 hour–
1.5 hours after OA administration (figure 4). Il6 is highly
expressed 3 hours after OA injection. Moreover, it has been
previously shown that serum triglyceride levels, serum total
cholesterol and LDL levels increased as a consequence of the
highly transcribed pro-inflammatory cytokines [47,49]. Simulta-
neously, during inflammation, there is a marked decrease in serum
levels of HDL [50]. We do not believe that high expression level of
genes involved in lipid metabolism is a direct consequence of OA
itself. Indeed, even if OA belongs to the fatty acid family, several
studies have shown that late disruption of the lipid metabolism is
associated with inflammation. Worgall, for example, showed that
expression of defective cystic fibrosis transmembrane conductance
regulator (CFTR), the cause for cystic fibrosis, is associated with an
inflammatory state and affects fatty acid and cholesterol
metabolism which is associated, in great majority of patients, with
decreased linoleic acid level and increased myristic, palmitoleic,
stearic and oleic fatty acids levels [51]. Recently, there has been
Figure 6. MAPKinase Signaling Pathway. The 3 major groupings of mitogen-activated protein kinase (MAPkinase) pathways are activated
rapidly after OA injection. Genes belonging to the extracellular signal-related kinases (ERK) (blue), the Jun amino-terminal kinases (pink) and the p38
proteins (green) are up-regulated early after OA injection. These genes are represented in bold.
doi:10.1371/journal.pone.0011485.g006
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much interest in using Statin for sepsis [52]. Statin, which has
lipid-lowering properties, reduce total cholesterol, LDL and
triglyceride levels [53]. These previous works showed that triggers
of inflammation which are not fatty acids led to disruption of lipid
metabolism. Feingold et al. observed that the hypertriglyceridemic
effect of LPS and cytokines is rapid, occurring 2 hours after
administration and is sustained for at least 24 hours [16].
Channaiyan et al. showed, in a transcriptional study of systemic
inflammation in a cecal ligation/puncture model (CLP) of sepsis in
rat, that several genes involved in lipid metabolism are up-
regulated in lung 6H after CLP [35]. In our study, the timing of
the cytokine effect on genes related to lipid metabolism is similar.
We showed here that lipid metabolism disturbance is a
consequence of inflammation.
Most of the changes in genes related to lipid metabolism that are
induced by inflammation are attributable to changes in gene
transcription. The expression level of 189 genes involved in at least
one out of the 25 GO categories belonging to the transcriptional
process are part of the annotation cluster 1 identified by DAVID.
They slowly increased 3 hours to 4 hours after OA injection to
reach a maximum expression level after 18 hours to 24 hours OA
incubation (supplementary table S1). This is probably the
consequence of the high expression level of many pro-inflamma-
tory cytokines identified in cluster Early (figure 5). In the promoter
region of Il6 and Il1, transcription factors Nfkb1 and Cebpb (NF-
IL6) are involved in the expression of many inducible cellular
genes that encode cytokines, immunoregulatory receptors, and
acute phase proteins [50]. Because many genes involved in
regulating immune response and acute phase reaction contain
both Cebpb and Nfkb1 sites, it is highly possible that cooperative
interactions between Cebpb and Nfkb1 play an important role in
the expression of cytokines. For many positive acute phase
proteins, transcription activities of their corresponding genes
increase during inflammation, reaching a maximum level between
18 hours and 36 hours after inducing an acute inflammation [54].
Our results confirm these findings. Indeed, pro- and anti-
inflammatory cytokines highly expressed respectively at early
and late stages of the inflammation process induce the transcrip-
tion of many other genes later after OA injection. Also, Calvano et
al. showed in their microarray study in 2005 that, in human blood
leukocytes, 4 hours to 6 hours after endotoxin injection, the
expression of numerous transcription factors was increased.
Among them, the expression of several members of the nuclear
factor kappa/relA family of transcription factors (Nfkb1, Nfkb2,
Rela, and Relb) reached their zenith [34].
We expected a massive release of inflammatory mediators soon
after OA injection followed by the release of anti-inflammatory
mediators [55]. This sequence of events has been previously
described by authors studying sepsis [56]. The response to
inflammation we observed and which lasted over 24 hours has
been previously described associated with infection [47]. Observ-
ing these responses associated with only inflammation justifies the
need to fully describe gene expression profiles during inflammation
and therefore, it will become possible for other research groups to
identify specific responses to infections during sepsis.
Potential targets for therapy
By looking at how changes in gene expression occur through
time during lung inflammation, we could confirm or invalidate
targets previously identified for therapy.
Among these candidates, Smad7 has been identified [57].
Transient gene transfer and expression of Smad7, introduced by
recombinant human type 5 adenovirus vector into the lungs,
prevented pulmonary fibrosis induced by bleomycin in mice [57].
Smad7 is an intracellular antagonist of Tgfb signaling [57]. It
inhibits Tgfb-induced transcriptional response. Moreover, it is
thought that prolonged overproduction of Tgfb induced by
repeated chemical or biological injury leads to the accumulation
of pathological amounts of extra-cellular matrix in the lung tissue,
which is followed by functional deterioration [17]. We believe
Smad7 is a good candidate for gene therapy because it belongs to
the set of significantly differentially expressed genes across time
and its expression level increased 3 to 4 hours after OA injection
to reach a maximum expression level 24 hours after injection.
We also considered the angiotensin-converting enzyme gene
(Ace) which can predict susceptibility and outcome in ARDS.
Circulating Ace derives largely from the pulmonary endothelium.
Its release in circulation is affected by extensive endothelial
damage [18]. Septic ARDS patients have markedly decreased
serum Ace levels compared to those of non-septic ARDS patients
[19]. In our non-septic model of ALI, Ace expression level did not
significantly change over time.
Finally, we considered transcription of surfactant lipid and
surfactant-associated proteins. During ALI in mice, epithelial cell
injury leads to reduced surfactant biosynthesis. It has been
previously shown that maintenance of surfactant-associated
protein B (Sftpb) transcript levels is necessary for over-expression
of mouse transforming growth factor a (Tgfa) involved in
protection against nikel-induced lung injury [20]. Out of the 10
candidate genes previously identified, 4 are present on
MUSV29K: Slc34a, Fasn, Sftpd and Napsa. In our study, Slc34a,
involved in surfactant lipid biosynthesis, is the only gene whose
expression level changed significantly over time. It belongs to the
cluster Late and its expression level increased over time after OA
injection to reach a peak at 24 hours incubation.
Our wide-scale transcriptional study identified pathways and
specific genes involved in response to inflammation. We found
several potential candidates for gene therapy such as Smad7. Since
there has been great progress in delivering genes to the lungs over
the past decade, gene therapy is expected to become a new tool in
addition to classical approaches for treating inherited and acquired
diseases including ARDS in the near future.
Conclusion
In this study, we pictured gene expression profiles during
inflammation according to the time-course. Overall, our micro-
array analysis gives a global overview of critical events occurring
during lung inflammation. We have first confirmed that gene-
expression profiling discriminates between pro- and anti-inflam-
matory phases during lung inflammation. The analysis of gene
functional annotation reveals several major features. First, it
visualizes at transcription level the pro-inflammatory stage
characterized by the release of immune response and activation
of inflammatory mechanisms. We observed that these pathways
are activated soon after the initiation of lung injury. Then the
Intermediate cluster revealed that the immune cells migrate into
inflamed tissues through interaction with vascular endothelial cells.
Finally, at late stage of the inflammation, metabolism is deeply
disturbed. We also showed here that inflammation is associated
with marked changes in lipid and lipoprotein metabolism
suggesting that lipoproteins seem to participate in innate
immunity.
This inflammation model in mouse is the first step toward the
identification of the molecular mechanisms involved in the
infection process at different steps of inflammation. From now
on, when studying the impact of an infection at the transcriptional
level, we will be able to distinguish between the gene expression
level variations due to the pathogen itself and the ones resulting
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specifically from the inflammation associated with infection. In our
study, by identifying numerous common pathways, we showed
that the inflammation alone which is a component of infection has
to be considered separately from infection.
Furthermore, it is reasonable to think that the impact of a
pathogen on an inflamed organ depends on the pre-existing
inflammation. Inoculation of an infectious agent has to take into
account timing of the pre-existing inflammation (pro- or anti-
inflammatory stage). We reached our first objective of character-
izing inflammation across a time-course. Next, we will induce an
infection in mouse undergoing inflammation at different time-points
(pro- vs. anti- inflammatory phases) using group B streptococcus.
Materials and Methods
Experimental groups
Wild-type female C57Bl/6J mice, 7 weeks old, were obtained
from Charles River and housed in a specific pathogen-free animal
facility. We studied 35 mice divided into 6 groups (figure 7). Each
group included one or two mice administered with physiological
serum and 3 to 7 mice administered with OA, which correspond to
biological replicates. Each group was identified according to the
incubation time: 1 hour, 1.5 hours, 3 hours, 4 hours, 18 hours
and 24 hours. All experimental procedures involving animals were
approved by the veterinary office of the Ministry of Agriculture,
France (authorization number: 13–27).
Injections
Female C57Bl/6J mice were anesthetized with 5% Xylazine–
20% Ketamine (0,1 ml/10 g). We injected 20 ml of physiological
serum in the control mouse at each time-point and 20 ml of OA
(1,2 ml/g body weight, sigma #27728-1L-R) in the other 27 mice
of our study. Administration of physiological serum and OA was
done through the tail vein with a 0.3-ml insulin syringe (BD
#320837).
Sacrifice and organ removal
Each group of mice was sacrificed 1 hour, 1.5 hours, 3 hours,
4 hours, 18 hours or 24 hours after injection of OA or
physiological serum by exanguination through the eye vein. For
each mouse, we collected the smallest lung for RNA extraction in
4 ml Trizol. The lung was immediately fractionated using a
polytron (T8 Ultra-Turrax, IKA WERKE #3420000) and kept at
220uC.
Lung histology
The lung was fixed in 4% Paraformaldehyde and paraffin
embedded. Five mm sections were cut and stained with Harri’s
hematoxylin and eosin (H&E) for morphological examination.
Lung inflammation was assessed by studying the following
morphological criteria: alveolar/interstitial edema, presence of
fibrin, alveolar/interstitial neutrophils. All slides were coded and
evaluated in a blinded fashion to prevent bias.
RNA extraction
Total RNA from lung was extracted using TRIzol reagent
(Invitrogen, #15596-026). The quality of RNA was confirmed on
a 1% denaturing agarose gel, and the concentration of RNA was
determined by reading absorbance at 260/280 nm.
Real-Time PCR
Real-time RT-PCR amplification was performed using primer
sets for one control gene: Actb (59-ACTCTTCCAGCCTTCC-
TTC-39 and 59-ATCTCCTTCTGCATCCTGTC-39), two pro-
inflammatory genes: Tnfa (59-CCCTCACACTCAGATCATCT-
TCT-39 and 59-GCTACGACGTGGGCTACAG-39) and Il6 (59-
TAGTCCTTCCTACCCAATTTCC-39 and 59-TTGGTCCTT-
AGCCACTCCTTC-39), and two anti-inflammatory genes: Il10
(59-GCTCTTACTGACTGGCATGAG-39 and 59-CGCAGCT-
CTAGGAGCATGTG-39) and Il4 (59-TGGATCTGGGAG-
CATCAAGGT-39 and 59-TGGAAGTGCGGATGTAGTCAG-
39). cDNA was synthesized using 5 mg of RNA, 1 mM dNTP,
and1 mg dt25 primer. After 5minutes at 65uC, 10 mMDTT, 40 U
RNAaseIN (Promega,#N261B) and 400U of Superscript II
transcriptase (Invitrogen, #18064-014) were added. This mix
has been maintained 2 hours at 42uC and 15 minutes at 70uC.
1 ml of RNAaseH (Invitrogen,#18021-014) has then been added
and the samples have been kept at 37uC for 20 minutes. 1 ml of the
RT product was then amplified for 2minutes at 50uC, 10minutes
at 95uC followed by 40 cycles (15 sec at 95uC, 30 sec at 60uC,
30 sec at 72uC) followed by one cycle of 72uC for 10minutes and
95uC for 15 sec. This was done in a 25 ml reaction mix containing
Figure 7. Experimental design of the experiment. We studied 35 mice C57BL6/J, female, 7 weeks old. We divided these mice into 6 groups
based on the incubation time (1H, 1H30, 3H, 4H, 18H, and 24H). In each group, mice are divided into 2 subgroups depending on the injection: OA or
physiological serum. 25 samples have been hybridized on 2 microarrays consisting in technical replicates and 10 samples have been hybridized once.
We performed 60 hybridizations.
doi:10.1371/journal.pone.0011485.g007
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1X Power SYBR Green PCR Master Mix (Applied Biosystem,
#4367659) and 25pM of each primer using the ABI PRISM 7000
sequence Detection System (Applied Biosystem).
Relative expression of the RT-PCR products was determined
using the comparative CT method based on the mathematical
model from M.W. Pfaffl [58]. Relative expression values for each
pro-inflammatory and anti-inflammatory gene were expressed as a
ratio of pro/anti-inflammatory gene expression level after OA
injection to the same pro/anti-inflammatory gene expression level
after physiological serum at the same time-point. Each sample was
run in triplicate. At least 2 negative controls without template or
with lung RNA were systematically conducted with each
amplification.
Microarray design
cDNA microarrays were designed and prepared as described by
Puthier et al. [59]. The microarrays used in this study, MUSV29K,
contain 7771 sequences. The following cDNA libraries were used:
the NIA Mouse 15K cDNA clone set, 2NbMT (thymus), NbMLN
(lymph node), and 3NbMS (spleen). Detailed descriptions of these
cDNA libraries are available at the UniGene database website
(2NbMT: Lib.544, 3NbMS: Lib. 553, NbMLN: Lib.567, NIA
15K: Lib. 8622) [60]. All of the libraries were cloned into
pT3T7D-Pac vector, except for the NIA 15K Mouse cDNA clone
set, which was cloned into pSPORT1 vector. The NIA 15K
Mouse cDNA clone set is a re-arrayed and resequenced set of 15
000 bacterial clones derived from 11 embryo cDNA libraries [61].
2NbMT, NbMLN and 3NbMS are sequenced I.M.A.G.E
libraries. These libraries contain 84127 clones. We used the
Microarrays Quality Control tool to select clones matching a
single region on the mouse genome and for which at least one 39
EST and one 59EST have been identified [62]. We selected 7771
bacterial clones matching 6622 mouse genes. 73% (4833) of the
genes are represented by a single cDNA clone and about 27%
(1789) of the genes included in this gene set are represented by two
or more different cDNA clones, providing internal controls to
assess the reproducibility of gene expression measurements. We
also added 8 positive controls (poly-A LBP2S and Cot1, a mix of
DNA fragments containing repeated sequences) and 2205 negative
controls (empty spots and CG03, an Arabidopsis thaliana cDNA
sequence). In summary, the MUSV29K mouse microarray we
designed contains 9984 spots, identifying 6622 mouse genes.
Microarray preparation
PCR amplifications were performed in 96-well microliters plates
using the following primers: 59-CCAGTCACGACGTTG-
TAAAACGAC-39 and 59-GTGTGGAATTGTGAGCGGATA-
ACAA-39. The reactions were performed as described in Diehl et
al. [63] by transferring few Escherichia coli from a growth culture
with a plastic 96pins replicator (Proteigene, #X5055) to 100 ml of
PCR mix pH 8,5 containing 1,5 mM MgCl2, 1 M Betain,
375 mM dATP, dTTP, dGTP, dCTP, and 5 U of GoTaq DNA
polymerase (Promega, #M3171). The plates were incubated for 6
min at 94uC, before 38 cycles of 94uC for 30 seconds, 65uC for 45
seconds and 72uC for 3.5 minutes, followed by a final elongation
phase at 72uC for 10 minutes. Amplification products were not
quantified, but their quality was systematically checked on 1%
agarose gels. 11,03% of the bacterial clones were estimated to be
non-amplified and 4,38% showed multiple bands after PCR
amplification. Unpurified PCR products were then transferred to
384-well microplates using the TECAN Genesis workstation 150,
before being evaporated. Each well was filled with 30 ml of distilled
water, and its content spotted onto nylon membranes (Hybond-
N+; Amersham Bioscience). This step was conducted using a
MicroGrid-II arrayer (Apogent Discoveries) equipped with a 64-
pin biorobotics printhead. Microarrays were hybridized with
xdATP 33P-labelled probe, whose oligonucleotide sequence is
common to all spotted PCR product (LBP2S 59-TCACACAG-
GAAACAGCTATGAC-39). It showed uniform signal intensities
across individual membranes [64].
Microarray data acquisition and analysis
10 mRNA samples extracted from 10 mice were run on a single
microarray. In addition, 25 samples were run on two microarrays,
and were considered as technical replicates. This corresponds to a
total of 60 microarrays. All microarray procedures were done at
our microarray core facility [65]. CDNA were designed and
prepared as described in Puthier et al. [59], using 5 mg of total
RNA in the presence of a-dCTP 33P.
After image acquisition, data were processed as described in
figure 3. Hybridization signals were quantified using the Bzscan2
software [66]. All images were carefully inspected and spots with
overestimated intensities due to neighborhood effects were
manually excluded. We used the NylonArray library for R locally
developed by A. Bergon and D. Puthier [67]. This package contains
functions to perform diagnosis and normalization of nylon
microarray data. For each microarray, we obtained two datasets:
the first was obtained by hybridizing the microarray with a probe,
whose oligonucleotide sequence is common to all spotted PCR
product (vector) and the second was obtained by hybridizing the
microarray with lung cDNA (sample). The sample datasets were
corrected for neighborhood effects and local background as
described by F. Lopez et al. [66]. Quantile normalization was
applied to sample data to correct for global intensity and dispersion.
Microarray data were statistically analyzed using the TIGR
MeV (MultiExperiment Viewer) V4.3.01 software [68]. SAM
(Significant Analysis of Microarrays) procedure was applied to look
for time specific variation in gene expression in the dataset [14]. A
each time-point, mean value of gene expressions in control
samples (physiological serum injection) were subtracted from gene
expression in OA samples. Hierarchical clustering (average linkage
clustering metrics and Pearson correlation for the distance) was
applied to the dataset (samples and genes) using the Cluster
software and results were visualized with the Treeview software
[15]. We identified biological annotation for the clusters using
DAVID [69] and interaction networks using the Kegg pathways
[70]. We applied a Bonferroni correction to account for multiple
tests performed. To interpret our data, we used two functionalities
in DAVID: the «Functional annotation» tool and the «Functional
annotation clustering» tool. The first one associated gene ID with
a biological term which belongs to one out of the 40 annotation
categories available in DAVID, including GO terms, protein-
protein interactions, protein functional domains, diseases associ-
ations and sequence feature. This extended annotation coverage
increases the analytic power by allowing investigators to analyze
their genes from many different biological aspects in a single space.
DAVID functional annotation clustering measured relationships
among the annotation terms based on the share of common genes.
This type of grouping of functional annotations was able to give a
more insightful view of the relationships between annotation
categories and terms compared with the traditional linear list of
enriched terms, as highly related/redundant annotation terms
may be dispersed among hundreds of other terms. Each cluster of
functional annotation was associated with an enrichment score,
which depended on the distribution of the enrichment (p-values) of
each member. A good enrichment score was obtained when most
of members had good p-values. This score is a relative score
instead of a statistical probability with a minimum and a
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maximum value. This means that enrichment scores could be
considered only together, by comparing them.
All data are MIAME compliant and have been submitted to the
GEO database (http://www.ncbi.nlm.nih.gov/geo/; accession
number GSE18712).
Supporting Information
Data file S1 Comparison of FDR5% and FDR0% to identify
significantly differentially expressed genes. In our study, we
applied a false discovery rate of 5%, which yielded to a set of
1000 genes significantly differentially expressed across the time-
course of our experiment. By filtering our data based on q,0.01
and FDR 5%, we end up with 121 genes significantly differentially
expressed in our experiment. By applying a false discovery rate of
0%, we identify 121 genes significantly differentially expressed
across the time-course and identical to the ones identified with
FDR 5% and q,0.01.
Found at: doi:10.1371/journal.pone.0011485.s001 (0.14 MB
PDF)
Data file S2 One thousand genes have been identified by SAM
with FDR 5%. Each gene is associated with its expression values in
OA samples. Each expression value has been normalized by
quantile and adjusted with its physiological serum value at the
same time point.
Found at: doi:10.1371/journal.pone.0011485.s002 (0.40 MB
TXT)
Data file S3 Identification of clusters of samples using
hierarchical clustering. Prior to partition samples ( =microarrays)
into 3 classes (early, intermediate and late), we performed a
hierarchical clustering of the samples in TMEV V4.3.01. using
average linkage clustering metrics and Pearson correlation for the
distance. This analysis partitioned the samples into 3 groups: early
(1H-1H30), intermediate (3H-4H) and late (18H-24H).
Found at: doi:10.1371/journal.pone.0011485.s003 (0.14 MB
PDF)
Data file S4 Sample of interesting genes differentially expressed
across the time-course. For each cluster, a set of genes mentioned
in the manuscript is listed associated with their average expression
level at each time-point.
Found at: doi:10.1371/journal.pone.0011485.s004 (0.00 MB
TXT)
Table S1 Functional annotation and enrichment of the 366
genes belonging to cluster Late. We identified biological
annotation for the cluster Late using DAVID [69] and interaction
networks using the Kegg pathways [70]. We applied a Bonferroni
correction to account for multiple tests performed. The functional
annotation functionality associated gene ID with a biological term
which belongs to one out of the 40 annotation categories available
in DAVID. DAVID functional annotation clustering measured
relationships among the annotation terms based on the share of
common genes.
Found at: doi:10.1371/journal.pone.0011485.s005 (0.05 MB
DOC)
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In our study, we applied a false discovery rate of 5%, which yielded to a set of 1000 genes significantly 
differentially expressed across the time-course of our experiment.
By selecting among these 1000 genes, the ones with q<0.01 and FDR 5%, we ended up with 121 genes 
significantly differentially expressed in our experiment (see supplementary data file #4). 
At the same time, we applied a false discovery rate of 0% and then identified 121 genes  significantly 
differentially expressed across the time-course and identical to the ones identified with FDR 5% and 
q<0.01.
We performed unsupervised hierarchical clustering on these 121 genes and identified 3 clusters:
−cluster 1: genes over-expressed at 1-1H30 
−cluster 2: genes  transitionally over-expressed at 3-4H
−cluster 3: genes over-expressed at 18-24H
To  analyze  functional  annotation  of  genes 
belonging to each cluster, we used DAVID V6.7.
In  cluster  Early,  GO  terms  related  immune 
response  such  as  to  regulation  of  T  cell 
differentiation  (3,2.10-3)  and  lymphocyte 
activation (1,3.10-2) were highly represented.
Most  of  the  genes  grouped  in  the  cluster 
Intermediate  were  found  to  be  involved  in 
regulation of transcription (7,9.10-3).
Finally, functional annotation analysis of genes 
belonging  to  the  cluster  Late  showed a  slight 
over-representation  of  GO  terms  related  to 
chromatin modification (7,4.10-2).
We can conclude that, by limiting our analysis 
to  a  very  small  set  of  genes  (121 genes  with 
FDR5%  and  q<0.01  =  121  genes  with  FDR 
0%), we lost  most of the information initially 
contained in the 1000 genes dataset filtered with 
FDR 5%. It has to be noted that, using FDR 5% 
and q<0.01,  the 121 genes are still grouped into 
3  clusters.  Functional  annotations  of  the  121 
genes are very unspecific and could be found in many other studies. Furthermore, several pathways 
such  as  modification  of  lipid  metabolism  and  migration  of  the  inflammatory  signal,  which  are 
meaningful because supported by previous studies, are swallowed up by very general descriptions.
Data file S2. 
One thousand genes have been identified by SAM with FDR 5%. Each gene is associated with its 
expression values in OA samples. Each expression value has been normalized by quantile and 
adjusted with its physiological serum value at the same time point.
Ce fichier n'est pas reproduit compte tenu du nombre important de pages qu'il 
représente  (tableau  contenant  les  valeurs  d'expression  au  sein  de  chaque 
échantillon des 1000 gènes identifiés).
Prior to partition samples (=microarrays) into 3 classes (early, intermediate and late), we performed a 
hierarchical clustering of the samples in TMEV V4.3.01. using average linkage clustering metrics and 
Pearson correlation for the distance. 
We can see that samples at 1H and 1H30 clustered together. The same way, samples at 3H and 4H 
clearly clustered together. Finally, samples at 18H and 24H clustered together with the exception of 
three 18H samples which have been grouped with the 3-4H cluster as an out-group.
This result support our decision to partition the samples into 3 groups: early (1H-1H30), intermediate 
(3H-4H) and late (18H-24H).
Fichier : /home/jtextori/Documents/Thes…rnal.pone.0011485.ALI.s004.txt Page 1 sur 2
MGI_ID Moy_1H Moy_1H30 Moy_3H Moy_4H Moy_18H Moy_24H
Cluster B – 1H-1H30
Chemokines
Cxcl5 -0,60 0,54 -0,05 -0,31 -0,83 -0,60
Ccl22 0,18 0,53 0,17 0,31 -0,04 -0,34
Ccl4 -0,20 1,15 -0,05 -0,35 -0,28 -0,05
Ccl3 0,14 1,63 -0,17 -0,69 0,12 -0,13
Ccl6 -0,48 0,49 -0,25 -0,27 0,48 -1,17
Ccl25 0,21 0,07 -0,12 -0,31 0,25 0,17
MapK signaling pathway
Fgf1 0,37 0,20 0,44 0,39 -0,17 0,05
Rasa2 -0,24 0,33 0,20 0,21 -0,05 -0,36
Rras -0,03 -0,20 -0,36 -0,01 -0,13 -0,26
Dusp1 1,27 0,90 0,29 -0,39 0,66 -1,16
Mknk1 -0,30 0,52 -0,16 -0,56 0,03 -0,49
Mknk2 0,18 0,01 -0,86 1,83 0,42 -0,59
Rps6ka3 0,23 0,19 -0,08 -0,27 0,16 -0,15
Mapk8ip3 0,50 -0,05 -0,25 0,34 0,24 0,21
Mapk9 0,12 0,39 0,06 -0,20 -0,09 0,23
Il1b -0,66 1,50 -0,59 0,10 0,8 -3,16
Map3k7ip1 0,08 0,54 -0,28 0,07 0,09 -0,18
Map3k7ip2 0,16 1,11 0,02 -0,35 -0,64 -0,96
Map3k6 -0,11 0,50 -0,16 -0,52 0,08 0,20
Il15ra 0,15 0,32 0,11 -0,44 0,03 0,30
Il12rb2 -0,27 0,11 -0,30 0,12 -0,37 -0,74
Il12rb2 -0,18 0,16 -0,03 -0,56 0,04 -0,23
Cluster A – 3-4H
Transmembrane and endothelial cell adhesion
Cd44 -0,78 0,73 0,10 1,34 0,31 -1,20
Cd44 -0,83 0,02 0,16 0,01 0,07 0,73
Pecam1 0,61 -0,43 -0,05 0,18 0,14 -0,09
Pecam1 -0,07 -0,38 0,07 1,30 -0,1 -0,05
Icam1 0,18 0,60 -0,01 0,91 -0,03 -0,86
Cd34 -0,56 -0,30 -0,08 0,87 -0,08 0,19
Cd34 0,39 0,37 0,13 -0,62 -0,13 0,30
Glycam1 0,05 -0,09 0,18 0,66 0,27 0,00
Blood cell synthesis
Cd34 -0,56 -0,30 -0,08 0,87 -0,08 0,19
Cd34 0,39 0,37 0,13 -0,62 -0,13 0,30
Il7r -0,38 0,38 0,51 0,99 0 -0,18
Il7r -0,19 0,29 0,46 0,53 0,23 0,00
Csf1 0,15 0,42 -0,17 0,07 -0,16 -0,06
Csf1 0,12 0,56 -0,23 -0,33 -0,14 -0,77
Cd38 -0,70 -0,78 -0,08 1,06 -0,06 -0,09
Cluster C – 18-24H
Lipid metabolism
Soat2 -0,36 -0,96 -0,17 -0,45 0,18 -0,51
Hdlbp 0,20 -0,05 -0,21 0,38 -0,09 -0,13
Hdlbp 0,14 -0,31 -0,13 -0,39 0,1 0,29
Hdlbp 0,46 -0,29 -0,25 -0,22 -0,06 0,67
Mbtps1 0,13 -0,31 -0,06 0,07 0,3 0,16
Cyb5r3 -0,11 -0,56 0,11 0,12 0 -0,29
Nsdhl 0,16 -0,20 0,08 -0,26 0,22 0,48
Osbpl5 -0,08 -0,27 -0,19 0,18 0,22 0,35
Il4 -0,75 -0,12 0,32 -0,23 0,01 0,22
Il4ra -0,21 0,33 0,04 0,26 0,11 -0,04
Hsd3b1 0,19 -0,11 0,16 -0,15 0,45 0,99
Osbpl11 -0,02 -0,35 0,16 0,50 0,06 0,53
Ppara 0,08 -0,79 -0,67 0,41 0,21 0,71
Pigv 0,11 -0,69 -0,02 0,23 0,15 0,36
Ltc4s 0,00 -0,41 -0,32 -0,30 0,34 0,25
D5Wsu178e -0,26 0,12 -0,21 -1,38 -0,24 -1,02
D5Wsu178e 0,06 -0,23 -0,32 -0,07 0,13 0,29
Ptdss1 -0,34 -0,07 -0,30 -0,18 0,18 0,27
Agps 0,10 -1,34 -0,23 0,81 0,12 0,93
Pisd -0,58 -0,55 -0,02 0,17 0,06 0,25
A4galt 0,07 -0,81 -0,05 -0,10 0,05 0,34
A4galt 0,54 -1,46 0,33 0,23 0,47 1,05
Acaa2 0,35 -0,64 -0,07 -0,07 0,21 0,72
Acadl 0,14 -0,36 -0,11 -0,28 0,3 -0,14
Fichier : /home/jtextori/Documents/Thes…rnal.pone.0011485.ALI.s004.txt Page 2 sur 2
Acadl 0,08 -0,15 0,02 -0,19 0,32 0,27
Serinc1 -0,18 -0,68 0,41 0,16 -0,49 1,06
Abhd4 0,00 -0,13 -0,24 -0,13 -0,06 0,65
Prei4 0,06 -0,14 -0,15 0,09 0,26 -0,19
Pck2 0,09 -0,09 0,17 -0,12 0,17 0,85
Pfkfb2 0,18 -0,64 -0,01 0,02 0,37 0,72
Th 0,10 -0,08 -0,27 -0,08 0,28 0,50
Table S1. Functional annotation and enrichment of the 366 genes belonging to cluster Late.
Functional classification
Database Term Count P-Value
Gene ontology DNA metabolic process 32 7.10E-04
Gene ontology Regulation of transcription 63 1.10E-03
Gene ontology Transcription. DNA-dependent 60 1.30E-03
Gene ontology Regulation of transcription. DNA dependent 59 1.40E-03
Gene ontology Transcription 65 1.40E-03
Gene ontology Metabolic process 186 2.20E-03
Gene ontology Cholesterol metabolic process 7 9.30E-03
Annotation Cluster 1 Enrichment score: 2.07
Database Term Count P-Value
Gene ontology Regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic process
65 7.70E-04
Gene ontology Regulation of transcription 63 1.10E-03
Gene ontology Transcription, DNA-dependent 60 1.30E-03
Gene ontology Regulation OF transcription, DNA-dependent 59 1.40E-03
Gene ontology Transcription 65 1.40E-03
Gene ontology Regulation of gene expression 65 3.20E-03
Gene ontology Transcription factor activity 26 4.30E-02
Gene ontology Transcription regulator activity 34 9.00E-02
Annotation Cluster 2 Enrichment score: 1.96
Database Term Count P-Value
Gene ontology Nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process
93 1.90E-03
Gene ontology Metabolic process 186 2.20E-03
Gene ontology Cellular metabolic process 173 2.30E-03
Gene ontology Primary metabolic process 172 4.50E-03
Gene ontology Macromolecule metabolic process 145 5.00E-02
Gene ontology Cellular process 229 7.10E-02
Annotation Cluster 3 Enrichment score: 1.44
Database Term Count P-Value
Gene ontology Cholesterol metabolic process 7 9.30E-03
Gene ontology Sterol metabolic process 7 1.10E-02
Gene ontology Steroid metabolic process 9 1.80E-02
Gene ontology Cellular lipid metabolic process 20 5.20E-02
Gene ontology Alcohol metabolic process 12 6.70E-02
Gene ontology Lipid metabolic process 21 9.40E-02
An  Evaluation  of  the  Role  of  Gene  Expression  in  the  Prediction  and 
Diagnosis of Ventilator-associated Pneumonia
Julien Textoris, Béatrice Loriod, Laurent Benayoun, Pierre-Antoine Gourraud, Denis Puthier, Jacques 
Albanèse, Jean Mantz, Claude Martin, Catherine Nguyen, Marc Leone.
Anesthesiology, (in press)
Les outils d'analyse haut-débit du transcriptome permettent d'explorer les voies métaboliques mises 
en  jeu  en  pathologie  et  d'identifier  de  potentiels  marqueurs  diagnostiques.  Cette  étude  a  analysé  les 
modifications  du  transcriptome sanguin  lors  de  la  survenue  d'une  pneumonie  associée  à  la  ventilation 
mécanique (PAVM), chez des sujets admis en réanimation pour traumatisme grave.
Cette étude multicentrique a inclus de manière prospective 165 patients, dont 41 ont développé une 
PAVM. Des échantillons de sang total ont été prélevés à l'admission, et au moment du diagnostic de PAVM.  
Afin d'identifier de potentiels marqueurs pronostiques de survenue de PAVM, nous avons comparé par puce 
à ADN le transcriptome des prélèvements initiaux des patients qui ont développé ou non une PAVM. Afin  
d'identifier des marqueurs diagnostiques, nous avons comparé le transcriptome des prélèvements appariés 
des patients qui ont développé une PAVM. Des patients traumatisés qui n'ont pas développé de PAVM ont  
été utilisés comme contrôles afin d'éliminer un effet du temps. Les résultats ont été confirmés par une autre 
technologie (NanoString®).
Les patients traumatisés dont l'évolution s'est compliquée d'une PAVM avaient un score lésionnel 
(ISS pour « Injury Severity Score ») plus élevé (36 vs.  29) et un traumatisme thoracique plus fréquent (28 
(68 %) vs. 57 (46 %)). Aucun marqueur transcriptionnel pronostique n'a été identifié. L'analyse des patients 
qui présentaient une PAVM a identifié une signature transcriptionnelle entre l'admission et le diagnostic de 
PAVM. L'analyse de sujets contrôles a montré que cette modulation est liée à l'évolution du traumatisme et 
non  au  processus  infectieux.  Toutefois,  une  diminution  de  l'expression  de  certains  médiateurs  pro-
inflammatoires est observée uniquement chez les patients qui développent une PAVM.
Contrairement  à  la  clinique,  l'analyse  du  transcriptome  sanguin  ne  permet  pas  de  prédire  ou  de 
diagnostiquer la survenue d'une PAVM chez des patients traumatisés. Il semble difficile de distinguer, au 
niveau  du  transcriptome,  inflammation  et  infection  en  pratique  clinique.  Toutefois,  il  serait  intéressant 
d'évaluer dans un travail complémentaire le rôle de la diminution des médiateurs pro-inflammatoires dans la  
survenue des PAVM.
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An Evaluation of the Role of Gene Expression in the
Prediction and Diagnosis of Ventilator-associated
Pneumonia
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ABSTRACT
Background: The SepsiChip project explored transcrip-
tional modulation associated with ventilator-associated
pneumonia (VAP) in patients admitted to the intensive care
unit for trauma. Genome-wide expression analysis may help
to identify potential diagnostic markers for diseases. The
current study examined the changes in blood transcriptome
during VAP.
Methods: The authors prospectively included 165 trauma
patients, and 41 developed VAP. Whole blood samples were
collected at admission and at VAP. To predict VAP, the
admission samples were compared by microarray in patients who did or did not develop VAP. To identify diagnosis
markers, paired samples of 35 patients who developed VAP
were analyzed. Using NanoString (Seattle, WA), the results
were confirmed in the patients who developed VAP. Trauma
patients who did not develop VAP served as controls to elim-
inate a time effect.
Results: The injury severity scores of the patients who did or
did not develop VAP were 36 and 29, respectively. No pre-
dictive biomarker was identified. For patients who developed
VAP, a transcriptional signature was identified between the
two sampling times. However, this signature was a general-
ized pattern related to trauma, independent of the infectious
process. Genes involved in the proinflammatory response
were down-regulated in the patients who developed VAP,
but this difference was not statistically significant.
Conclusions: In contrast to clinical assessment, transcrip-
tional analysis of whole blood samples cannot predict or
diagnose VAP in trauma patients. Differentiating infection
from inflammation seems challenging.
I N trauma patients, nosocomial infections are a commoncause of morbidity and mortality. Pulmonary infection is
one of the most life-threatening infections.1 Prompt initiation
of appropriate antimicrobial therapy is critical in the care of
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What We Already Know about This Topic
• The clinical diagnostic criteria for ventilator-associated pneu-
monia (VAP) do not exclude patients who do not have VAP
(true negatives)
What This Article Tells Us That Is New
• Transcriptional analysis, using DNA microarrays containing
8,682 genes, of 165 trauma patient’s blood was done in pa-
tients with (41) and without (42) VAP but could not distinguish
inflammation from infection
 Supplemental digital content is available for this article. Direct
URL citations appear in the printed text and are available in
both the HTML and PDF versions of this article. Links to the
digital files are provided in the HTML text of this article on the
Journal’s Web site (www.anesthesiology.org).
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these patients.2 Unfortunately, trauma induces a major inflam-
matory response, making the diagnosis of ventilator-associated
pneumonia (VAP) difficult. Chest imaging often is irrelevant
because of contusions. In this setting, clinical scores are not
informative.3 Thus, biologic markers may have a role in predict-
ing or diagnosing VAP in patients. The concentrations of pro-
calcitonin can reinforce the diagnosis of infection, but its value
as a diagnostic tool remains a matter of debate.4,5 Several high-
throughput studies suggest that genome-wide expression analy-
sis could help with the diagnosis of VAP.6
High-throughput technologies may prove to be helpful
for deciphering the complex host response to infection.
These technologies may provide tools for predicting the oc-
currence of infection or facilitating its diagnosis. Using ge-
nome-wide expression analysis, the signature profiles of in-
flammation have been characterized by many groups (e.g.,
trauma,7–9 lipopolysaccharide infusion,10 malaria,11 septic
shock in children,12,13 severe sepsis and septic shock in
adults,6,14–17 and Gram-specific infections6,18,19).
To investigate the host response to infection, we at-
tempted to reduce the background noise of inflammation by
using trauma patients who developed VAP as their own con-
trols. We prospectively included trauma patients and col-
lected whole blood samples for transcriptome analysis. We
conducted an unbiased analysis by exploring the transcrip-
tome using DNA-microarray technology. We compared
samples taken at the time of admission from trauma patients
who did or did not develop VAP to identify prognostic mark-
ers. We also compared paired samples taken from trauma
patients at the time of admission and at the time of diagnosis
of VAP to identify potential diagnostic markers of VAP.
Finally, to eliminate general gene expression patterns related
to the elapse of time after trauma, we collected late samples
from control trauma patients who did not develop VAP. To
confirm our microarray findings, we analyzed the transcrip-
tome with an alternative technology (NanoString nCounter
Analysis System; NanoString Technologies, Seattle, WA).
We used this technology to confirm our potential gene ex-
pression signature and to investigate the expression of some
already known inflammatory markers.
Materials and Methods
Patients
The study protocol was approved by the Ethics Committee
(Comite´ de Protection des Personnes Sud-Me´diterrane´e II,
no. 206–005). All trauma patients admitted to two surgical
intensive care units (ICU) in teaching hospitals (Hoˆpital de
Beaujon, Clichy, France; Hoˆpital Nord, Marseilles, France)
were screened for inclusion. All trauma patients with an in-
jury severity score greater than 15, who fit the criteria of
systemic inflammatory response syndrome, and were be-
tween the ages of 18 and 60 yr were invited to participate in
the study. They were included after informed consent was
signed by their next of kin. Exclusion criteria were preg-
nancy, immunodeficiency, high-dose corticotherapy (more
than 20 mg prednisone or equivalent), or expected death
within the first 48 h.
Overall Study Design
The diagnosis of VAP was established when the following
criteria were fulfilled: purulent bronchial sputum; body tem-
perature more than 38°C or less than 36°C; leukocytes more
than 10  109  l1 or less than 4  109  l1; chest radio-
graph showing new or progressive infiltrates; presence of at
least one microorganism at a concentration of 104 colony-
forming units (cfu)/ml in bronchoalveolar lavage, or 106
cfu/ml in tracheal aspirates.20 Senior intensivists and micro-
biologists made the final diagnosis of VAP.
We defined two sample time points (fig. 1). A blood
sample was collected within the first 24 h after ICU admis-
sion in all trauma patients fulfilling inclusion criteria (S1).
Those who developed VAP were sampled a second time at the
onset of antibiotic administration (S2). One hundred thirty-
one samples (from 90 patients) were run on microarrays,
including 49 S1 samples from patients who did not develop
VAP and 41 S1-S2 pairs of samples from patients who de-
veloped VAP. Because of technical difficulties, some mi-
croarrays were discarded. Therefore, data from 77 patients
were analyzed, including 35 paired S1-S2 samples from pa-
tients who developed VAP, and 42 S1 samples from patients
who did not develop VAP. To exclude a generalized effect
related to the elapse of time after trauma, 15 trauma patients
who did not develop VAP were sampled between days 5 and
10. Because of a lack of RNA, blood was sampled in 13
additional trauma patients who developed VAP. These 28
samples were used to confirm microarray results. We
checked that the two groups of patients analyzed by either
microarray (n  90) or NanoString (n  28) were similar to
the whole population included in the study (see Supplemental
Digital Content 1, a table summarizing patients’ characteristics
for each subgroup, http://links.lww.com/ALN/A756).
Fig. 1. Flow chart. Samples were collected in 165 trauma
patients at admission (S1). In the 41 patients who developed
ventilator-associated pneumonia (VAP), a second sample
was collected (S2). ISS  injury severity score.
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Sample and Data Collection
Whole blood samples were collected within 24 h of ICU
admission (Paxgene-PreAnalytiX; Qiagen/Becton Dick-
son, Valencia, CA) and at the onset of VAP (fig. 1). Blood
was withdrawn from an arterial line directly into the Pax-
Gene tubes. Mixed samples were stored 8 h at 4°C, 24 h at
18°C, and were then maintained at 80°C until RNA
extraction. Clinical and biologic data were collected from
patient charts at the time of sample collections using our local
web-based database.
RNA Extraction and Labeling
Total RNA was isolated from whole blood samples using the
PaxGene Blood RNA System (PreAnalytiX) according to
the manufacturer’s specifications. RNA quality was analyzed
using an Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA), which analyzes the entire RNA electropho-
retic trace to evaluate RNA integrity. RNA was extracted
from three independent tubes for each time point. High-
quality samples were pooled (for each patient and time
point). RNA was quantified by spectrophotometry (Nano-
Drop; ThermoFisher Scientific, Waltham, MA). As re-
ported previously, hybridization from whole blood samples
collected with the PaxGene system results in a low percent-
age of genes termed “present” in the microarray analysis.
This was mostly attributable to the high expression levels of a
small number of genes in the erythrocytes.21 To improve the
hybridization signals, 15 g each RNA sample, instead of the
5 g recommended in the standard protocol, was reverse-
transcribed into double-stranded complementary DNA
(cDNA) and labeled with P33-cytosine.22 For each time
point, all RNAs of each patient that were of good quality,
based on the peak profiles of 18S and 28S ribosomal RNA,
were pooled. All labeled cDNA generated from these mes-
senger RNA (mRNA) were of the expected radioactive inten-
sity and were hybridized to the microarrays.
Microarray Design and Hybridization
The microarray (HuSG9 k) was developed in our laboratory
(Technologie Avance´es pour le Ge´nome et la Clinique
[TAGC], INSERM U928, Marseilles, France) as described
elsewhere.22 Briefly, HuSG9 k is a human cDNA library,
designed from IMAGE clones, which is arranged on a nylon
microarray. The microarray contains 9,216 probes compris-
ing 8,682 genes, 100 duplicated genes, and 434 controls.
The microarray design was not enriched in specific pathways.
Only genes with known functions were selected. Probes were
selected by bioinformatics analysis to match the 3 end of the
major transcripts of each gene (Microarray Quality Control,
TAGC, INSERM U928). Polymerase chain reaction (PCR)
amplification was performed as described previously,22 and
PCR products were spotted onto nylon membranes (Hy-
bond-N; GE Healthcare, Little Chalfont, Buckingham-
shire, England) with a MicroGrid II arrayer (Affymetrix,
Santa Clara, CA). PCR amplification products of selected
clones were 1,500 base pairs long on average. The robot used
a print head with a 16  4 arrangement of print tips. Each tip
printed 144 spots in a 12  12 grid. Additional details re-
garding the HuSG9 k microarray are available on the TAGC
Web site.§§ Because of the high abundance of erythrocyte-
related mRNA species in the samples, certain probes were
overexpressed and interfered with analysis of the neighboring
probes on the microarray. These overly abundant probes
were diluted before being spotted on the microarrays. cDNA
preparations, hybridizations, and washes were carried out as
described previously.22
NanoString nCounter Assay
In several studies, the NanoString nCounter assay has been
shown to be a novel, effective alternative to SYBR green
real-time PCR.23,24 In brief, a multiplexed probe library is
made with two sequence-specific probes for each gene of
interest. The first probe contains a 35- to 50-base pair se-
quence, complementary to a particular target mRNA, plus a
short common sequence that is coupled to an affinity tag. In
our study, the affinity tag is biotin. The second probe con-
tains a second 35- to 50-base sequence, complementary to
the target mRNA, which is coupled to an RNA-based, color-
coded tag that provides the detection signal. The linear order
of these differently colored RNA segments creates a unique
code for each gene of interest. Unique pairs of capture and
reporter probes are constructed to detect transcripts for each
gene of interest. All probes are mixed together with total
RNA in a single hybridization reaction that proceeds in so-
lution. After each complex is captured on a surface coated
with streptavidin, an applied electric field extends and orients
each of them in the solution in the same direction. The
complexes are then immobilized in an elongated state and
imaged. Each target molecule of interest is identified by the
color code generated by the ordered fluorescent segments
present on the reporter probe. The level of expression is
measured by counting the number of codes for each mRNA.
A complete description and performance analysis of the
NanoString nCounter assay can be found in the seminal
article.25 In our study, 100 ng each sample total RNA was
sent to Seattle’s NanoString laboratories. Samples were col-
lected from a cohort of 28 patients who were not analyzed by
microarray. The raw results were normalized using internal
controls provided by the manufacturer. Differences in the
normalized counts were assessed with the Wilcoxon rank
sum test and were called significant if P  0.05.
Microarray and Statistical Analysis
Microarray image files were captured with a phosphor imager
(BAS5000; FujiFilm, Tokyo, Japan). Data S from .INF or
.IMG files were extracted with BZScan2 software (TAGC,
INSERM U928).26 Data files were loaded and analyzed with
R and Bioconductor,27 using the NylonArray library devel-§§ http://tagc.univ-mrs.fr/. Last accessed on April 12, 2011.
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oped by the TAGC to support BZScan2 files (library avail-
able upon request). Raw data were normalized using quantile
normalization. Supervised analysis (supervised methods
aimed at finding a set of genes whose expression profiles best
correlate with a known phenotype) between admission sam-
ples (S1) from patients who developed and those who did not
develop VAP, and between the S1 and the S2 groups of
samples, was conducted using the significance analysis of
microarray algorithm28 with the siggenes library.29 All statis-
tical analysis used corrections for multiple comparisons
(Benjamini and Hochberg30). The power of each analysis
was estimated using the Bioconductor library sample size and
power analysis.31 CoPub was used as a literature-based key
word enrichment tool for the identified genes.32 Identified
key words are presented along with enrichment significance
(P value from Fisher exact test).
For clinical and biologic variables, quantitative data are
presented as the median and interquartile range, and categor-
ical data are presented as an absolute count and percentages.
The differences between groups were evaluated with the Wil-
coxon rank sum test or the chi-square test as appropriate. All
statistical tests were two-tailed.
Results
Characteristics of Patients
A cohort of 165 trauma patients was prospectively included
in the study. Of these, 41 (25%) patients developed VAP. All
patients had severe multiple trauma involving the head
(86%), chest (52%), abdomen (36%), and limbs (48%). At
the time of admission, the injury severity score was higher in
the trauma patients who developed VAP than in those who
did not develop VAP (median [interquartile range]: 36 [26–
43] vs. 29 [24–37], P  0.04). At the thoracic level, an acute
injury score greater than 2 was found in 28 (68%) patients
who developed VAP, compared with 57 (46%) patients who
did not develop VAP (P  0.02) (table 1). Death occurred in
11 (27%) patients who developed VAP and in 24 (19%)
patients who did not develop VAP (P  0.42). Median onset
day of pneumonia was day 8. Clinical and laboratory vari-
ables of patients who developed VAP are provided in table 2.
The clinical and laboratory characteristics of these pa-
tients were similar, except for PaO2, which was lower at the
onset of VAP.
No Transcriptional Signature Predicts VAP in Trauma
Patients
To identify prognostic markers of VAP, we compared sam-
ples collected at the time of ICU admission from trauma
patients who developed VAP and those who did not develop
VAP. After we excluded hybridizations because of technical
difficulties, 39 admission samples from patients who devel-
oped VAP were compared with 42 admission samples from
patients who did not develop VAP. The expression profile
was similar in the trauma patients who developed VAP and
Table 1. Patient Characteristics at Admission
Patients Who Did Not Develop
VAP (n  124)
Patients Who Developed
VAP (n  41)
Age (yr) 31 23–41 30 22–46
BMI (kg/m2) 24 23–25 25 23–26
Head trauma
n (%) 104 (84) 38 (92)
AIS 5 3–5 5 4–5
Chest trauma
n (%) 57 (46) 28 (68)*
AIS 3 0–3 3 2–4
Glasgow Coma Scale 7 4–11 5 3–8
SAPS II 41 36–51 47 43–53
Injury Severity Score 29 24–37 36 26–43*
Heart rate (/min) 116 100–129 114 99–124
Mechanical ventilation n (%) 96 (77) 38 (92)
Body temperature (°C) 37.9 36.1–38.7 38.7 36.2–39.2
Creatinine (M) 81 70–97 73 57–90
Leukocytes (g/l) 11.9 8.8–14.7 13.1 10.4–16.7
Hemoglobin (g/dl) 10.5 8.9–12.5 10.3 8.7–11.5
Platelets (g/l) 178 135–275 172 123–218
Fibrinogen (mM) 2.4 1.9–3 4.5 2.5–6.6*
PaO2/FiO2 ratio 282 268–345 218 195–287
Plasma lactate (mM) 1.9 1.4–3.5 1.6 1.2–2
Death n (%) 24 (19) 11 (27)
Data are presented as median interquartile range or as absolute count (percentage).
* P  0.05.
AIS  Acute Injury Score; BMI  body mass index; SAPS  Simplified Acute Physiological Score; VAP  ventilator-associated
pneumonia.
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those who did not develop VAP. Therefore, no transcrip-
tional signature predicted the onset of VAP in our trauma
patients.
Differential Gene Expression between Admission Time
and Onset of VAP in Trauma Patients
To identify diagnostic markers of VAP, we compared admis-
sion samples from trauma patients who developed VAP with
samples collected in the same patients at the onset of VAP.
After the exclusion of six hybridizations (because of technical
issues), we analyzed 35 paired samples.
The analysis of normalized gene expression identified
207 probes whose expression levels differed between the
two sampling times (false discovery rate less than 10%).
The heat map shows this signature by representing, ac-
cording to a color code, the expression value of each gene
(row) in each sample (column) (see Supplemental Digital
Content 2, a figure showing the signature as a heat map,
http://links.lww.com/ALN/A757). After hierarchical clus-
tering of expression data, all samples but eight (four patients)
clustered together according to the time of sampling. Genes
clustered into two groups: 137 (66%) were up-regulated and 70
(34%) were down-regulated at the onset of VAP (see Supple-
mental Digital Content 2, http://links.lww.com/ALN/A757).
Literature-based annotation using CoPub identified sev-
eral enriched molecular functions (see Supplemental Dig-
ital Content 3, a table showing the signature’s functional
annotation, http://links.lww.com/ALN/A758).32 Thirty-
six genes were up-regulated with a ratio above 2 and seven
genes were down-regulated with a ratio below 2 (see Sup-
plemental Digital Content 4, a table showing the 43 most
modulated genes, http://links.lww.com/ALN/A759).
To further select potential diagnostic markers, we selected
up-regulated genes with a false discovery rate less than 1%.
The heat map shows a signature of 10 genes (see Supplemen-
tal Digital Content 5, a figure showing the concise signature
as a heat map, http://links.lww.com/ALN/A760). The fold
changes ranged from 1.3 to 4.2. Supplemental Digital Con-
tent 6 lists the identified genes, with their known biologic
functions, http://links.lww.com/ALN/A761.
Table 3 reports the ratio and baseline expression levels of
a sample of genes described previously as markers of inflam-
mation or infection. Although not statistically significant,
the expression of interleukin (IL)1B, IL1RN, HMGB1, and
TREM1 were down-regulated in the trauma patients at the
onset of VAP.
Confirmation of the Selected Markers with the
NanoString nCounter Technology
The NanoString nCounter technology was used to validate
the expression changes of the 10 genes that are potential
diagnostic markers of VAP. We used samples from a new
cohort of 13 trauma patients who developed VAP. Results
with the NanoString nCounter assay confirmed the modu-
lation of five (ALAS2, AHSP, SPARC, PPBP, and PCSK1)
of the 10 selected genes (fig. 2A). For these five genes, we
found a statistically significant up-regulation in the time be-
tween admission and onset of VAP.
To exclude a generalized effect on gene expression related
to trauma and not VAP, we analyzed samples from 15
trauma patients who did not develop VAP. These patients
were free of infection and antibiotic treatment. These samples
Table 2. Characteristics of Patients Who Developed
Ventilator-associated Pneumonia
Admission
(n  41)
Onset of VAP
(n  41)
Heart rate (/min) 108 95–124 114 99–128
Body temperature
(°C)
38.4 36.3–39.2 38.5 36.1–39.7
Creatinine (M) 77 69–99 65 54–75*
Glycemia (mmol/l) 6.5 5.8–7.3 6.4 5.8–7.3
Leukocytes (g/l) 13 10–17 13 10–18
Plasma lactate
(mmol/l)
1.8 1.2–2.6 1.5 1.2–1.8
PaO2 (mmHg) 135 96–175 91 79–110*
FiO2 (%) 48 40–56 50 40–60
SaO2 (%) 99 98–99 98 97–99
Clinical and biological characteristics of the patients who devel-
oped a ventilator-associated pneumonia (VAP), at admission and
at the onset of VAP. Data are presented as median interquartile
range.
* P  0.01.
Table 3. Inflammatory Modulation between Admission
and Onset of VAP
Gene
Symbol
Fold Change
Microarray
VAP
Fold Change
NanoString
VAP Control
IL1B 0.80 0.40 0.92
IL1RN 0.60 0.57 0.84
IL6 1.03 — —
IL6R 0.93 0.77 0.84
HMGB1 0.77 0.86 0.81
TREM1 0.87 0.70 0.90
ICAM1 0.95 0.97 0.88
TNF — 0.70 1.04
CALCA 1.21 — —
CALCB 1.23 — —
CRP 1.01 — —
Microarray fold changes are presented for patients who devel-
oped VAP. NanoString fold changes are presented for patients
who developed VAP and controls. Eleven markers were tested.
TNF was not tested in microarray. Four genes were not ex-
pressed in NanoString nCounter assay: IL6, CALCA, CALCB, and
CRP I.
CALCA  calcitonin-related polypeptide alpha; CALCB  calci-
tonin-related polypeptide beta; CRP  C-reactive protein;
HMGB1  high mobility group box 1; ICAM1  intercellular
adhesion molecule 1; IL1B  interleukin 1 beta; IL1RN  inter-
leukin 1 receptor antagonist; IL6  interleukin 6; IL6R  interleu-
kin 6 receptor; TNF  tumor necrosis factor; TREM1  triggering
receptor expressed on myeloid cells 1; VAP  ventilator-associ-
ated pneumonia.
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were collected between days 5 and 10. The signature of 10 genes
was tested in these samples. A similar profile of expression was
found, including the five selected genes (fig. 2A).
Decrease of Proinflammatory Gene Expression Is
Associated with VAP
We also tested a set of already known inflammatory genes:
TREM1, TNF, IL6R, IL6, IL1B, IL1RN, ICAM1, HMGB1,
CRP, CALCA, and CALCB. Not enough signal was detected
for IL6, CRP, CALCA, and CALCB. These four genes were
excluded from the analysis. With the use of NanoString
nCounter technology, IL1B, IL1RN, TNF, IL6R, and
TREM1 were down-regulated in samples from patients at the
onset of VAP. In addition, these five proinflammatory markers
differentiated patients who developed VAP and those who did
not develop VAP (fig. 2B).
Discussion
Using a whole blood transcriptome analysis, the SepsiChip
project was designed to identify a signature of gene expres-
sion associated with the development of VAP. Among 165
multiple trauma patients, 41 developed VAP. As previously
described, we confirmed an association between the develop-
ment of VAP and the severity of trauma.33 Despite these
clinical differences, the transcriptome analysis does not show
any difference between trauma patients who did or did not
developed VAP. Therefore, this analysis cannot serve to pre-
dict the clinical outcome of trauma patients. Comparison of
samples at the time of admission and at the time of VAP
onset identifies a 207-gene transcriptional signature. These
genes are involved in basal cell functions, such as transcrip-
tion, translation, apoptosis, immune response, hemostasis,
and coagulation. Of note, genes involved in the proinflam-
matory response are nonsignificantly down-regulated. Fo-
cusing on genes with a false discovery rate less than 1%, we
identified a 10-gene signature for the potential diagnosis of
VAP. Using NanoString, we confirmed the up-regulation of
5 of these 10 genes. However, we found a similar signature in
a cohort of trauma patients who did not develop VAP, suggest-
ing a generalized effect related to trauma. In an additional anal-
ysis, we identified a down-regulation of proinflammatory medi-
ators only in the patients who developed VAP.
In contrast to experimental studies, clinical investigations
often are limited by excessive heterogeneity of the included
patients.34 To reduce this bias, we selected trauma patients in
a predetermined age range. We also used a single model of
infection. Because genetic backgrounds can differ among pa-
tients, we constructed a paired analysis. In our study, analysis
of samples from the same patient at admission and at onset of
VAP serves as a control for genetic heterogeneity. This design
also let us compare the host response to inflammation
(trauma) and infection (VAP). This may improve the char-
acterization of genes modulated by infection, independently
of inflammation. In agreement with the findings of previous
Fig. 2. Confirmation analysis by NanoString nCounter assay in trauma patients who developed ventilator-associated pneumonia
(VAP) and trauma patients who did not develop VAP (controls). Patients were sampled at admission (S1). A second sample (S2)
was collected in patients who developed VAP (at the onset of VAP). A second sample was collected in controls between days
5 and 10 (S2). Counts in log2 scale for the five confirmed genes of the concise signature (A) and five proinflammatory markers
(B) are presented as box plots (green  S1; red  S2 in patients with VAP; blue  S2 in controls).
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studies,4,35,36 classic markers of the inflammatory response
in our study were up-regulated at admission. This early and
transient proinflammatory response was also found in a mu-
rine model of acute lung injury.37 A signature of 207 probes
discriminates the samples of patients at the time of admission
and at the onset of VAP. Actually, we found that this signa-
ture is related to a generalized response after trauma. Thus,
no specific signature of infection is found in trauma patients
who developed VAP.
This striking finding shows that the transcriptional
changes observed in the trauma patients are caused by in-
flammation and other general effects after trauma. In other
studies reporting signatures for severe sepsis, the controls are
healthy volunteers.10,12,38 Thus, these studies cannot differ-
entiate infection and inflammation. The signatures that were
reported in these previous studies may be related to inflam-
mation and not specifically to the infectious process.
In a seminal paper, McDunn et al. suggest that the onset
of an infection-specific transcriptional program may precede
the clinical diagnosis of VAP. Using a bench-to-bedside ap-
proach, 85 genes were modulated during the 7 days bracket-
ing the diagnosis of VAP. A general trajectory (entitled “ri-
boleukogram”) was identified.6 In our study, we tested 52 of
these 85 genes. Forty-one (79%) genes exhibited a similar
modulation. In light of our findings, the trajectories associ-
ated with the riboleukogram may be related to inflammation
more than infection. However, the concept of a general tra-
jectory may be more useful diagnostically than a single-point
analysis.
Obtaining high-quality genomic data from critically ill
patients remains a challenge. Cell collection methods, mRNA
extraction, and labeling methods influence the expression pro-
files. Buffy coat versus whole blood sampling is discussed else-
where.8,21 As described previously, whole blood samples re-
sulted in a weak hybridization signal. Because a few probes
exhibited overexposed signals in preliminary experiments
(data not shown), we changed our protocols by diluting these
probes on all microarrays. Next, we increased the quantity of
RNA and P33-cytosine for the cDNA preparations. These
changes corrected the percentage of present calls into a nor-
mal range. These issues are related to the use of whole blood
samples. However, both its reproducibility and its simplicity
in the setting of a multicenter clinical study drive the choice
of Paxgene.
Our microarray findings were confirmed by using the
novel NanoString nCounter Analysis System. NanoString
uses digital technology based on direct multiplexed measure-
ment of gene expression. It offers a high level of sensitivity,
precision, and reproducibility.25 NanoStrings are fluorescent
bar codes that bind to target mRNA for gene expression
analysis. The advantages are its sensitivity comparable with
PCR, the lack of enzymology or amplification, and the abil-
ity to analyze the expression levels of as many as 800 genes in
a single assay. Using this system, we confirm the modulation
observed by microarray analysis for 5 of the 10 gene of the
signature.
To exclude a general effect after trauma, we tested these
five potential biomarkers in a set of patients who did not
develop VAP. Indeed, the inflammatory profile of trauma
patients is affected by different procedures, such as mechan-
ical ventilation, parenteral nutrition, and surgical proce-
dures. In this cohort, the five genes are up-regulated, despite
that these patients did not develop VAP. Thus, these genes
are not specific for an infectious process. We also tested a set
of markers that are classically involved in inflammation and
infection. Five proinflammatory mediators are down-regu-
lated in the patients who developed VAP, whereas they are
unchanged in our controls. The same down-regulation is also
detected in the microarray data.
This down-regulation in patients who develop VAP is of
interest because the polarization of the immune response in
ICU patients remains a matter of debate. This supports the
concept of immunosuppression in ICU patients with infec-
tion.39 As highlighted elsewhere,40 the immune system of
septic patients is unable to respond to a second challenge of
endotoxin. This state of nonresponsiveness is known as “an-
ergy.”41 Autopsy studies in persons who died of sepsis
showed a profound, apoptosis-induced loss of adaptive im-
mune system cells.40 Notably, most studies aimed at inhib-
iting proinflammatory cytokines failed to improve survival.
In contrast, stimulating the immune response in selected
immunodeficient septic patients, by granulocyte/macrophage-
colony stimulating factor, for example, may improve their out-
come.42 In the current study, we found a decreased expression of
TNF, IL1B, IL1RN, IL6, and TREM1 in the patients who
developed VAP. Therefore, we confirm the association between
a relative immunodeficiency and the sepsis occurrence. This
suggests the need to monitor the immunologic status of trauma
patients.
Our study has several limitations. It is possible that the
heterogeneity of patients included in the study precludes the
identification of a positive effect. However, our patients were
composed of a relatively homogeneous population of pa-
tients with multiple traumas, including 80% with a head
injury. To reduce the effect of age, our inclusion criteria were
restrictive. Our endpoint was restricted to the development
of VAP. Except for seven positive urine cultures, for which
the rate of occurrence was similar in patients who did or did
not develop VAP, no infection interfered with VAP. The
initial analysis, designed to compare the transcriptome at the
time of admission for trauma patients who did or did not
develop VAP, was negative. Even with a high false discovery
rate (20%), we did not find any differentially expressed
genes. Thus, we interpreted this result as the absence of prog-
nostic biomarkers of VAP in trauma patients. We also con-
ducted subgroup analysis to infer the potential effect of sex,
age, or other infection on transcriptome modulation. No
effect was found, but these results (data not shown) should be
interpreted with caution because of low power estimates.
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Because the blood can be described as a black box,43 one can
suggest that it may not reflect the transcriptional modulation
in the lung. Analysis of whole blood from trauma patients
most likely does not reflect transcriptional changes in the
lung. To address this, we have studied time-related changes
in the lung using an animal model of lung injury.37
Conclusion
In conclusion, we explored the transcriptome of whole blood
samples from 165 trauma patients, 41 of whom developed
VAP. Our goal was to identify a gene expression profile that
could be used to identify trauma patients at risk for VAP. At
the time of admission, the trauma patients who developed
VAP had a higher severity score than did those who did not
develop VAP. In addition, we found that chest trauma is a
risk factor for VAP. Within the limitations of our study, for
patients that developed VAP, a transcriptional signature was
identified that reflected differential gene expression at time
of admission and time of VAP diagnosis. This signature is
attributed to a generalized pattern related to trauma and
seems independent of the infectious process. Interestingly,
five proinflammatory markers are down-regulated at the on-
set of VAP, although the differences are not statistically sig-
nificant. They are expressed at a steady level in the patients
who did not develop VAP. These results support the concept
that infection in the ICU results from an unbalanced shift
toward an antiinflammatory state. The trajectory of the in-
flammatory balance in trauma patients at clinical risk of VAP
should be assessed in future studies.
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Supplemental  Figure  1:  Transcriptional  signature  in  trauma  patients  who  developed 
ventilator-associated pneumonia (VAP). 
Heatmap representation of the 207 identified genes with a false discovery rate below 10%.  Samples 
were classified according to sampling time (admission: yellow; onset of VAP: blue). Four patients 
were misclassified.  Genes are represented as rows, and samples as columns. The level of gene 
expression is color-coded from green (under-expression) to red (over-expression).
Supplemental Figure 2: Concise transcriptional signature in trauma patients who developed 
ventilator-associated pneumonia (VAP).
Heatmap representation of the 10 identified genes with a false discovery rate below 1%.  Samples 
were classified according to sampling time. Five patients were misclassified. Genes are represented 
as rows, and samples as columns. The level of gene expression is color-coded from green (under-
expression) to red (over-expression).
Table S1: Patient characteristics according to type of analysis
All 
population
Patients analyzed 
by microarray
Patients analyzed 
by NanoString
n = 165 n = 90 n = 28
Age (year) 31 [23-42] 30 [22-45] 29 [21-43]
SAPS II 43 [38-52] 45 [40-52] 41 [36-51]
Injury Severity Score 30 [24-39] 33 [26-41] 30 [24-40]
Head trauma n (%) 142 (86) 79 (88) 23 (82)
Chest trauma n (%) 85 (52) 54 (60) 15 (54)
Death n (%) 35 (21) 21 (23) 5 (18)
Comparison of general characteristics for the whole population, patients 
analyzed by microarray, and patients analyzed by NanoString nCounter. SAPS : 
Simplified Acute Physiological Score. Data are presented as median [inter-
quartile range] or absolute count (percentage).
Table S2: Signature genes' functionnal annotation
Keyword p-value
Number of 
genes
Growth 1.3x10-5 84
Transcription 6.9x10-5 88
Translation 7.0x10-5 50
Hemostasis 2.6x10-4 12
Innate immune response 5.2x10-4 19
Apoptosis 9.2x10-4 60
Immune response 4.8x10-3 31
Coagulation 5.8x10-3 12
Main  keywords,  extracted  from  the  literature,  associated 
with  the  signature's  genes   with  number  of  genes  in  the 
signature, and corresponding p-value (Fisher exact test).
Table S3: Most differentially expressed genes
Up-regulated genes Down-regulated genes
Gene symbol Fold change Gene symbol Fold change
PCSK1 4.2 LPIN1 -2.4
AAMP 4.1 ORF1-FL49 -2.4
SPARC 3.5 ACSL1 -2.4
ZNF317 3.4 CD3G -2.2
IGHG3 3.1 ZDHHC19 -2.2
DEFA4 3.0 CHDH -2.1
AURKB 2.9 PVM1 -2.1
AHSP 2.8
PPBP 2.7
NARG1 2.7
BPGM 2.7
PRSS25 2.6
TREML1 2.5
KHDRBS2 2.4
EIF2AK1 2.4
SELENBP1 2.4
LCN2 2.3
GTF2E2 2.3
FBXO41 2.3
NRGN 2.3
IGHA1 2.2
TMCC2 2.2
IGKV1-5 2.2
SFRS3 2.1
ITGA10 2.1
TENS1 2.1
FOXO3A 2.1
RAB40A 2.0
ALAS2 2.0
P2RY5 2.0
PF4 2.0
CSDA 2.0
HDGF 2.0
RPL35A 2.0
STK19 2.0
EPB42 2.0
Genes  differentially  expressed  between  admission  and  onset  of 
ventilator-associated  pneumonia  (VAP)  in  trauma  patients  who 
developed  VAP.  Gene  symbols  are  provided  according  to  fold 
changes.  Only  genes  with  an  absolute  fold  change  above  2  are 
presented.
Table S4: Concise signature genes' functions.
Symbol Function (from UNIPROT)
Fold 
change
GAS6
Ligand for tyrosine-protein kinase receptor AXL, TYRO3 and MER whose 
signaling is implicated in cell growth and survival, cell adhesion and cell 
migration. Plays a role in thrombosis by amplifying platelet aggregation and 
secretion in response to known agonists.
1.3
ALAS2
Erythroid specific 5-aminolevulinate synthase. Catalyzes Succinyl-CoA + 
Glycine <=> 5-aminolevulinate + CoA + CO2.
2.0
FBXO41
Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-
type E3 ubiquitin ligase complex 
2.3
PPBP
LA-PF4 stimulates DNA synthesis, mitosis, glycolysis, intracellular cAMP 
accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid 
and sulfated glycosaminoglycan. It also stimulates the formation and secretion 
of plasminogen activator by human synovial cells. NAP-2 is a ligand for 
CXCR1 and CXCR2, and NAP-2, NAP-2(73), NAP-2(74), NAP-2(1-66), and 
most potent NAP-2(1-63) are chemoattractants and activators for neutrophils. 
TC-1 and TC-2 are antibacterial proteins, in vitro released from activated 
platelet alpha-granules. CTAP-III(1-81) is more potent than CTAP-III 
desensitize chemokine-induced neutrophil activation. 
2.7
AHSP
Acts as a chaperone to prevent the harmful aggregation of alpha-hemoglobin 
during normal erythroid cell development. Specifically protects free alpha-
hemoglobin from precipitation. It is predicted to modulate pathological states 
of alpha-hemoglobin excess such as beta-thalassemia
2.8
AURKB
May be directly involved in regulating the cleavage of polar spindle 
microtubules and is a key regulator for the onset of cytokinesis during 
mitosis. Component of the chromosomal passenger complex (CPC), a 
complex that acts as a key regulator of mitosis. The CPC complex has 
essential functions at the centromere in ensuring correct chromosome 
alignment and segregation and is required for chromatin-induced microtubule 
stabilization and spindle assembly. Phosphorylates 'Ser-10' and 'Ser-28' of 
histone H3 during mitosis. Required for kinetochore localization of BUB1 
and SGOL1.
2.9
ZNF317
May function as a transcription factor. May play an important role in 
erythroid maturation and lymhoid proliferation.
3.4
SPARC
Appears to regulate cell growth through interactions with the extracellular 
matrix and cytokines. Binds calcium and copper, several types of collagen, 
albumin, thrombospondin, PDGF and cell membranes. There are two calcium 
binding sites; an acidic domain that binds 5 to 8 Ca2+,with a low affinity and 
an EF-hand loop that binds a Ca2+ ion with a high affinity.
3.5
AAMP
Plays a role in angiogenesis and cell migration. In smooth muscle cell 
migration, may act through the RhoA pathway.
4.1
PCSK1
Involved in the processing of hormone and other protein precursors at sites 
comprised of pairs of basic amino acid residues. Substrates include POMC, 
renin, enkephalin, dynorphin somatostatin and insulin.
4.2
Genes function. Known function extracted from UNIPROT for each of the ten identified genes 
with the concise signature.
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Sex-Related  Differences  in  Gene  Expression  Following  Coxiella  burnetii 
Infection in Mice: Potential Role of Circadian Rhythm
Julien Textoris, Leang Heng Ban, Christian Capo, Didier Raoult, Marc Leone, Jean-Louis Mege
PLoS ONE 5(8): e12190
La fièvre Q est  la forme clinique de l'infection par  Coxiella  burnetii.  Cette zoonose présente un 
dimorphisme sexuel ; les hommes sont atteints de manière plus fréquente et plus sévère que les femmes,  
bien que l'exposition soit identique. Cette étude explore le rôle du sexe dans un modèle murin d'infection par  
C. burnetii.
Des souris ont été infectées par  C. burnetii pendant 24 h, puis le transcriptome hépatique a été 
analysé par puces à ADN. Une analyse multiclasse a permis d'identifier 2 777 sondes dont l'expression est  
modulée par l'infection à C. burnetii. Seuls 14 % des gènes présentaient une modulation de leur expression 
indépendante du sexe, alors que 86 % des gènes étaient modulés spécifiquement chez les mâles et les 
femelles. Une analyse similaire conduite chez des animaux castrés montre que les hormones sexuelles  
influencent plus de 60 % de la modulation induite par l'infection. La réduction de modulation de l'expression 
était prépondérante chez les mâles castrés. L'annotation fonctionnelle des gènes modulés a identifié quatre 
clusters  fonctionnels  chez  les  mâles,  reliés  à  l'adhésion  inter-cellulaire,  la  transduction  du  signal,  les 
défensines et la voie Jak/Stat. L'induction précoce de la transcription de l'IL10 et de Stat3 pourrait expliquer 
la plus forte susceptibilité des hommes infectés par  C. burnetii  à développer des formes cliniques. Deux 
clusters fonctionnels ont été identifiés chez les femelles, dont le contrôle du rythme circadien, constitué de 
plusieurs facteurs de transcription interagissant au niveau d'une boucle de rétro-contrôle. L'expression de 
Clock et d'Arntl (bras inducteur de la boucle) est diminuée alors que l'expression de Per (bras inhibiteur de la  
boucle) est augmentée. Cette modulation précoce pourrait être associée à une élimination plus efficace des 
bactéries chez les souris femelles par rapport aux mâles chez lesquels l'infection est plus marquée.
Cette étude confirme au niveau transcriptionnel l'existence d'un dimorphisme sexuel dans l'infection 
par  C. burnetii. Elle montre pour la première fois que le rythme circadien joue un rôle important dans la  
réponse anti-infectieuse chez la souris, et pose de nouvelles bases pour élucider le rôle du dimorphisme 
sexuel en pathologie infectieuse humaine.
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Abstract
Background: Q fever, a zoonosis due to Coxiella burnetii infection, exhibits sexual dimorphism; men are affected more
frequently and severely than women for a given exposure. Here we explore whether the severity of C. burnetii infection in
mice is related to differences in male and female gene expression profiles.
Methodology/Principal Findings: Mice were infected with C. burnetii for 24 hours, and gene expression was measured in
liver cells using microarrays. Multiclass analysis identified 2,777 probes for which expression was specifically modulated by
C. burnetti infection. Only 14% of the modulated genes were sex-independent, and the remaining 86% were differentially
expressed in males and females. Castration of males and females showed that sex hormones were responsible for more than
60% of the observed gene modulation, and this reduction was most pronounced in males. Using functional annotation of
modulated genes, we identified four clusters enriched in males that were related to cell-cell adhesion, signal transduction,
defensins and cytokine/Jak-Stat pathways. Up-regulation of the IL-10 and Stat-3 genes may account for the high
susceptibility of men with Q fever to C. burnetii infection and autoantibody production. Two clusters were identified in
females, including the circadian rhythm pathway, which consists of positive (Clock, Arntl) and negative (Per) limbs of a
feedback loop. We found that Clock and Arntl were down-modulated whereas Per was up-regulated; these changes may be
associated with efficient bacterial elimination in females but not in males, in which an exacerbated host response would be
prominent.
Conclusion: This large-scale study revealed for the first time that circadian rhythm plays a major role in the anti-infectious
response of mice, and it provides a new basis for elucidating the role of sexual dimorphism in human infections.
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Introduction
Social factors such as gender inequity can explain differences in
the distribution of infectious diseases between men and women. As
shown elsewhere, poor women may be at a disadvantage in their
ability to access quality health care [1]. However, biological
differences are also responsible for part of the epidemiological
variation observed between males and females in infectious
diseases due to intra- and extracellular pathogens [2]. Gender-
based biological differences also affect host immune responses to
pathogens. Women elicit more vigorous humoral and cell-
mediated immune responses than men in response to antigenic
challenges, while men have frequently been observed to exhibit
more aggressive and harmful inflammatory responses to pathogens
[3]. Tuberculosis [4,5] and Legionnaire’s disease [6] are reported
to be more prevalent and severe in men than in women. Although
biological differences have been largely attributed to sex hormones
[7], the precise nature of the cross-talk between sex and infection
remains largely unknown.
Q fever is a zoonosis due to Coxiella burnetii, an intracellular
bacterium [8,9]. Following primary infection, half of infected
patients experience acute Q fever. The disease is characterized by
clinical polymorphism and includes fever, granulomatous hepati-
tis, and pneumonia. For a similar exposure risk, men are 2.5 times
more likely to become symptomatic than women [10]. Hyperin-
flammatory Q fever with granulomatous hepatitis and auto-
antibodies has been reported in male patients who respond poorly
to antimicrobial agents [11]. In addition, Q fever complications
are higher in males than in females. As a result, males represent
75% of patients diagnosed with C. burnetii endocarditis [12]. In
mice, the severity of C. burnetii infection is also sex-dependent, with
females exhibiting lower bacterial load than males. Ovariectomy
increases the bacterial load in the liver and spleen, and this is
corrected by 17b-estradiol treatment [13], demonstrating that
estrogens limit tissue infection. Nevertheless, the underlying
mechanisms that govern the differential responsiveness of males
and females to bacterial infection are poorly understood. To
investigate these differences, we adopted a large-scale approach
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consisting of a microarray covering the whole genome. Unexpect-
edly, 86% (2,379/2,777) of the probes that were modulated by C.
burnetii infection were dependent on sex. We identified a specific
pathway related to the circadian cycle in females that may control
the severity of C. burnetii infections.
Results and Discussion
Mice were infected with C. burnetii for 24 hours, and changes in
gene expression were investigated in liver cells. C. burnetii infection
generated more transcriptional changes in males than in females.
When samples were plotted according to the weight of variances
due to sex and infection, principal component analysis (PCA)
clearly discriminated males and females and revealed that the
distance between uninfected and infected males was higher than
that found between uninfected and infected females (Fig. 1A). A
multiclass analysis identified 2,777 probes that were modulated in
response to C. burnetii. These probes were classified into four
distinct clusters (Fig. 1B). The first cluster is sex-independent and
includes 398 probes (14% of the total) that were similarly regulated
in both males and females. The other three clusters, representing
the majority of probes modulated by C. burnetii infection (86% of
the total), are sex-dependent: 1,459 probes (53%) were specifically
modulated in males whereas 892 (32%) were specifically
modulated in females. The fourth cluster of 28 probes is divergent
between males and females, with 14 probes up-regulated in males
and 14 up-regulated in females (for the list, see Table S1). Using in
silico analysis, we related the modulated genes to the subcellular
distribution of their encoded proteins (Fig. 2). In infected males,
the modulated genes encode proteins that have a high degree of
interconnection. These interactions spread across the membrane,
underlying that a profound reorganization occurred at the
membrane after infection. In infected females, there were less
interactions between proteins encoded by modulated genes at the
membrane level than in males, but the interconnection between
the cytosol and the nucleus was apparently more developed. These
results highlight important changes in transcription in male and
female mice infected with C. burnetii.
It is known that nonsexual tissues and cells manifest sex-related
differences in most animals including humans. Many of these
differences are dependent on sex hormones but it is seems difficult
to attribute other differences to hormones [14]. A microarray
approach performed on long-lived mice has showed that 381 genes
(on over 14,000 genes) are altered in these mice compared to wild
type mice in a sex-independent manner while 110 genes are
affected in a sex-dependent manner [15]. Our analysis take into
account genes modulated in response to C. burnetii: these genes are
included in two categories, namely sex-independent and sex-
dependent genes. Unexpectedly, sex-dependent genes represent
86% of the total number of genes modulated in response to C.
burnetii. Among them, the majority (80%) were not modulated
upon sex in uninfected animals. It is well known that, in humans,
the clinical expression of different infectious diseases including
tuberculosis [5], Legionnaire’s disease [6] and Q fever [10] is
associated to sex. Sex has been often described as involved in the
incidence of common infectious diseases such as pneumonia [16].
Similar results have been obtained in mice infected with Listeria
monocytogenes [17] or Plasmodium berghei [18]. Bacterial sepsis, a
major cause of morbidity and mortality in humans, is due to an
exaggerated response of hosts [19]. The frequency and the severity
of bacterial sepsis are also associated with sexual dimorphism
[2,20]. Interestingly, such differences are also found in isolated
human circulating leukocytes [21] and animal models of
endotoxemia [22]. Finally, only few data show that sex does not
influence human infections: this has been reported for cerebro-
spinal [23] and soft tissue [24] infections.
The molecular mechanisms that underlie the differences
between males and females in bacterial infections are only in part
Figure 1. Impact of sex on C. burnetii infection.Male and female mice were infected with C. burnetii for 24 hours. Transcriptional responses were
assessed by microarray. A, The impacts of sex and infection on gene expression were analyzed by principal component analysis using R. Each axis
distance represents the amount of variance in gene expression explained by the corresponding factor (sex or infection). B, Hierarchical clustering
analysis was used to classify selected up-regulated and down-regulated genes in four clusters: sex-independent genes, male-dependent genes,
female-dependent genes and genes inversely modulated in males and females (red vertical bar).
doi:10.1371/journal.pone.0012190.g001
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characterized. As sexual hormones may play a major role in the
transcriptional responses to C. burnetii infection in male and female
mice, we investigated the effect of castration on these responses.
Castration shortened the distance between uninfected and infected
males, reflecting less pronounced changes in gene expression (Fig.
S1A). Castration did not substantially modify the impact of
infection on females (Fig. S1B). After C. burnetii infection, the
number of modulated probes designated as sex-independent
remained remarkably constant in castrated mice (396 vs. 398 in
intact mice). In contrast, among the sex-dependent probes, only
902 probes were modulated in castrated mice compared with
2,379 probes in intact mice, suggesting that sex hormones were
responsible for more than 60% of the gene modulation (Fig. S2).
This reduction was most significant in males: 378 probes were
specifically modulated in castrated males (vs. 1,459 in intact males)
compared to 516 in castrated females (vs. 892 in intact females),
suggesting that testosterone was responsible for the major changes
observed after C. burnetii infection. This finding is in line with
previous studies suggesting the predominant effect of testosterone
on sexual dimorphism [25,26]. It is important to note that about
40% of sex-dependent genes that were modulated in response to C.
burnetii were not linked to hormonal status. This is reminiscent of
previous data that showed that sex differences are not completely
abrogated or accentuated by hormone ablation or supplementa-
tion, respectively [27].
We next used functional annotation of the modulated genes to
identify major pathways that were possibly involved in the
response to C. burnetii infection. In the sex-independent cluster,
four groups of enriched keywords were identified (Table 1). Group
1, with an enrichment score of 4.3, is related to early induction of
the acute phase liver response. Acute phase response is a major
function of the liver that contributes to bacterial clearance in acute
Q fever [10]. The gene encoding serum amyloid A1–3 was
expressed with a fold change (FC) of over 25. The genes encoding
orosomucoid 1–3, serine peptidase inhibitor and complement
components (C8a, C9) were also up-regulated. Group 2 (enrich-
ment score of 3.9) is related to lipid metabolism and group 3
Table 1. Functional annotation of the sex-independent
cluster.
Ontology Keywords P-value
Acute phase response (ES : 4.3–25 genes)
SAA1, SAA2, SAA3, SAA4, ORM3, SERPINA3N, C8a, C9
SP_PIR_KEYWORDS Acute phase 2.961026
GO_BP Acute-phase response 6.461026
GO_BP Acute inflammatory response 1.861025
INTERPRO Serum amyloid A protein 8.661025
SMART SAA 6.161026
Lipid metabolism (ES : 3.9–38 genes)
CRAT, ACOX1, ACOT2, ACOT5, EHHADH, ACAA1A, CPT1B, PLTP
GO_BP Fatty acid metabolic process 1.361027
GO_BP Monocarboxylic acid metabolic process 9.161029
SP_PIR_KEYWORDS Fatty acid metabolism 8.461026
BO_BP Lipid metabolic process 1.661029
GO_CC Peroxysome 3.361025
GO_CC Microbody 3.361025
Steroid metabolic process (ES : 3.3–14 genes)
STAR, IDI1, MOGAT1, LEPR, FABP5, PCTP, AKR1C18, FBP2, HMGCS1
GO_BP Steroid metabolic process 1.761024
GO_BP Alcohol metabolic process 5.561024
GO_BP Cholesterol metabolic process 6.861024
GO_BP Sterol metabolic process 1.061023
Thrombospondin (ES : 1.8–5 genes)
SPON2, C9, SEMA5B, ADAMTS20, C8A
SMART TSP1 1.761023
INTERPRO Thrombospondin, type I 1.961023
The enrichment score (ES), the number of genes and example genes in each
group of genes were indicated.
doi:10.1371/journal.pone.0012190.t001
Figure 2. Subcellular distribution of proteins encoded by modulated genes. The InteractomeBrowser plugin of TranscriptomeBrowser was
used to generate a graph of protein interactions in males and female mice according to their cellular distribution [65].
doi:10.1371/journal.pone.0012190.g002
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(enrichment score of 3.3) is related to steroid metabolism. Most of
the genes annotated with keywords of groups 2 and 3 were down-
regulated by a mean FC of 2. This finding is apparently related to
disturbed lipid metabolism during C. burnetii infection since
pronounced lipid infiltration and increased cholesterol have been
reported in the livers of C. burnetii-infected guinea pigs [28]. In
addition, C. burnetii replication requires free access to host
cholesterol stores [29]. Group 4 is related to genes encoding
proteins with a thrombospondin domain. Thrombospondin is a
family of multifunctional proteins involved in coagulation,
angiogenesis, apoptosis, and immune regulation [30]. One of
these genes (Spon2) is a pathogen-associated molecular pattern
recognition molecule known to recognize Escherichia coli lipopoly-
saccharide and numerous gram negative bacteria [31]. Although
some partners of thrombospondin such as avb3 integrin have been
described as C. burnetii receptors [32], there is no evidence that
Spon2 recognizes C. burnetii.
Functional annotation of genes that were modulated only in
infected males identified four groups of keywords (Table 2).
Groups 1 and 3 are related to signal transduction and cell-cell
adhesion, respectively. Keyword group 2 is related to genes
encoding defensins. Although defensins are peptides with antimi-
crobial properties [33,34], their role against C. burnetii infection has
never been reported. Defensins such as Defcr3, Hamp1 and
Hamp2 were down-regulated in infected males, suggesting that the
reduced expression of defensins favors early infection in males.
Hepcidins (Hamp1 and Hamp2) reduce iron availability for
invading microorganisms by reducing extracellular iron concen-
trations [35]. As has been recently suggested, greater iron
availability in males may favor C. burnetii replication [36]. It has
also been shown that hepcidins are differentially expressed in male
and female mice [37,38]. Keyword group 4 is related to cytokines
and the Jak/Stat pathway. The gene encoding interleukin (IL)-10
was up-regulated in males. These results were confirmed by RT-
PCR (Table S2), and a time course study showed that males
overproduced interleukin (IL)-10 mRNA compared with females
independently of the duration of infection (Fig. 3A). Note that the
expression of the gene encoding Stat 3, a transcription factor
known to be targeted by IL-10, was higher in males than in
females. We previously showed that IL-10 enables monocytes to
support C. burnetii replication [39,40] and that chronic evolution of
Q fever is associated with increased production of IL-10 [41].
However, to our knowledge, a link between IL-10 and sexual
dimorphism in C. burnetii infection has never been reported.
Interferon (IFN)-c, which is critical for protection against
intracellular bacteria and C. burnetii infection [42], was weakly
modulated in male and female mice one day after infection as
determined by microarray and RT-PCR (Table S2). A time course
analysis revealed that the gene encoding IFN-c was dramatically
up-regulated at days 4 and 7 post-infection (Fig. 3B), suggesting
that IFN-c induces deleterious effects in parallel with the
resolution of C. burnetii infection. The expression of the IL-6 gene
was slightly up-regulated in females (Table S2), and a time course
study showed that the IL-6 gene was dramatically over-expressed
at days 4 and 7 post-infection, especially in females (Fig. 3C). After
trauma-hemorrhage, IL-6 release by macrophages is suppressed in
male mice but not in female mice [43], suggesting that sex and IL-
6 production are related. Taken together, these results suggest that
males develop an early anti-inflammatory response that may favor
increased bacterial burden at the onset of infection and may
promote antibody production in an IL-10-dependent manner.
This may account for the presence of auto-antibodies in men with
Q fever.
The specific signature of infected females, which includes
892 genes (Fig. 1B), was characterized by two major groups of
keywords (Table 3): intracellular location and transcriptional
activity, and unexpectedly, circadian rhythm. The latter pathway
was further investigated with RT-PCR and network analysis.
Circadian rhythm is controlled by an auto-regulated transcription-
translation feedback loop that regulates the expression of rhythmic
genes in a tissue-specific manner [44]. In liver cells, a significant
number of clock-regulated genes are associated with the cell cycle
and proliferation. Clock and Arntl form the positive limb of the
transcriptional loop, while the Per and Cry protein families form
the negative limb of the feedback loop by inhibiting their own
Clock/Arntl-induced transcription [44]. The turnover of Per and
Cry allows the cycle to begin again (Fig. S3). Microarray and RT-
PCR data showed that Clock and Arntl expression were down-
regulated in females infected with C. burnetii for one day while Per
expression was up-regulated (Table S2). We questioned whether
these variations were persistent because we had previously found
that C. burnetii infection of liver cells peaks after four days and
decreases thereafter [13]. The levels of Arntl and Clock transcripts
remained constant in males over seven days, but in females, these
Table 2. Functional annotation of male-dependent cluster.
Ontology Keywords P-value
Signal transduction (ES : 9.9–418 genes)
EXTL1, CDH11, RHO, ADRA2B, IL12RB2, CD36 GLP2R, OLFR981
SP_PIR_KEYWORDS Transmembrane 1.261029
GO_BP Signal transduction 3.961027
GO_MF Transmembrane receptor activity 1.761029
GO_BP G-protein coupled receptor signal
transduction
4.161027
INTERPRO Olfactory receptor 8.861028
GO_GC Transmembrane region 2.061026
Defensin (ES : 8.2–45 genes)
DEFB3, DEFA1, DEFCR7, DEFCR17, DEFCR9, DEFCR25, HAMP2
SMART DEFSN 5.7610211
INTERPRO Mammalian defensin 1.7610210
GO_BP Defense response to bacterium 2.261028
SP_PIR_KEYWORDS Antimicrobial 9.461027
GO_BP Defense response 1.461023
SP_PIR_KEYWORDS Defensin 1.261026
Cell-cell adhesion (ES : 3.7–52 genes)
CDH1, CDH4, FAIM2, MMD2, PCDHA5, PCDHB19, CDH11
INTERPRO Cadherin 2.961027
SP_PIR_KEYWORDS Cell adhesion 2.861024
GO_BP Cell adhesion 2.561023
SP_PIR_KEYWORDS Calcium 3.061023
Cytokines/Jak-STAT pathway (ES : 2.3–28 genes)
IFNA1, IL5, PDGFA, IL1RN, STAT3, EGF,CXCL12, IL10, IL11, IFNG, IL13
BIOCARTA Cytokines and Inflammatory response 2.661024
KEGG_PATHWAY Jak-STAT signalling pathway 1.761023
KEGG_PATHWAY Cytokin-Cytokin receptor interaction 4.261023
INTERPRO Four-helical cytokine, core 7.161023
SP_PIR_KEYWORDS Cytokine 2.161022
GO_MF Cytokine activity 2.061022
The enrichment score (ES), the number of genes and example genes in each
group of genes were indicated.
doi:10.1371/journal.pone.0012190.t002
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transcripts declined at day one and increased thereafter to
approach the number observed in males (Fig. 3D and 3E,
respectively). The expression of Per2, which increased in females
at day one, remained high during the seven days of the infection.
In males, the expression of the Per2 gene increased at day four
(Fig. 3F). The differences between males and females regarding the
expression of Arntl, Clock and Per2 were lost after castration of
the mice (Fig. S4). Taken together, these findings show that C.
burnetii infection affected the circadian rhythm of female mice.
These results are distinct from those shown in a recent report in
which the expression of the Clock, Arntl and Per genes was down-
modulated in blood leukocytes after the administration of
endotoxin to human volunteers. However, the relationship
between these changes and sexual dimorphism was not investi-
gated [45].
The circadian rhythm modification associated with C. burnetti
infection may affect numerous biological functions. The biological
clock controls the secretion of estrogen hormones [46] by
regulating the intracellular levels of estrogen receptors a and b
[47,48]. Lower Per2 levels lead to the stabilization of estrogen
receptor b. As Per2 is estrogen-inducible, a feedback mechanism
may attenuate stimulation by estrogens [48]. Male steroid
hormones retroactively play a role in the circadian rhythm at
the brain level [49]. Orchidectomy leads to a loss of androgen
receptor expression and circadian-specific locomotor activity, both
of which are restored by testosterone replacement [49,50].
Interestingly, circadian rhythm and immune responses are
interconnected [51]. For instance, the susceptibility or resistance
of flies to infection varies according to the time when they are
infected [52]. The circadian oscillation of clock genes affects IFN-c
Table 3. Functional annotation of female-dependent cluster.
Ontology Keywords P-value
Circadian rhythm (ES : 2.8–14 genes)
CLOCK, PER1, PER2, PER3, PTGDS, OPN3, MTNR1A, ARNTL, AFP
GO_BP Circadian rhythm 2.961028
GO_BP Rhythmic process 1.061026
SP_PIR_KEYWORDS Biological rhythms 2.061026
KEGG_PATHWAY Circadian rhythm 3.661025
INTERPRO PAS domain 8.561024
Intracellular/Transcription (ES : 2.2–328 genes)
SOX9, PBEF1, STX1B1, RNF20, UGT1A2
GO_CC Intracellular 3.561025
GO_CC Membrane-bound organelle 2.561023
GO_CC Nucleus 7.361023
INTERPRO Basic helix-loop-helix dimerization region 2.061023
GO_BP Metabolic process 2.861024
The enrichment score (ES), the number of genes and example genes in each
group of genes were indicated.
doi:10.1371/journal.pone.0012190.t003
Figure 3. Time course of gene modulation. Male (squares) and female (triangles) mice were infected with C. burnetii for one, four and seven
days, and gene expression was determined by qRT-PCR and normalized with the GAPDH gene. A–C, genes encoding cytokines. D–F, genes involved
in circadian rhythm. Horizontal lines indicate the selected fold change cut-off of 61.75.
doi:10.1371/journal.pone.0012190.g003
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production through the regulation of Per2 [53] or the activity of
natural killer cells [54]. Circadian rhythm may also control the
steroid pathway since it post-translationally inhibits glucocorticoid
receptors [55]. Cross-talk between these pathways may reinforce
the effect of sex on C. burnetii infection. Finally, we hypothesize that
an early response involving circadian rhythm likely promotes
efficient bacterial elimination in females, while in males, the early
phase of the response to C. burnetii infection is inefficient, due at
least in part to an anti-inflammatory response that favors bacterial
growth [13].
In conclusion, different transcriptional responses to C. burnetii
were associated with the severity of the infection in male and
female mice. Functional annotation showed that the modulated
genes were organized in different networks in males and females
and we hypothesize that circadian rhythm may be involved in C.
burnetii infection. As the percentage of sex-dependent genes that
were modulated by C. burnetii infection was dramatically high, one
can expect that numerous genes would be modulated in other
infectious diseases described as epidemiologically associated with
sexual dimorphism. Our data provide a new basis for elucidating
the role of sexual dimorphism in human infections. It would be
also interesting to determine if differences in gene expression occur
in infectious diseases not described as epidemiologically sex-
dependent.
Materials and Methods
Infection of Mice
The following experimental protocol was approved by the
Institutional Animal Care and Use Committee of the Universite´ de
la Me´diterrane´e. Forty C57BL/6 mice (20 males and 20 females)
were obtained from Charles River Laboratories. Ten females and
ten males were sterilized at seven weeks of age. Ovaries were
removed through bilateral incisions of the lumbar region and testes
were removed through bilateral scrotum incision. After three
weeks, ten males and ten females, including five non-castrated and
five castrated animals of each gender, were killed. The other series
of mice were injected intraperitoneally with 105 C. burnetii
organisms at the same time and sacrificed at day one after
infection [56]. In another set of experiments, 16 mice (4 intact
males, 4 castrated males, 4 intact females and 4 castrated females)
were killed at zero, one, four and seven days after C. burnetii
infection. Organs were aseptically excised. Samples for RNA
extraction were stabilized in RNAlater (Qiagen, France). All
specimens were stored at 280uC until use.
RNA isolation and real-time PCR
Total RNA extraction and reverse transcription were performed
as previously described [57]. The primers were designed by
Primer3 (v. 0.4.0) available at http://frodo.wi.mit.edu/. Reverse
trancriptase was omitted in negative controls. The FC in target
gene cDNA relative to endogenous control (glyceraldehyde
3-phosphate dehydrogenase, GAPDH) was determined with the
formula: fold change= 22DDCt, where DDCt= (CtTarget2
CtGAPDH)infected mice2(CtTarget2CtGAPDH)uninfected mice. Ct values
were defined as the cycle number at which fluorescence signals were
detected [58].
Microarray procedures and data analysis
Whole Mouse Genome Oligo Microarray 4644K Kit (44,000
60-mer oligonucleotides) and One-Color Microarray-Based Gene
Expression Analysis (Agilent Technologies) were used as recently
described [57]. Slides were washed, dried, and scanned at 5-mm
resolution with a G2505B DNA microarray scanner (Agilent
Technologies). Intensity signals were generated using the Agilent
Feature Extractor Software A.9.1.3 after image quality control was
performed manually. Four aberrant samples (two infected males,
one uninfected male and one uninfected female) were eliminated
before starting the analysis because of technical problems. Raw
signal data were normalized with the quantile method [59] and
then transformed into binary logarithm. The Significance Analysis
of Microarrays test (SAM [60]) was used to study the gene
expression in intact animals with a multiclass analysis (sex and
infection). False Discovery Rate (FDR) was set to 0.05 to filter
modulated genes. Then, selected probes (n = 13,814) were filtered
using the FC obtained from dividing the median intensity of
infected and non-infected mice. FCs of male and female mice were
calculated with a cut-off at 1.75 as selection criterium for
differentially expressed genes. Thus, the selected genes which
were annotated as ‘‘sex-specific’’ were also ‘‘infection-specific’’.
Supervised analyses were carried out with R (R for statistical
computation and graphic version 2.7.2, GPL) with the library
BioConductor [61]. Functional annotations and classifications
were performed using the DAVID Bioinformatics Resource 2008
[62]. Keywords from the following ontologies were analyzed (GO,
SP_PIR_KEYWORDS, UP_SEQ_FEATURE, SMART, IN-
TERPRO, KEGG_PATHWAYS, and BIOCARTA). Gene
Ontology (GO) keywords are further classified according to their
main category: Biological Process (GO_BP), Cellular Component
(GO_CC) or Molecular Function (GO_MF). PCA was used to
visually explore global effects for genome wide trends, unexpected
effects and outliers in the expression data (library made4 for R
[63]). The data discussed in this publication have been deposited
in NCBI’s Gene Expression Omnibus [64] and are accessible
through GEO Series accession number GSE21065 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21065).
Supporting Information
Figure S1 Impact of castration on C. burnetii infection. Male and
female mice were castrated and then infected with C. burnetii for
24 hours. Transcriptional responses were assessed by microarray.
The impacts of castration and infection on gene expression were
assessed by principal component analysis in males (A) and females
(B) using R. Each axis distance represents the amount of variance
in gene expression explained by the corresponding factor
(castration or infection).
Found at: doi:10.1371/journal.pone.0012190.s001 (7.19 MB TIF)
Figure S2 Castration reduces the number of genes regulated by
infection in males. Genes modulated by C. burnetii infection in
sterilized or intact male and female mice are represented by a
Venn diagram.
Found at: doi:10.1371/journal.pone.0012190.s002 (1.46 MB TIF)
Figure S3 Overview of the tissular components of the biological
clock. The heterodimer Clock/Arntl positively regulates transcrip-
tion of the Per and Cry genes, which in turn negatively regulate
Clock and Arntl transcription, creating cyclic expression of these
proteins.
Found at: doi:10.1371/journal.pone.0012190.s003 (1.78 MB TIF)
Figure S4 Time course of circadian gene modulation in
castrated animals after infection. Castrated male (squares) and
ovariectomized female (triangles) mice were infected with C.
burnetii for one, four and seven days, and gene expression was
determined by qRT-PCR and normalized to the GAPDH gene.
A–C, Genes involved in circadian rhythm. Horizontal lines
indicate the selected fold change cut-off of 61.75.
Found at: doi:10.1371/journal.pone.0012190.s004 (4.08 MB TIF)
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Table S1 Inversed fold changes in males and females.
Found at: doi:10.1371/journal.pone.0012190.s005 (0.05 MB
PDF)
Table S2 Fold changes assessed by microarray and RT-PCR.
Found at: doi:10.1371/journal.pone.0012190.s006 (0.04 MB
PDF)
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Table S1. Inversed fold changes in males and females
  down-modulated in males
   up-regulated in females
               up-regulated in males
            down-modulated in females
BB505010 - 12.5 2.6 D930050A07Rik 1.8 - 2.0
Gm534 - 6.7 1.9 PPP1R3C 1.8 - 2.2
AK007854 - 5.6 1.9 CHKA 1.9 - 2.6
LHX8 - 3.1 1.9 BAIAP2 1.9 - 2.7
CYP3A44 - 2.4 2.7 MLL5 1.9 - 2.0
AACS - 2.3 2.8 MYBPC2 1.9 - 2.2
RGS16 - 2.2 11.5 FST 1.9 - 1.8
AK051762 - 2.1 1.8 CSPG5 2.0 - 2.7
OPRM1 - 2.0 1.9 BC057022 2.1 - 1.9
6030468B19Rik - 2.0 1.9 AK040776 2.3 - 1.9
Gm7231 - 1.9 3.4 LOXL4 2.4 - 4.3
OLFR1321 - 1.9 2.3 EMID2 2.9 - 1.8
BAI3 - 1.8 1.9 COG4 3.2 - 1.8
Gm10001 - 1.8 2.0 OLFR914 3.8 - 3.0
Table S2. Fold changes assessed by microarray and RT-PCR
                                                        Fold change     
               microarray   RT-PCR
males females males females
IL6 1.3 2.2 1.3 1.2
IFNG - 1.1 - 1.1 - 1.7 1.0
IL10 1.7 1.2 2.1 1.2
ARNTL 1.4 - 11.1 1.0 -18
CLOCK 1.1 - 2.6 1.0 - 4.7
PER2 1.2 3.91 1.1 4.0
Gene  Expression  Signature-Based  Screening  Identifies  new  Broadly 
Effective Influenza A Antivirals
Laurence  Josset,  Julien  Textoris,  Béatrice  Loriod,  Olivier  Ferraris,  Vincent  Moules,  Bruno  Lina, 
Catherine N’Guyen, Jean-Jacques Diaz, Manuel Rosa-Calatrava
PLoS ONE 5(10): e13169
Les  anti-viraux  classiques  ciblent  des  protéines  virales  et  sont  donc  exposés  à  l'émergence  de 
résistances.  Pour  contourner  ce  problème,  l'idée  de  s'attaquer  aux  protéines  de  l'hôte  a  été  proposée 
comme stratégie alternative. Notre hypothèse est que cette approche permettrait d'identifier de nouveaux 
antiviraux à large spectre.  Le virus  Influenza A   a été utilisé comme modèle en raison de sa diversité 
antigénique. De plus, comme l'a souligné la récente pandémie H1N1, il est nécessaire de développer des 
stratégies thérapeutiques permettant de faire face à l'émergence d'un nouveau variant. Nous avons donc 
proposé l'identification d'une signature transcriptionnelle de réponse à l'infection par différentes souches de 
virus  de  la  grippe.  L'idée  est  que  cette  réponse  commune permettrait  d'identifier  de  potentielles  cibles 
cellulaires permettant le développement d'antiviraux à large spectre. 
Nous avons donc analysé les modulations du transcriptome induites lors de l'infection par cinq souches 
humaines  ou  aviaires  du  virus  Influenza  A.  Cette  approche  a  conduit  à  l'identification  d'une  signature 
transcriptionnelle de 300 gènes dont l'expression est modulée entre les cellules infectées et non infectées. A 
partir de cette signature, une liste des vingts gènes présentant la plus forte modulation a été utilisée pour  
interroger  la  base  ConnectivityMap. Cette  base de données regroupe des signatures transcriptionnelles 
induites par diverses molécules. Les molécules induisant un profil d'expression inverse à celui obtenu après 
l'infection ont été choisies comme potentiels candidats antiviraux. Notre hypothèse est que ces molécules 
entraîneraient  un  environnement  défavorable  à  la  réplication  virale.  Huit  antiviraux  potentiels  dont  la  
ribavirine ont été sélectionnés et leur effet sur la réplication des cinq souches a été évalué in-vitro. Six de 
ces molécules inhibent la réplication virale. De plus, la réplication du virus H1N1 responsable de la récente  
pandémie était inhibée par cinq de ces huits molécules, alors que cette souche n'avait pas été utilisée pour 
définir la signature transcriptionnelle. 
Ce résultat démontre que notre stratégie permet d'identifier des antiviraux à large spectre, actif sur des 
souches virales émergentes. Les gènes de la signature transcriptionnelle identifiée codent probablement 
pour des protéines cellulaires impliquées dans le cycle viral. Il s'agit de la première étude démontrant le 
potentiel de l'analyse du transcriptome pour identifier de nouvelles cibles thérapeutiques. Cette approche 
accélère  considérablement  le  développement  de  nouvelles  molécules  et  pourrait  être  envisagée  pour 
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d'autres modèles infectieux. 
Ce travail a donné lieu au dépôt d'un brevet national (09-58810 en date du 9 décembre 2009), américain 
(62/267,997, en date du 9 décembre 2009) et international portant le numéro PCT/EP2010/069023 (Office 
Européen des Brevets). 
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Abstract
Classical antiviral therapies target viral proteins and are consequently subject to resistance. To counteract this limitation,
alternative strategies have been developed that target cellular factors. We hypothesized that such an approach could also
be useful to identify broad-spectrum antivirals. The influenza A virus was used as a model for its viral diversity and because
of the need to develop therapies against unpredictable viruses as recently underlined by the H1N1 pandemic. We proposed
to identify a gene-expression signature associated with infection by different influenza A virus subtypes which would allow
the identification of potential antiviral drugs with a broad anti-influenza spectrum of activity. We analyzed the cellular gene
expression response to infection with five different human and avian influenza A virus strains and identified 300 genes as
differentially expressed between infected and non-infected samples. The most 20 dysregulated genes were used to screen
the connectivity map, a database of drug-associated gene expression profiles. Candidate antivirals were then identified by
their inverse correlation to the query signature. We hypothesized that such molecules would induce an unfavorable cellular
environment for influenza virus replication. Eight potential antivirals including ribavirin were identified and their effects
were tested in vitro on five influenza A strains. Six of the molecules inhibited influenza viral growth. The new pandemic
H1N1 virus, which was not used to define the gene expression signature of infection, was inhibited by five out of the eight
identified molecules, demonstrating that this strategy could contribute to identifying new broad anti-influenza agents
acting on cellular gene expression. The identified infection signature genes, the expression of which are modified upon
infection, could encode cellular proteins involved in the viral life cycle. This is the first study showing that gene expression-
based screening can be used to identify antivirals. Such an approach could accelerate drug discovery and be extended to
other pathogens.
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Introduction
Antiviral drug development is currently based on two
approaches: i) the conventional approach of inhibiting the activity
of a viral enzyme which often leads to the emergence of drug
resistant viruses due to viral genomic variability and ii) the more
recent approach of targeting cellular factors that are required for
viral replication. Indeed, coding for a limited number of proteins,
viruses hijack the cellular machinery and rely on many host
proteins for their replication. The major recognized advantage of
targeting a host factor is therefore to limit the development of
resistance as the virus cannot replace a missing cellular protein [1].
Such an approach has been used in antiretroviral therapy with the
development of a CCR5 antagonist showing promise as an anti-
HIV drug [2]. We have also demonstrated that this strategy is
efficient at inhibiting the replication of herpes viruses resistant to
conventional antivirals [3]. In influenza research, the effective in
vitro and in vivo inhibition of two different cellular pathways
without inducing resistance has been reported, and both are
currently undergoing preclinical trials (recently reviewed in [4]).
Targeting cellular proteins may provide another crucial
advantage: if a cellular pathway is critical to the viral cycle,
agents that target such a pathway should represent potential
broad-spectrum antivirals. The influenza virus represents a
constant threat to public health due to the emergence of new
viral strains and is therefore an ideal model on which to test this
hypothesis.
Belonging to the orthomyxoviridae family, influenza viruses
have genomes composed of single-stranded RNA and are classified
into three types: A, B and C according to their internal protein
sequences [5]. The influenza A viruses are further subtyped based
on the antigenicity of the two envelope glycoproteins hemagglu-
tinin (HA) [H1 to H16] and neuraminidase (NA) [N1 to N9]. All
influenza A subtypes are endemic in aquatic birds but only two,
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H1N1 and H3N2, are presently circulating among humans. Since
the influenza genome is segmented, two different viral strains
infecting the same cell are able to reassort their genomic segments.
Variability can also be due to the low fidelity of the viral RNA
polymerase, which causes yearly epidemics owing to an antigenic
drift in glycoproteins. Novel pathogenic strains of the influenza
virus have also emerged with antigenically different HA and/or
NA and have caused three pandemics in the 20th century: the
Spanish influenza (H1N1) in 1918, responsible for approximately
50 million deaths; the Asian influenza (H2N2) in 1957 during
which about 2–4 million people died; and the Hong Kong
influenza (H3N2) in 1968 responsible for 1–2 million deaths [6].
Considering this pandemic potential and with up to 500,000
annual deaths worldwide during usual winter outbreaks, influenza
A viruses represent a major public health concern [7]. Prevention
relies on vaccination which has several major limitations including
the lag time for vaccine preparation and the low vaccination
coverage rate. Once a patient becomes infected, the current
etiologic treatment of flu relies on M2 channel blockers or NA
inhibitors [8]. However, these existing therapies are inappropriate
for use in cases of severe infection and may be limited due to the
risk of rapid emergence of drug resistant viruses. Thus there is an
obvious need to complement existing therapies with new anti-
influenza drugs.
To search for new antivirals, we hypothesized that common
viral effects on cell metabolism should occur after infection with
different avian and human influenza viruses and that this pattern
should lead to the identification of drugs effective on all influenza
A viruses potentially. We first sought to identify a common gene
expression signature following the infection with different human
and avian influenza A viruses. While several microarray analyses
have already compared the pandemic 1918 H1N1 virus [9,10] or
some H5N1 strain [11,12] to other less pathogenic strains, our
study is the first to demonstrate that a global influenza-induced
gene-expression signature can be defined. This proof-of-concept
study was conducted on a home-made nylon array using a human
pulmonary epithelial cell line infected by five influenza A virus
subtypes (H1N1, H3N2, H5N1, H5N2 and H7N1). Using this
signature, we determined if molecules disturbing this pattern of
infection would have a broad-influenza antiviral effect. By
consulting the Connectivity Map, a database of drug-associated
gene expression profiles [13,14], we identified molecules that
induced gene expression changes after cell treatment that were
mainly opposite to those induced by infection. These molecules
were tested in vitro for their effect on the five different viruses. To
confirm our methodology, we took the opportunity of using the
new emerging pandemic H1N1 virus as a model to test the effect
of these molecules on a new unknown virus.
Materials and Methods
1 Cell lines and viruses
Cells of the human lung epithelial cell line A549 were grown as
monolayers in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum, 2 mM L-glutamine,
100 U of penicillin/mL, and 100 mg of streptomycin sulfate/mL
at 37uC.
Influenza viruses A/New Caledonia/20/99 (H1N1), A/Mos-
cow/10/99 (H3N2), A/Lyon/969/09 (H1N1 SOIV), A/Turkey/
582/2006 (H5N1), A/Finch/England/2051/94 (H5N2), and A/
Chicken/Italy/2076/99 (H7N1) were produced in MDCK cells in
EMEM supplemented with 2 mM L-glutamine, 100U of penicil-
lin/mL, 100 mg of streptomycin sulfate/mL and 1 mg of trypsin/
mL. Viruses were titrated to determine tissue culture infection
dose 50% (TCID50) in MDCK cells as described in our previous
study [15].
For the microarray analysis, A549 cells were infected for 24 h at
37uC with influenza viruses at a multiplicity of infection (moi) of 1 in
DMEM supplemented with 2 mM L-glutamine, 100 U of penicil-
lin/mL, 100 mg of streptomycin sulfate/mL and 0.5 mg of trypsin/
mL (infection medium). This moi was chosen to ensure that 100% of
the cells were infected 24 h postinfection. The microarray
experiments were performed in five independent replicates.
For kinetics on A549 cells, confluent cells were infected with
influenza viruses at a moi of 0.1 or 2 for one hour under a minimal
volume of infection medium at 37uC. The cells were then overlaid
with fresh infection medium and incubated at 37uC. Samples of
supernatants were collected at defined time points and stored at
280uC until end point titration assays (TCID50) in MDCK cells.
2 RNA preparation and hybridization to the gene chip
Total RNA was extracted from cell pellets using an RNeasy
Mini Kit (Qiagen,Valencia,CA) for the BSL2 viruses. For H5N1
infections, total RNA was extracted with Trizol LS (Invitrogen).
mRNAs were labeled with 33P for the reverse transcription using
the Superscript III RT (Invitrogen), (a33P)dCTP and an
oligodT25. Generated cDNAs were hybridized on home-made
Nylon microarrays (HuSG9k) containing 9216 spotted IMAGE
human cDNA clones, representing 8682 genes and 434 control
clones [16]. Further details on the HuSG9k microarray are
available on the TAGC website (http://tagc.univ-mrs.fr/). All
membranes used in this study belonged to the same batch. After
hybridization and exposure on Micro Imager, arrays were scanned
in a Fuji BAS 5000 machine and hybridization signals quantified
using the BZ Scan Software [17]. Primary data, in accordance
with the proposed MIAME standards, are accessible through
GEO Series accession number GSE22319 (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc =GSE22319).
3 Data normalization and analysis
Data files were loaded and analyzed with R (v2.9.2) and
Bioconductor (v2.4.1) [18], using the NylonArray library developed
by the TAGC to support BZScan2 files (library available upon
request). Raw data were normalized by quantile normalization.
Supervised analysis (supervised methods aim at finding a set of genes
whose expression profiles best correlate with a known phenotype)
between groups Infected and Mock samples was conducted using the
Significance Analysis of Microarray algorithm (SAM) [19], using the
siggenes library (v1.18.0) [20]. All statistical analyses involved
corrections for multiple comparisons (Benjamini and Hochberg)
[21]. Agglomerative hierarchical clustering was performed by the
pairwise average-linkage method using the Pearson correlation
distance (Cluster 3.0, Eisen, Stanford University).
4 Quantitative real-time RT-PCR validation
To validate the microarray results with real-time RT-PCR
assay, another set of A549 cells were infected with influenza viruses
at a moi of 1 and total cell RNA was extracted at 24 hpi with
Trizol LS (Invitrogen). Five hundred ng of total RNA were reverse
transcribed using oligo(dT)18 and RevertAid M-MuLV (Fermen-
tas) according to the manufacturer’s instructions. One mL of
cDNA was then amplified and analyzed in the 7500 Real Time
PCR System (Applied Biosystems) using the Platinum(R) SYBR(R)
Green qPCR SuperMix-UDG kit (Invitrogen) according to the
manufacturer’s instructions. Six genes were chosen according to
their level of expression (Fold change in log2 . 2 or ,22) and the
availability of primers for the quantitative PCR (Table S1).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA was
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used as an internal control. The reaction mix contained a total
volume of 20 mL and the thermal cycling consisted of UDG
incubation at 50uC for 2 min, 40 cycles of 95uC for 15 s and 60uC
for 33 s for amplification. All data were normalized to the internal
standard GAPDH mRNA. For each single-well amplification
reaction, a threshold cycle (Ct) was observed in the exponential
phase of amplification. Relative changes in gene expression were
determined using the 2DDCt method as previously described [22]
and reported as the n-fold difference relative to a control cDNA
(mock cells) prepared in parallel with the experimental cDNAs
(infected cells). Statistical significance was calculated using Welch’s
two sample t-test between mock and infected samples using R
software.
5 In silico experiment: query the Connectivity Map with
the infection signature
To select potential antivirals, an unbiased in silico search for
molecules that reverse the infection signature identified in the
present study was performed using the publicly available Connec-
tivity Map database (build 02) [13]. The Connectivity Map (also
known as CMAP) is a collection of genome-wide transcriptional
data from cultured human cells treated with different kinds of
molecules. The 20 most differentially expressed genes in the
infection state (Fold Change in log2. 2 or,22) were selected from
the initial 300 gene set identified by SAM. These were then mapped
to the U133A probe sets in order to query the Connectivity Map
database. In total, 28 U133A probe sets mapped to the selected
genes from this study. The connectivity scores and p-values were
obtained using the CMAP algorithm [13].
6 Molecules
2-aminobenzenesulfonamide (Sigma), calcium folinate (Sigma),
harmol hydrochloride (MP Biomedical), merbromine (Sigma),
midodrine (Sigma) and ribavirin (Valeant Pharmaceuticals) were
dissolved in sterile water to a stock concentration of 5 g/L, 5 g/L,
4 g/L, 3.4 g/L, 5 g/L and 10 mM respectively. Rilmenidine
(Sigma) was dissolved in dimethylsulfoxide (DMSO) to a stock
concentration of 13 g/L and brinzolamide was in suspension at
10 g/L in the collyrium AZOPT.
Sulfameter (Sigma), pyrvinium (Sigma), moxalactam (Sigma)
and methylbenzethoniumchloride (Sigma) were dissolved in sterile
water to a stock concentration of 50 g/L. Alvespimycin (Sigma)
was dissolved in sterile water to a concentration of 0.03 g/L.
Sulodictil (Sigma) and DL-Thiorphan (Sigma) were dissolved in
DMSO to a concentration of 50 g/L.
7 Viability assays
Cell viability was measured by the neutral red assay, an
indicator of cytotoxicity used in cultures of different cell lines [23]
with the same sensitivity as the MTT assay [24,25]. The neutral
red assay is based on the initial protocol described by Borenfreund
and Puerner (1984) and determines the accumulation of the
neutral red dye in the lysosomes of viable, uninjured cells. Cells
were seeded into 96-well plates and treated with molecules or
solvent. 72 h after treatment, cells were incubated for 3 h with
neutral red dye (100 mg/ml) dissolved in serum free medium
(DMEM). Cells were then washed with phosphate buffered saline
(PBS) and fixed in a formol/calcium mix (40%/10%) for 1 min
before being lysed with EtOH/AcCOOH, (50%/1%) followed by
gentle shaking for 15 min until complete dissolution was achieved.
Absorbance at 550 nm was measured using a microplate
spectrophotometer system (Microplate Reader 2001, BioWhit-
taker) and results were presented as a ratio of control values.
8 Neuraminidase assay
Standard fluorometric endpoint assays used to monitor NA
activity was recently shown to be suitable to quantify influenza
virus in a high-throughput screening test [26]. Briefly, cell
supernatants (25 ml) were transferred to a black 96-well plate
and 75 ml of 29-(4-methylumbelliferyl)-alpha-N-acetylneuraminic
acid (MUNANA, Sigma Chemical Co.) to a final concentration of
50 mM were added. After incubation of the plate at 37uC for 1 hr,
150 ml stop solution (0.05 M glycine, pH 10.4) was added to each
well and the fluorescence read on a FluoStar Opima (BMG
Labtech) with excitation and emission filters of 355 nm and
460 nm respectively. Relative fluorescence units (RFU) were
corrected by subtracting specific blanks, ie medium with or
without molecules.
For the NA activity test on L3 viruses (H5N1), viruses were
inactivated as previously described [27]. Cell supernatants were
mixed with freshly prepared Triton X-100 to a final concentration
of 1% (vol/vol) Triton X-100 and incubated for 1 h at room
temperature. The inactivated supernatants were then transported
out of the BSL3 to the BSL2 laboratory and used for NA assays as
described above.
Potential interference of test molecules on the NA enzymatic
activity was tested by incubating the A/Moscow/10/99 (H3N2)
viral stock diluted in DMEM (107.8 TCID50/mL final) with
increasing concentrations of the test molecule (or DMEM for
control) for 0.5 h at room temperature. Specific blanks were
measured for each molecule. 25 mL were used for the NA test as
described above and results were expressed as a ratio of corrected
RFU of the sample to RFU of controls. Two independent
experiments were performed in duplicate.
9 Viral growth assays in the presence of the molecules
For the viral growth assays in the presence of the molecules,
A549 cells were seeded into 96-well plates at 0.156105 cells per
well and cultured for 3 days to 100% confluence. Cells were then
washed with DMEM and incubated with various concentrations of
the different molecules diluted in infection medium (DMEM
supplemented with 2 mM L-glutamine, 100 U/mL penicillin,
100 mg/mL streptomycin, 20 mM HEPES and 0.5 mg/mL
trypsin). Six hours after treatment, cells were infected with
influenza viruses at a moi of 2 or 0.2 by adding 25 mL per well
of virus diluted in infection medium. Infection was allowed to
proceed for 65 h at 37uC, 5% CO2 after which 25 mL of
supernatant were collected for the NA activity test. Results are
expressed as a ratio of corrected RFU of the sample to RFU of
control (incubation with infection medium without test molecule).
To check for cytotoxicity, viability assays were performed in
parallel to each viral growth assay.
10 Test of infection efficiency after cell or virus
pre-incubation with the molecules
A549 cells were seeded into 96-well plates at 0.156105 cells per
well and cultured for 3 days to 100% confluence. For the ’Cell
Preincubation’ test, cells were washed with DMEM and incubated
with various concentrations of the different molecules diluted in
200 mL per well of infection medium for 14 h. After two washings
with DMEM, cells were infected with influenza A/Moscow/10/99
(H3N2) virus at a moi of 7 during 15 min and washed twice with
infection medium. Infection was allowed to proceed for 5 h at
37uC. For the ‘Virus Preincubation’ assay, the molecules were
diluted in infection medium and A/Moscow/10/99 (H3N2) viral
stock (108.8 TCID50/mL) was treated with increasing concentra-
tions of the molecules for 14 h. Cells were then washed with
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DMEM and incubated for 15 min with the virus and molecule
mix diluted 12 times. Infection was allowed to proceed for 5 h at
37uC. In both assays, the number of infected cells was estimated
with a NA test. Cells were washed with PBS and lysed by shaking
for 1 h with 25 mL per well of Triton 1X. The cell lysis extracts
were used for a neuraminidase test as described above. Results
were expressed as a ratio of corrected RFU of sample to RFU of
control (solvent treated infections). Statistical significance was
calculated in comparison to results for control cells using two tailed
Welch t test.
11 EC50 and CC50 calculations
Viability and antiviral data were analyzed using the following
three-parameter non linear logistic regression (l3) function [28]
y~Dz
D
1z
x
E
 B
were y is the response, D is the upper limit (response when the
dose x is ‘infinite’), E is denoted EC50 or CC50 and is the dose
producing a response half-way between the upper limit and lower
limit (0), and B is the relative slope around E. This model is the
shortened form of the four parameter logistic function where the
lower limit is fixed to 0. Results were obtained by fitting the l3
function using the package drc [29] in the R Statistical Language
(version2.7.1). Parameters of the l3 model were estimated and
fitted curves were plotted only if the data set contained one
response ,D/2.
Results
1 Global transcriptional signature of influenza A infection
To characterize the global cellular gene-expression response to
influenza A infection, human pulmonary epithelium A549 cells
were infected with human A/New Caledonia/20/99 (H1N1) and
A/Moscow/10/99 (H3N2) and avian A/Turkey/582/2006
(H5N1), A/Finch/England/2051/94 (H5N2), and A/Chicken/
Italy/2076/99 (H7N1) influenza viral strains. These viruses are
herein referred to as H1N1, H3N2, H5N1, H5N2 and H7N1. A549
cells express both sialic acid a2,6- and a2,3-galactose receptors
[30,31] and were shown to be infected by human, avian and swine
influenza viruses [32,33]. Infections were performed at 37uC, a
temperature at which both human and avian influenza viruses
efficiently infect cell cultures [34] and at a moi of 0.1. In these
conditions, there was evidence of productive viral replication of all
viruses but with some kinetic and yield differences between viruses,
as determined by infectious titers (TCID50) of supernatants of
influenza virus infected A549 cells (Figure 1). The H5N1 virus titers
peaked higher and earlier (24 hpi) compared to other viruses titers.
Avian H7N1 and H5N2 viruses replicated with correct efficiencies,
similar to the human H3N2 virus. In contrast, the human H1N1
virus strain replicated slower (titers peaked at 65 hpi) and grew to
lower titers than other viruses (p-value ,0.05 at 24 hpi).
To determine the host gene-response to infection, total cellular
RNA was extracted at 24 hpi and submitted to reverse
transcription in the presence of 33P. Each condition was performed
in 5 independent replicates. All labeled cDNAs provided a good
radioactive intensity and were hybridized onto home-made nylon
microarrays containing 8782 IMAGE cDNA clones. All hybrid-
izations were of good quality according to signals within
acceptable range, number of features present, and signals from
control spots.
Supervised analysis of normalized gene expression data was
conducted using the SAM algorithm. This algorithm was used to
identify genes whose expression levels were significantly altered by
influenza infection. We set the delta threshold in the SAM analysis
to allow an acceptable false discovery rate (FDR) of 10%. We
found that the expression levels for a total of 300 genes
(representing 3.4% of the genes considered present on the chip)
differed significantly between mock and infected samples (Table
S2). Using the DAVID Bioinformatics Resources database, we
annotated this signature using the gene ontology (GO) terms. This
Figure 1. Comparison of viral replication kinetics between influenza viruses in A549 cells. A. A549 cells were infected at a moi of 0.1 with
influenza virus A/New Caledonia/20/99 (H1N1), A/Moscow/10/99 (H3N2), A/Turkey/582/2006 (H5N1), A/Finch/England/2051/94 (H5N2), and A/
Chicken/Italy/2076/99 (H7N1) and supernatants were collected at 24, 41, 48 and 65 hpi for end point titration assays. B. Each bar represents the mean
of viral titers at 24 hpi for two independent experiments and titers were statistically analyzed by the one tailed Welch t-test; *: titers greater than
H1N1 titers (p-value ,0.05), #: titers lower than H5N1 titers (p-value ,0.05).
doi:10.1371/journal.pone.0013169.g001
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revealed an enrichment of genes related to various cellular
processes such as protein complex biogenesis, membrane and
microtubule organization, DNA metabolic and catabolic process-
es, cell proliferation regulation, cell cycle and cell death (Figure 2).
A subset of six genes with absolute fold changes in log2 (FCs)
above 2 was selected to validate the microarray analysis by
quantitative RT-PCR (RT-qPCR) analysis: DNMT1, NTE and
CAPN1 that were found downregulated in infected cells and G1P2,
Figure 2. Gene enrichment analysis of the 300 genes of the infection signature. Discriminatory genes were analyzed by DAVID for
associations with particular Gene Ontology terms. The negative Log10(P-values) of enriched terms (plotted in bar) refer to how significant an
association a particular ontology term has with the gene list. The 30 most significant biological process are grouped according to their biological
meaning.
doi:10.1371/journal.pone.0013169.g002
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OAS1 and ICAM1 that were upregulated. The 6 genes were chosen
at random among the most 20 dysregulated genes upon infection.
This quantification was performed on new samples equivalent to
those used for the microarray analysis. Figure 3 shows the
confirmation by RT-qPCR of the microarray data. For each gene
and each strain, microarray FCs are presented as a black boxplot
and RT-qPCR results are depicted as a gray histogram. Results
from RT-qPCR were in good agreement with the cDNA
microarray analyses for five out of six genes tested. Indeed, except
for CAPN1 (p-value = 0.1), significant difference between infected
and non infected cells was also observed in quantitative RT-PCR
analysis (p-value ,0.05, Welch t-test), similar to DNA microarray
analysis. This result was acceptable considering that samples
analyzed by RT-qPCR were different from those used in the
microarray analysis.
To visually compare the changes in mRNA abundance for the
300 genes found to be influenced by influenza infection,
hierarchical clustering analysis in both dimensions was performed.
Results are depicted in the heatmap representation of Figure 4.
Dendrograms indicate the correlation between samples and genes.
We verified that mock samples were sorted together vs infected
ones. The H1N1 samples co-clustered with the mock samples
suggesting that infection with this strain induced few gene
expression changes. We verified this result by conducting a
virus-specific SAM analysis on the mock vs one virus samples. For
a FDR of 10%, only 36 genes were found to be regulated by H1N1
infection in comparison to 2298 genes by H3N2, 1510 by H5N2,
3020 by H7N1 and 1455 by H5N1. The main difference between
H1N1 and other viruses lay in the number of down-regulated
genes during infection. Whereas H3N2, H5N1, H5N2 and H7N1
influenza viruses induced a down-regulation of most of the genes
tested, a similar number of genes were down- and up-regulated by
H1N1 (highlighted by the blue vertical line in the heatmap
Figure 4). As H1N1 viral titer was lower at 24 hpi than titers of
other viruses (Figure 1B), the scope of gene-expression changes
induced upon infection correlated, at least partially, to the viral
replication efficiency of the virus-cell system used in this study.
Interestingly, out of the 300 genes of the global infection
signature, only 16 were upregulated in all infected cells. These 16
genes were associated to three GO biological process, including
two related terms, ‘‘viral reproductive process’’ and ‘‘viral
reproduction’’, that annotate genes encoding proteins involved
in the virus life cycle. Two genes were associated to these terms:
ICAM1, which is the major receptor for human rhinovirus [35],
and IRF7, which activates the expression of Epstein-Barr Virus
Latent Membrane Protein 1 [36] (p-value = 0.07 and 0.08,
respectively). While IRF7 has not been directly involved in
influenza virus life cycle yet, ICAM1 was recently identified as a
proviral factor that may be co-opted by influenza virus [37]. The
third associated biological process was the term ‘‘immune
response’’ (p-value = 0.04) annotating 4 genes (ICAM1, OASL,
OAS1 and CFD). Therefore, the upregulated genes were mostly
associated with the immunological response. Besides, seven of the
16 genes were interferon stimulated genes (ISGs): IFITM1,
Figure 3. Validation of microarray results by real-time quantitative RT-PCR analysis. Expression of 6 genes from DNA microarray analysis
(black cross) is compared with real-time quantitative PCR data (grey bar). Cross represent fold changes (mean6 S.D.) given by the microarray analysis =
Log2 (normalized amount of target gene in infected samples) - Log2 (normalized amount of target gene in mock samples) (right). The formula used to
determine the amount of target gene in infected cells by RT-qPCR, normalized to GAPDH and relative to mock is: 22DDCt where Ct is the threshold cycle
and DDCt = (Ct target infected – Ct gapdh infected) – (Ct target mock – Ct gapdh mock). Bar represented Log2 expression level (mean6S.D.) of target
genes in two independent quantitative RT-PCR analysis (left).
doi:10.1371/journal.pone.0013169.g003
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ICAM1, IFIT3, OAS1, G1P2 (or ISG15), IRF7 and OASL. These
results were in accordance with previous studies showing the
upregulation of immune response associated genes in samples
infected in vitro and in vivo with various influenza viruses
[9,11,12,37,38,39,40]. Gene expression levels in each group of
samples are depicted in Figure S1. All ISGs were markedly more
up-regulated in H5N1 infected cells than in other samples. This
hyperstimulation has been described in other transcriptional
studies [11,40,41] reinforcing the validity of the experimental
cell-virus system developed in the present study.
2 In silico drug screening of the Connectivity Map
The Connectivity Map is a collection of genome-wide
transcriptional expression data from cultured human cells treated
with bioactive small molecules [13]. The associated website
provides tools to find molecules connected to the query signature
i.e. any list of genes associated with a biological test. The similarity
of the query signature to each of the reference expression profiles is
assessed and quantified by a normalized score, from -1 for a
molecule that reverses the signature to +1 for a molecule which
induces gene expression changes similar to the query signature.
Our strategy was to query the Connectivity Map with a list of
genes differentially expressed in infected cells to find molecules
that induced the opposite gene expression changes. We hypoth-
esized that such molecules may influence host cell metabolism in
such a way that effective viral replication would be altered.
A critical step in this screening was to define the query
signature. As the number of upregulated genes was very low
(5.3%) in the list of 300 genes defined by the analysis, a lack of
specificity resulting from a loss of information for up-regulated
genes could be introduced in drug selection if the signature was not
corrected for this bias. By selecting genes with the most drastic
changes in level of expression (fold change in log2 . 2 or ,22),
we were able to define a signature of 20 genes for influenza A virus
infection with similar amounts of those up and down regulated
(Figure 5A, Table 1).
By querying the connectivity map with this concise signature, we
obtained c-scores for 6100 instances, representing more than 1000
molecules in various conditions [14]. We selected those associated
with the most strongly anticorrelated signatures (negative enrich-
ment) and which had a p-value less than 0.5% (Figure 5B and 5C).
Applying this filtering step left us with eight candidate molecules:
harmol, rilmenidine, brinzolamide, ribavirin, calcium folinate,
2-aminobenzenesulfonamide, merbromin and midodrine (from
the most negatively correlated to the least negatively correlated
drug). The relevance of our selection was supported by the fact that
ribavirin, an already known influenza virus inhibitor, was identified
with a negative enrichment of -0.83 and a pvalue of 0.00157. Except
for the topical antiseptic merbromin, the other selected molecules
have various therapeutic indications (depicted in Table S3) but are
not referenced as antivirals.
Graphs in Figure 5C report how the different genes of the
infection signature behave in the expression profile of the selected
molecules. Although the genes down-regulated during infection are
generally up-regulated in response to the molecule and conversely
the up-regulated genes of the signature are globally down-regulated
by the molecule, none of the molecules available in this data bank
were able to completely reverse the infection signature.
3 Evaluation of the antiviral potency of the selected
drugs on H3N2 viral growth
We assessed the effect of the eight selected molecules on influenza
replication in vitro. Cell viability, as assessed by the neutral red
assay, and viral growth, as quantified by a neuraminidase (NA)
activity test, were conducted in parallel. Before using the NA activity
test as an indirect measurement for viral impairment, we checked
firstly that the different influenza viruses used in this study had
sufficient neuraminidase activities to be quantified using this method
(Figure S2A). For all tested viruses and for a signal to background
ratio between 2 and 70, the fluorescence was proportional to the
amount of virus present (TCID50/mL). During the evaluation of the
drug panel, all signal to background ratios were included between 2
and 70. Secondly, we controlled that the different molecules did not
inhibit the enzymatic activity of NA to be sure that a drop in RFU
would only reflect a drop of viral titer. While concentrations of
merbromin above 50 mM and harmol above 500 mM inhibited NA
activity, incubation of the virus with increasing concentrations of the
molecules otherwise resulted in no inhibition (Figure S2B).
Therefore, for these two molecules below these concentrations
and for other molecules of the drug panel, viral growth can be
assessed by a neuraminidase test.
Evaluation of the drug panel was first conducted on influenza
A/Moscow/10/99 (H3N2) virus. A549 cells were incubated with
increasing concentrations of the molecule for 6 h before infection.
This time was chosen based on the duration of treatment indicated
in the Connectivity Map to obtain similar cellular response before
infection [14]. Infection was allowed to proceed for 65 h which
represents multiple cycles of infection, however similar results were
observed at 24 and 48 hpi (Figure S3).
The viability data of five independent experiments are given in
Figure S4. The 50% cytotoxic concentrations (CC50) were
determined by regression analysis. The CC50 of calcium folinate,
2-aminobenzenesulfonamide and midodrine could not be deter-
mined since none of these molecules was cytotoxic at the highest
tested dose.
The effect of each of the molecules on viral growth was tested
using the H3N2 virus at a moi of 0.2 and 2. Dose-response curves
were fitted by regression analysis (Figure S5) and used to
determine the 50% effective concentration (EC50) of each
molecule if at least one response was inferior to 50%. Selective
indexes (SI) were calculated as CC50/EC50 and used to classify
selected molecules as inactive (SI,2), weak inhibitors (2,SI,10),
moderate inhibitors (10,SI,50) and strong inhibitors (SI.50)
(Figure 5). In agreement with previous observations [42], we noted
that SI were dependent on the moi, since molecules are more
effective at lower moi. In our conditions, at a moi of 0.2, two
molecules (calcium folinate and 2-aminobenzenesulfonamide)
were ineffective, two (harmol and merbromin) were weak
inhibitors, two (brinzolamide and midodrine) were moderate
inhibitors and one (ribavirin) was a strong inhibitor. At a moi of 2,
whereas brinzolamide was reclassified as a weak inhibitor, the
other molecules remained in the same class despite their SI being
Figure 4. Hierarchical clustering and heatmap of the 300 genes that discriminate mock and infected samples. Heatmap representing
the expression levels of the 300 genes differentially expressed between infected and mock cells. Red squares indicate the expression levels above the
median of the gene abundance across the sample and green squares the expression levels below. The median values were clustered hierarchically in
both dimensions. Dendograms indicate the correlation between groups of samples (horizontal) and genes (vertical). Vertical lines in the right portion
indicate the 2 distinct gene expression patterns: up and down-regulated genes during infection. The blue line stands for the genes down-regulated in
samples infected with H1N1 influenza virus. Gene expression data for the 300 genes are reproduced in table S2.
doi:10.1371/journal.pone.0013169.g004
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weaker. As an example, the CC50 for midodrine was superior to
4250 mM and EC50 was comprised between 322 mM (moi of 0.2)
and 532 mM (moi of 2). Concerning rilmenidine, which was
dissolved in DMSO, it was not possible to conclude on an effect.
DMSO has previously been shown to be cytotoxic and to inhibit
influenza infection above 4% (vol/vol) [43] however it is still used
as a major solvent for molecules in high-throughput screening. In
this study, the CC50 for DMSO was 2.9% (v/v) - the concentration
used to obtain 1550.7 mM of rilmenidine- and the EC50 was
comprised between 1.0% (moi of 0.2) and 1.8% (moi of 2). The
EC50 of rilmenidine was significantly different from that of DMSO
at a moi of 2 (p = 2e24) but not at a moi of 0.2 (p = 0.85).
However, even if this molecule is considered ineffective against
the H3N2 influenza virus, we did obtain a very high confirmation
rate (62.5%) in comparison with the hit rate of classical high-
throughput screening (3.2% in [43]). This clearly indicates that
Figure 5. Gene expression-based screening identifies eight potential antiviral molecules. A. List of cellular genes chosen to query the
Connectivity Map. A circumscribed signature of infection was derived from the 300 genes discriminating mock and infected samples by selecting
genes with a fold change . 2 or ,22. The fold change is defined as the ratio of the mean gene expression in infected samples to the mean for the
corresponding mock infection in log2. This selection resulted in a list of 20 genes, 12 being up-regulated during infection and 8 down-regulated (see
Table 1). These genes constituted the signature used to query the online database Connectivity Map. B. Drugs with significant enrichment to
influenza virus infections in the Connectivity Map. Significance cut-off was set at p-value ,0.005. The permutation p-value estimates the likelihood
that the results would be observed by random chance. Mean: the arithmetic mean of the connectivity scores for the post-dose changes (or instances)
by the given molecule; n: the number of instances of a given molecule in the CMAP database; Enrichment: a measure of the enrichment of those
instances in the order list of all instances, Positive enrichment scores are of interest if perturbagens inducing the biological state represented by the
signature used to produce the result are sought. Likewise, if reversal or repression of the biological state encoded in the query signature is required,
perturbagens with negative enrichment scores are of interest. The specificity value is defined as the frequency at which the enrichment of a set of
instances equals or exceeds that of the same set of instances in queries executed on 312 published, experimentally derived signatures using the
Molecular Signatures Database. Lower values are associated with a greater specificity; the non null percentage represents a measure of the support
for the connection between a set of instances and a signature of interest based on the behavior of the individual instances in that set. C. 8 molecules
are negatively connected to influenza virus infection (p-value ,0.005). A graphical representation of the location of the signature of infection is
depicted for each molecule, taking the instance with the most negative connectivity score of each molecule. The x-axis represents the genes of the
expression profile of the molecule, rank ordered according to their differential expression relative to the control. The location of each gene of the
infection signature is appreciated along the x-axis.
doi:10.1371/journal.pone.0013169.g005
Table 1. Genes of the circumscribed signature of infection.
Gene Gene symbol I.M.A.G.E. CloneID Fold Change
Transcription Regulation
Ets variant gene 3 ETV3 1473929 7.24
Myocyte enhancer factor 2D MEF2D 4209 5.13
FBJ murine osteosarcoma viral oncogene homolog B FOSB 79022 22.69
DNA (cytosine-5-)-methyltransferase 1 DNMT1 768241 22.06
Ankyrin repeat and BTB (POZ) domain containing 2 ABTB2 204456 2.28
Immune response
ISG15 ubiquitin-like modifier, G1P2 ISG15 742132 3.48
29,59-oligoadenylate synthetase 1, 40/46kDa OAS1 666703 2.07
Complement factor D (adipsin), DF CFD 666128 2.99
Cell surface protein
Patatin-like phospholipase domain containing 6, NTE PNPLA6 431990 22.01
Heparan sulfate proteoglycan 2 HSPG2 3339 22.23
Solute carrier family 2 (facilitated glucose transporter) SLC2A2 207963 2.23
PTPRF interacting protein, binding protein 1 (liprin beta 1) PPFIBP1 263094 2.04
Intercellular adhesion molecule 1 (CD54) ICAM1 3383 3.36
Lysophosphatidic acid receptor 1 LPAR1 505524 3.63
Enzyme
Hyaluronoglucosaminidase 4 HYAL4 668088 2.90
Asparagine-linked glycosylation 2 homolog ALG2 150443 2.35
Calpain 1, (mu/I) large subunit CAPN1 70555 22.20
Protein phosphatase 1, PP1 PPP1R14D 140525 23.13
Nuclear protein
Karyopherin (importin) alpha 6 KPNA6 16650 22.21
Hypothetical protein HSPC111 NOP16 505242 22.08
Fold Change = log2(Inf/Mock).
doi:10.1371/journal.pone.0013169.t001
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our in silico screening was effective and strongly supports its power
at selecting the antivirals: harmol, merbromin, brinzolamide,
midodrine and ribavirin.
4 Antiviral effects of most of the molecules are due to an
action on cells rather than on viruses
Molecules selected by the in silico screening were chosen from
the Connectivity Map based on the gene expression changes they
induce in treated cells. To check that the antiviral properties of the
five efficient molecules were actually mediated by an action on
cells and not by an indirect effect on the virus, we conducted two
assays in parallel in which either the cells or the H3N2 virus
were preincubated with a series of concentration of the molecules.
The efficiencies of infection were estimated by measuring the
neuraminidase activity associated to cells at an early time of
infection. In the preincubated cells assay, cells were in contact with
molecules for 14 hours before being infected with H3N2 virus
without any drugs. As the cells were washed twice before infection,
we assumed that the virus should not be in contact with the
molecules during infection. Thus the molecules should not alter
the viral structure nor change parameters playing a direct role on
viral entry (as the extracellular pH for example). Consequently an
inhibition of infection in this assay would mean that the molecule
had an effect on cells. In contrast, in the preincubated virus test,
the viral stock was treated with the molecules during 14 hours
while the cells were in contact with molecules though after dilution
and for only 15 minutes during infection. We assumed that this
exposure time and molecule concentrations were too low to induce
any effect on the cells. If a molecule should inhibit viral growth by
altering the functional properties of the virus (viral structure or
surface glycoprotein), infection would be inhibited in the
preincubated virus condition but not in the preincubated cells one.
Results of both tests for the five efficient molecules are depicted
in Figure 6. After preincubating the viral stock with the molecules,
a few infection efficiencies were significantly different of the
control (p-value ,0.05, two tailed Welch t-test). However, except
for merbromin, infection efficiencies after virus preincubation
were included between 64% (for ribavirin c = 400 mM) and 110%
of the control (for rilmenidine c = 8 mM). Therefore, the different
drugs exerted very limited effects on the virus. In contrast,
statistically significant inhibitions of infection efficiency were noted
after cells preincubation with each molecule at higher concentra-
tions (above 10 mM for brinzolamide, 40 mM for harmol, 1 mM for
merbromin, 140 mM for midodrine, 160 mM for ribavirin and
80 mM for rilmenidine). Infection efficiency decreased to 23% for
brinzolamide (100 mM), 5% for harmol (800 mM), 2% for
merbromin (250 mM), 40% for midodrine (1400 and 4250 mM),
26% for ribavirin (800 mM) and 23%3 for rilmenidine (1600 mM).
We concluded from these tests that the antiviral effect of these
molecules is due to an action on cells rather than on the virus.
Merbromin on the other hand inhibited viral infection in both
assays. This was not surprising since this molecule is a topical
antiseptic known to inactivate influenza viruses [44]. However, our
results indicate that this molecule may also inhibit viral replication
through a cellular effect.
5 None of the molecules which are positively correlated
to the infection signature, impaired H3N2 influenza viral
growth
In order to control that the antiviral effect of the molecules is
specifically associated with inversion of the infection signature, we
assessed the effect of some molecules positively correlated to the
signature. Seven drugs, alvespimycin, DL-Thiorphan, latamoxef,
methylbenzethonium chloride, pyrvinium, sulfameter (or sulfame-
toxydiazine) and sulodictil, were chosen according to the following
criterion: p-value ,0.5%, mean . 0.35 and a specificity ,0.1
(Figure 5B).
Viability and viral growth assays were performed on A549 cells
infected with H3N2 virus at a moi of 0.2 and 2, as described for
negatively correlated drugs. Dose-response curves (Figure S6 and
S7) were used to determine CC50 and inhibitory EC50 (Table S4).
In these conditions, inhibitory SI were lower than 2, or than SI of
DMSO for DL-Thiorphan and Sulodictil. Thus none of the
positively correlated drugs inhibited viral replication at both moi.
In contrast, four drugs (alvespimycin, methylbenzethoniumchlor-
ide, pyrvinium and sulodictil) enhanced viral production at a moi
of 0.2. Increase of viral titers (TCID50/mL) was up to 2 log10 and
was statistically significant for alvespimycin, methylbenzetho-
niumchloride, and sulodictil 40 mM (p-value ,0.05, two tailed
Welch t-test). Therefore, these results strengthen our hypothesis
that modulation of host cell transcription may have an impact on
viral replication.
6 Some antivirals are effective against a broad range of
influenza A virus strains, including the pandemic H1N1
influenza virus
We hypothesized that one advantage of our gene-expression
based screening is that the selected molecules would have an
activity against various influenza A viruses. Indeed, since we
selected a gene signature of infection common to different human
and avian strains, we assumed this as a prevailing cellular response
to many influenza viruses. Therefore, we tested the effect of the
selected molecules on the viral growth of the different strains used
for the initial microarray analysis, i.e A/New Caledonia/20/99
(H1N1), A/Turkey/582/2006 (H5N1), A/Finch/England/2051/
94 (H5N2), and A/Chicken/Italy/2076/99 (H7N1). Two inde-
pendent assays in duplicate (4 replicates in total) for each virus
were conducted in the conditions previously defined for the H3N2
virus. EC50 and SI were determined for each molecule and are
summarized in Table 2, Table 3 and Figure 7. Molecules that
inefficiently inhibited growth of the H3N2 strain (2-aminobenze-
nesulfonamide and calcium folinate) were also inefficient against
other tested viruses. Conversely, the strongest H3N2 inhibitor,
ribavirin, was also classified as a strong inhibitor of all viruses
tested. However, ribavirin obtained different SI depending on the
viral strain tested, allowing the viruses to be classified according to
their sensitivities to this molecule: H3N2 . H5N2 and H1N1 .
H7N1 . H5N1. Other drug screening tests carried out previously
on MDCK cells (with an moi of 0.001) had already reported a
higher sensitivity of H3N2 viral strains compared to H1N1
[42,45]. In our tests, ribavirin EC50 was comprised between 6 mM
(for H1N1 and H3N2 with an moi of 0.2) and 632 mM (for H5N1
with an moi of 2) in concordance with previously published results
[42,45]. Midodrine, the second most active molecule against the
H3N2 strain, also showed an antiviral effect against both H1N1
(SI.2.7 for moi 2 and SI.142.5 for moi 0.2) and H5N2 (SI.2.5
for moi 2 and SI .8.9 for moi 0.2) viral strains. Brinzolamide was
a moderate inhibitor of human H3N2 and H1N1 influenza viruses
and a weak inhibitor of avian H5N2 and H7N1 influenza viruses.
Harmol weakly inhibited all viruses tested, as did merbromin the
EC50 for which were near to 50 mM, a concentration noted to
interfere with the neuraminidase activity test. Finally, rilmenidine
had an obvious antiviral effect on the H1N1 strain. Some of the
molecules identified by our approach were therefore able to inhibit
viral growth of all the viruses used to define the gene expression
signature of infection.
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To determine if this strategy identified broadly effective
influenza antivirals which could be active against emerging
influenza viruses, we tested their effect on the viral growth of the
recent pandemic H1N1 virus (referred to as H1N1 SOIV) (Figure
S8). Interestingly, in comparison with A/New Caledonia/20/99
(H1N1) virus, a weak to moderate antiviral effect was observed for
2-aminobenzenesulfonamide whereas rilmenidine was ineffective.
The other molecules had comparable effects on the two H1N1
virus strains, with brinzolamide, midodrine and ribavirin being the
most effective antivirals. The EC50 of ribavirin were comprised
between 61 mM (for an moi of 0.2) and 292 mM (moi of 2)
revealing a resistance to this molecule that was 4 (moi 2) to 10 (moi
0.2) times more in the H1N1 SOIV strain compared to the H1N1
strain (pvalue = 3.6e26 and 0.0012 respectively).
We compared drug sensitivities to viral growth curves of
different viruses after infection of A549 cells at two moi (Figure
S9). Viruses with good replication efficiencies and the faster
kinetics (H5N1 and H7N1) were the most resistant to the drug
panel. In contrast, selected antivirals had a better effect on delayed
replication viruses (H1N1 and H1N1 SOIV). Drug sensitivities
Figure 6. Antiviral effects of most of the molecules are due to an action on cells rather than on the virus. In the ‘Cell Preincubation’
assay, A549 cells were treated with increasing concentrations of the molecules or solvent for 14 h and washed twice before incubation with H3N2
influenza A virus at an moi of 7 during 15 min and infection for 5 h in medium without drug. In the ‘Virus Preincubation’ assay, H3N2 viral stock was
treated with increasing concentrations of molecules or solvent for 14 h and diluted 12 times before incubation with cells during 5 min and infection
for 5 h. In both assays, the number of infected cells was estimated with a neuraminidase test after cell lysis with Triton 1X. The normalized infection
efficiency was calculated as RFU in treated cells/RFU in control cells. Values represent the mean of two independent experiments (+/2 standard
deviation). Results of the preincubated cell test are plotted with colored dots and results of the virus preincubated assay are depicted with grey
bars. * and # indicate statistically significant differences of infection efficiency in comparison to untreated control cells (Welch two-sample t test,
pvalue ,0.05), for the preincubated cell test and for the preincubated virus test, respectively.
doi:10.1371/journal.pone.0013169.g006
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therefore partially correlated with viral growth kinetics. However,
some strain specificity may also account for drug sensitivities.
Indeed, H3N2 virus was one of the most drug sensitive virus, while
replicating as efficiently than H7N1 virus (but a bit slower).
To conclude, five molecules out of the eight potential molecules
selected by our in silico screening inhibited viral growth of the
H1N1 SOIV, a virus that was unknown when we first defined the
signature of infection and queried the Connectivity Map. These
results are promising and strongly indicate that this approach
identifies molecules with a broad anti-influenza spectrum of activity.
Discussion
The virally induced gene-expression signature
Influenza infection induces various intracellular signaling
cascades and important downstream gene expression host-cell
modifications [46]. Despite their host-range restriction that may
reflect the better adaptation to host factors [47], all influenza A
viruses can infect the same cells in vitro, prompting us to assume
that they may hijack common cellular proteins for their own
replication. This is the first study to compare the cellular gene
expression modifications induced by five different influenza A
virus subtypes. As already described in previous transcriptional in
vitro [40] and in vivo studies [11,12], we found that H5N1
infection induced a strong upregulation of interferon response
genes. This sustained hyperinduction has been correlated with the
high virulence of this virus in animal models [11,12]. In patients,
H5N1 infection results in a massive production of cytokines and
chemokines, referred to as the cytokine storm, which could be
responsible for the severity of the disease [48]. Here we observed
that H5N1 induced the expression of more, and to a greater
extent, inflammatory/immune response genes than any of the
other subtypes. Molecular mechanisms supporting the higher
activation of interferon signaling by H5N1 in comparison with
other subtypes remain undetermined. In contrast, we found that
A/New Caledonia/20/99 (H1N1) infection leads to the smallest
change in gene expression at 24 hpi. One could speculate that
H1N1 virus, as a human influenza virus, would be well adapted to
Table 2. Potency of the inhibitors against human influenza A viruses in A549 cells.
H1N1 moi 2 H1N1 moi 0.2 SOIV moi 2 SOIV moi 0.2 H3N2 moi 2 H3N2 moi 0.2
CC50 (mM) EC50 (mM) EC50 (mM) EC50 (mM) EC50 (mM) EC50 (mM) EC50 (mM)
2-Aminobenzenesulfonamide .6900 .690 .690 1821.67 533.83 .6900 6020
Brinzolamide 665.51 435.06 28.95 166.65 21.55 131.14 23.00
Calcium Folinate .2400 .800 .800 .2400 .2400 .2400 .2400
Harmol 94.98 60.36 20.53 53.74 6.76 20.07 11.68
Merbromin 103.80 29.55 61.98 37.53 .50 32.38 42.87
Midodrine .4250 1566.7 29.82 929.96 108.79 321.99 531.53
Ribavirin 29528 73.79 6.63 291.52 61.08 12.53 5.79
Rilmenidine 1125.3 506.22 24.22 1073 864.48 475.55 489.87
DMSO 1550.7 .1600 173.63 606.40 344.03 957.2 554.39
p-value (Rilmenidine, DMSO) p= 0.0026 p=ND p=7e204 p = 0.6128 p= 0.3552 p= 2e24 p= 0.88
CC50: molecule concentration of 50% cytotoxicity; EC50: molecule concentration of 50% inhibition of viral replication; p-value: t-statistic for testing Rilmenidine values
equal to DMSO values.
doi:10.1371/journal.pone.0013169.t002
Table 3. Potency of the inhibitors against avian influenza A viruses in A549 cells.
H5N1 moi 2 H5N1 moi 0.2 H5N2 moi 2 H5N2 moi 0.2 H7N1 moi 2 H7N1 moi 0.2
CC50 (mM) EC50 (mM) EC50 (mM) EC50 (mM) EC50 (mM) EC50 (mM) EC50 (mM)
2-Aminobenzenesulfonamide .6900 .690 .690 .690 .690 .690 .690
Brinzolamide 665.51 .500 .500 232.40 145.61 551.05 139.19
Calcium Folinate .2400 .800 .800 .800 .800 .800 .800
Harmol 94.98 77.49 43.36 4.06 13.45 49.35 27.96
Merbromin 103.80 44.99 45.98 36.45 21.93 43.70 46.74
Midodrine .4250 .4250 3896.3 1670.7 475.58 .4250 .4250
Ribavirin 29528 632.27 48.36 16.40 6.71 32.39 12.47
Rilmenidine 1125.3 2037.7 1466.8 514.32 358.69 1050.4 777.85
DMSO 1550.7 .1600 1829.6 733.6 564.1 1109.3 801.08
p-value (Rilmenidine, DMSO) p= 0.0026 p=ND p=0.40 p = 2e204 p= 0.1881 p= 0.53 p = 0.9
CC50: molecule concentration of 50% cytotoxicity; EC50: molecule concentration of 50% inhibition of viral replication; p-value: t-statistic for testing Rilmenidine values
equal to DMSO values.
doi:10.1371/journal.pone.0013169.t003
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human A549 cells and could replicate in these cells with basal level
of proteins, thus without having to induce much gene-expression
changes. However a well adapted virus would efficiently replicate
in these cells. We performed replication kinetics in A549 cells with
the different viruses and observed that H1N1 virus grew to lower
titers than other viruses. Two hypothesis can be formulated to
explain the correlation between the weak growth of H1N1 virus
and the few changes of host transcription. Either the reduced virus
replication efficiency of H1N1 virus is responsible for the lower
host response. This is supported by previous study where the
replication efficiency of the virus-cell system accounts for the level
of the host innate immune response [49]. Or it is also possible that
H1N1 viral replication is impaired because of its inability to
modulate the host response, especially to induce proviral
pathways. This hypothesis is based upon previous demonstration
that stronger virus-induced MAPK activation resulted in higher
viral replication efficiency [50].
Nevertheless, beyond these subtype-specific profiles, we were
able to identify a list of 300 genes differentially expressed in both
mock and infected samples. Strikingly, only about 5% of these
genes were upregulated. A similar imbalance has previously been
observed in other transcriptional profiles of infected cell lines
[40,51]. One could hypothesize that this may reflect the virally-
induced cellular arrest of protein expression and could be due to
the 59cap snatching and subsequent degradation of cellular mRNA
[52] and/or the inhibition of processing and export of cellular
mRNA by NS1 [53]. Nevertheless these downregulated genes
represented only 3.3% of the total number of genes detected,
suggesting that a selective inhibition of their expression may occur
during infection. The downregulated genes are implicated in
different cellular processes such as ATP binding, regulation of
translation, cellular protein complex assembly, glucose metabolic
processes, cell cycle and apoptotic mitochondrial changes. On the
other hand, the 16 genes found upregulated are specifically
associated with innate cellular immunity. Seven of these are
induced by interferon: OAS1, ISG15, IRF7, OASL, ICAM1,
IFITM1, and IFIT3. These 7 ISGs have already been found
upregulated together with other interferon genes upon H1N1 PR8
endothelial primary cell cultures infection [37] (Table S5). We also
found an upregulation of CFD, a gene coding for a component of
the alternative complement pathway. Complement is an impor-
tant player in immunity and is induced by influenza infection
[11,54,55]. Other induced genes of the infection signature
determined in this study have never before been associated with
influenza infection. They include ETV3 which encodes a
transcriptional repressor [56] that could be partially responsible
for the downregulation of other genes belonging to the signature.
Signature use for drug screening
Here we identified a list of genes whose expression is
significantly altered during infection with different human and
avian influenza virus subtypes. Since the outcome of infection
appeared successful in our experimental conditions, it can be
concluded that such a virally-induced cellular environment is
favorable for virus replication. We therefore hypothesized that any
molecule able to inverse the infection signature should be harmful
to influenza virus replication. In contrast to many published
transcriptomic studies [1,11], we did not focus on a particular gene
with a known function or large annotation that can be assumed to
have a link with viral infection. To conduct the in silico screening,
we filtered the infection signature genes according to their level of
expression and selected the twenty most differentially expressed
(with statistical significance) between mock and infected cells. We
therefore took into account all of the information retrieved from
the transcriptional analysis, which was a major advantage when
using the Connectivity map. We selected eight molecules which
induced gene expression modifications which anti-correlated with
the infection signature. The hit-rate for this in silico screening was
0.53%.
Our experimental strategy presented several limitations: (i) we
used a nylon microarray containing only 8000 genes thus meaning
that the transcriptional profile of infected cells is incomplete; (ii)
Figure 7. Antiviral potency of the 8 negatively correlated molecules on different influenza A viruses (moi 0.2 and moi 2). Selective
indexes (SI) were calculated as CC50/EC50 (Tables 2 and 3) and used to classify molecules as inactive (SI,2), weak inhibitors (2,SI,10), moderate
inhibitors (10,SI,50) and strong inhibitors (SI.50).
doi:10.1371/journal.pone.0013169.g007
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this profile was assessed for an established cell line, A549, which is
different from those used in the Connectivity Map (MCF7, HL60
and PC3); (iii) the Connectivity Map contains data for only 1000
molecules and none of the molecules we identified was able to
induce a full inversion of the infection signature (Figure 5C).
Despite these limitations, seven molecules out of the eight selected
by the in silico screening presented an antiviral effect on at least
one of the tested viruses (87.5% of molecules confirmed). 2-
aminobenzenesulfonamide and rilmenidine had only a modest
antiviral effect on one specific virus (respectively H1N1 SOIV and
H1N1 New Caledonia). Harmol and merbromin were weak
inhibitors of most of the tested viruses. Brinzolamide and
midodrine were weak to moderate inhibitors of most of the tested
viruses. As expected, ribavirin was a strong inhibitor of all tested
viruses. In light of these results, we conclude that we have
identified a common signature whose partial inversion is strong
enough to inhibit viral replication.
Hypothesis on the mechanisms supporting a molecule’s
antiviral effect
We cannot rule out that some in silico selected drugs exert a
possible direct effect on a viral activity or on a cellular pathway
exploited by the virus. Among the seven molecules, three in
particular could have such an effect: ribavirin and merbromin
which could both directly inhibit a viral function, and harmol
which could inhibit a proviral pathway. Harmol is a beta-carboline
alkaloid of the medicinal plant, Perganum harmala L. (Zygophyla-
ceae). Few specific effects are described for harmol except that it
exerts a psychoactive effect by inhibiting monoamine oxydase
[57], moderately inhibits platelet aggregation by inhibiting PLCc2
[58] and induces apoptosis in some cell lines by activating caspase
8 [59]. PLCc2 is implicated in the protein kinase C (PKC)
activation pathway, the activity of which is crucial for influenza
virus entry [60]. Therefore its inhibition by harmol could in part
be responsible for the antiviral effect shown by this molecule.
Likewise, activation of apoptosis could limit viral replication [61].
However, three types of evidence support our hypothesis that
the selected molecules have an antiviral effect by modifying the
host cell gene expression. First, the results of our test of infection
efficiencies demonstrate that none of the molecules except for
merbromin had an effect on viral structure or function before
infection (Figure 6). Second, the high confirmation rate of the in
silico selected drug panel validate the rational of the selection.
Last, some molecules that regulated the host cell transcription in
the same way that influenza virus infection enhanced viral
production.
To our knowledge, modulation of the cell gene expression has
never been described to support the effects of the in silico selected
drug, except for ribavirin. This antiviral drug with in vitro activity
against both DNA and RNA viruses [62], has several mechanisms
of action proposed to support its antiviral effect (reviewed in [63]:
i) the depletion of the intracellular GTP-pool by inhibition of
inosine monophosphate dehydrogenase compromises the synthesis
of progeny viral RNA; ii) the inhibition of viral RNA-dependent
RNA polymerase activity has been shown for hepatitis C and
influenza viruses; and iii) it could act as a RNA virus mutagen
causing error catastrophe). Which mechanisms contribute to its
anti-influenza effect in vivo remains undetermined. In this study,
we selected ribavirin because it inversed the gene expression
signature of infection, which could highlight a new potential
antiviral mechanism of this molecule. An effect of ribavirin on the
cellular gene expression has been reported to contribute to its
antiviral effect on the respiratory syncytial virus (RSV) [64] and
the hepatitis C virus (HCV) [65]. In these studies, ribavirin
enhanced the expression of ISG in infected cells. It was concluded
that ribavirin potentiates the interferon response induced by
peginterferon (during treatment of HCV) [65] or induced by RSV
infection [64]. However, ribavirin has also been shown to alter the
expression of many genes implicated in various other cellular
pathways such as apoptosis [66], cell cycle control or intracellular
signaling [64]. We propose that these modifications contribute to
its antiviral effect.
Does this study now allow us to define co-factors and
antiviral proteins?
None of the selected molecules fully inversed the infection
signature. Therefore to try to identify anti or proviral factors, we
first searched for genes whose expression could be inverted by all
effective molecules. This was the case for only one gene, calpain 1,
which was up-regulated by all the selected molecules and down-
regulated during infection. The calpains, or calcium-regulated
non-lysosomal thiol-proteases, are ubiquitous enzymes which
catalyze limited proteolysis of substrates involved in cytoskeletal
remodeling and signal transduction. We found no data in the
literature describing any antiviral role for calpain 1. Such potential
activity remains to be tested in the future.
It is also possible that each different molecule exerts its antiviral
effect through different mechanisms and different combinations of
gene expression modifications could be implied. These changes are
listed in the Connectivity Map but except for midodrine and
ribavirin, have yet to be confirmed by other studies. Midodrine is
the prodrug of desglymidodrine, which is an alpha1-adrenergic
receptor agonist used in the clinical management of patients with
orthostatic hypotension [67]. Its effect on cellular gene expression
can be derived from several microarray studies [68,69] showing
many transcriptional changes after stimulation of the alpha1
adrenoreceptor, involving for example genes encoding integrin-
mediated cell adhesion proteins and proteins involved in
hyaluronan signaling [70]. These observations are consistent with
the observed midodrine-induced downregulation of ICAM1 and
HYAL4 reported in the Connectivity Map. Both of these genes
were up-regulated during infection. Their potential role in the
influenza cell cycle remains to be determined.
Recently, several human RNAi screens identified host cell
factors which are required for influenza virus replication
[37,71,72,73]. We wondered if the 20 genes of the concise
infection signature were found to be important for the influenza
virus in any of these screens (Table S5). Notably, the concise
infection signature is specifically more enriched in regulators of
influenza infection than random chance (compared to 8676 genes
of the array, p-value = 0.0072 with Fisher’s exact test). Four genes
(SLC2A2, ICAM1, OAS1, ISG15) out of the 12 up-regulated genes
were defined as proviral factors in these screens [37,71,72]. Three
genes are ISGs: ICAM1, OAS1 and ISG15 that may be co-opted by
the virus. Their down-regulation by the drugs could support
partially their antiviral activity. On the other hand, none antiviral
factor was identified in the list of 8 genes down-regulated during
infection. This could be due to the low number of antiviral factors
found by published screens (180 in total [37,71], compared to 875
(unique) proviral factors [37,71,72,73]). Therefore, the down-
regulated genes of the infection signature can be considered as
potential antiviral factors, which should be further tested.
Outcomes and perspectives
To conclude, our investigation of transcriptional profiles of cells
infected with different strains of influenza A viruses highlights virus
specificity but, above all, has allowed us to define a universal
influenza A virus-induced gene expression signature. Here we
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proposed to correlate this signature to gene expression profiles of
cells treated by different molecules. This is the first study using the
Connectivity Map to identify antivirals thought to act at the
genomic level. One considerable advantage of some of these
antivirals is their potential broad spectrum of action against all
influenza A viruses, including novel pandemic viruses such as the
H1N1 SOIV.
Except for harmol, all the antiviral molecules tested in this assay
are approved for various different therapeutic indications. Our
drug repositioning strategy should therefore contribute to the
discovery of new alternative antivirals with accelerated regulatory
registration. In the event of an unknown emerging virus, this
approach may be of great interest to relatively quickly identify all
available commercialized drugs with potential antiviral effects.
This study conducted in vitro in an established human cell line
and with a nylon microarray represents a first proof of principle
study. To identify effective anti-influenza molecules for use in
clinical practice, we will now study the transcriptional response of
patients to infection using a pan-genome microarray. Gene
response to infection within a tissue in vivo should be more
complex, with many cell types being implicated and with those
infected being influenced by cytokines and the surrounding tissue.
Importantly, our dual experimental approach associating
transcriptional study and in silico screening could be transferred
to other pathogens. We are interested in identifying common
gene-expression signatures of different viruses causing the same
clinical disease to find useful therapies before etiologic diagnosis.
Supporting Information
Figure S1 Boxplots for the 7 interferon stimulated genes (ISGs)
upregulated during infection. These boxplots show the averaged
normalized expression values of the 7 ISGs in each group of
samples. The bottom edge of the box represents the 25th
percentile of the data while the top edge of the boxplot represents
the 75th percentile. The line inside the box represents the 50th
percentile of the data or the median.
Found at: doi:10.1371/journal.pone.0013169.s001 (0.13 MB TIF)
Figure S2 Neuraminidase assay is suitable for evaluation of the
drug panel. A. Neuraminidase activity can be used to quantify
virus. Different influenza viral stocks (A/New Caledonia/20/99
(H1N1), A/Moscow/10/99 (H3N2), A/Lyon/969/09 (H1N1
SOIV), A/Turkey/582/2006 (H5N1), A/Finch/England/2051/
94 (H5N2), and A/Chicken/Italy/2076/99 (H7N1)) were serially
diluted in DMEM. 25 ml of the viral dilutions were incubated with
75 mL of 20 mM MU-NANA for 1 hour at 37uC. Stop solution
was added before reading the fluorescence. The signal to
background ratio at each TCID50 is shown. Under these
conditions, the signal to background ratio was proportional to
the amount of virus between 2 and 70. At hightest titer, the
enzyme activity reaches a plateau due to limiting substrate. Triton
X-100 treatment of H5N1 viral stock enhanced NA activities, as
previously described [27]. B. Molecules did not inhibit the
neuraminidase activity of the influenza virus. A/Moscow/10/99
(H3N2) viral stock diluted in DMEM (107,8 TICD50/mL final)
was incubated with increasing concentration of molecule (or
DMEM for controls) for 0.5 h at room temperature before testing
the neuraminidase activity as described in materials and methods.
Found at: doi:10.1371/journal.pone.0013169.s002 (0.52 MB TIF)
Figure S3 Effective molecules inhibit H3N2 viral growth at early
and later times of infection. A. A549 cells were treated with
increasing concentrations of the molecule or solvent for 6 h and
were subsequently infected with A/Moscow/10/99 (H3N2)
influenza virus at a moi of 2. A neuraminidase test was performed
at 24, 42 and 65 hpi to assess influenza viral growth. Values
represent the mean of two independent experiments performed in
duplicate. B. Potency of the inhibitors against A/Moscow/10/99
(H3N2) according to different times of infection. CC50: molecule
concentration of 50% cytotoxicity; EC50: molecule concentration
of 50% inhibition of viral replication; SI: selective index.
Found at: doi:10.1371/journal.pone.0013169.s003 (0.89 MB TIF)
Figure S4 Concentration-viability curves of the eight molecules.
A549 cells were treated with increasing concentrations of each
molecule or solvent for 72 h and their viability was measured using
Neutral Red dye (as described in materials and methods). Data are
presented as a ratio of absorbance at 550 nm of treated cells to
control cells. Values represent the mean of six independent
experiments performed in duplicate, and error bars show the
standard deviation of the mean. (+/2 standard deviation).
Horizontal lines are drawn to show the scatter of the control
values (mean +/2 standard deviation).
Found at: doi:10.1371/journal.pone.0013169.s004 (0.34 MB TIF)
Figure S5 Six molecules inhibited H3N2 influenza viral growth.
A549 cells were treated with increasing concentrations of the
molecule or solvent for 6 h and were subsequently infected with
A/Moscow/10/99 (H3N2) influenza A virus at a moi of 0.2 (Panel
A) or 2 (Panel B). Viral titers were determined at 65 hpi using a
neuraminidase test as described in materials and methods. Results
in A and B are representative of three independent determinations
in duplicate. Data are presented as a ratio of RFU (relative
fluorescence unit) in supernatants of treated cells to RFU in control
cells (mean +/2 standard deviation). The dose-response curves are
the results of a fit with a 3-parameter logistic equation (if at least one
normalized response was less than 0.5). Horizontal lines are drawn
to show the scatter of the control values (mean +/2 standard
deviation).
Found at: doi:10.1371/journal.pone.0013169.s005 (0.68 MB TIF)
Figure S6 Concentration-viability curves of the seven positively
correlated molecules. A549 cells were treated with increasing
concentrations of each molecule or solvent for 72 h and their
viability was measured using Neutral Red dye (as described in
materials and methods). Data are presented as a ratio of
absorbance at 550 nm of treated cells to control cells. Values
represent the mean of three independent experiments performed
in duplicate, and error bars show the standard deviation of the
mean. (+/2 standard deviation). Horizontal lines are drawn to
show the scatter of the control values (mean +/2 standard
deviation).
Found at: doi:10.1371/journal.pone.0013169.s006 (0.30 MB TIF)
Figure S7 Three molecules enhanced H3N2 influenza viral
growth at a moi of 0.2. A549 cells were treated with increasing
concentrations of the molecule or solvent for 6 h and were
subsequently infected with A/Moscow/10/99 (H3N2) influenza A
virus at a moi of 0.2 (Panel A) or 2 (Panel B). Viral titers were
determined at 65 hpi using a neuraminidase test as described in
materials and methods. Results in A and B are representative of
two independent determinations in duplicate. Data are presented
as a ratio of RFU (relative fluorescence unit) in supernatants of
treated cells to RFU in control cells (mean +/2 standard
deviation). The dose-response curves are the results of a fit with
a 3-parameter logistic equation (if at least one normalized response
was less than 0.5). Horizontal lines are drawn to show the scatter of
the control values (mean +/2 standard deviation). Enhancement
of H3N2 virus replication was verified by measuring viral titers at
65 hpi by end point titration assays in MDCK cells (TCID50/mL).
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For these assays, sample supernatants of duplicate were harvested
at 65 hpi and stored at280uC until analysis. Increase of viral titers
were statistically significant for alvespimycin, methylbenzetho-
niumchloride, and sulodictil 40 mM (p-value ,0.05, two tailed
Welch t-test).
Found at: doi:10.1371/journal.pone.0013169.s007 (0.64 MB TIF)
Figure S8 Five molecules inhibit H1N1 SOIV influenza viral
growth. A549 cells were treated with increasing concentrations of
the molecule or solvent for 6 h and were subsequently infected
with A/Lyon/969/09 (H1N1 SOIV) influenza virus at a moi of
0.2 (Panel A) or 2 (Panel B). Viral titers were determined at 65 hpi
using a neuraminidase test as described in materials and methods.
This assay was performed in duplicate. Data are presented as the
ratio of RFU in the supernatant of treated cells to RFU in control
cells (mean +/2 standard deviation). The dose-response curves are
the results of a fit with 3-parameter logistic equation (if at least one
normalized response was less than 0.5). Horizontal lines are drawn
to show the scatter of the control values (mean +/2 standard
deviation).
Found at: doi:10.1371/journal.pone.0013169.s008 (0.69 MB TIF)
Figure S9 Comparison of viral replication kinetics between
different influenza A viruses in A549 cells. A549 cells were infected
at a moi of 0.1 (Panel A) or at a moi of 2 (Panel B) with influenza
virus A/New Caledonia/20/99 (H1N1), A/Lyon/969/09 (H1N1
SOIV), A/Moscow/10/99 (H3N2), A/Turkey/582/2006 (H5N1),
A/Finch/England/2051/94 (H5N2), and A/Chicken/Italy/2076/
99 (H7N1).
Found at: doi:10.1371/journal.pone.0013169.s009 (0.45 MB TIF)
Table S1 Specific primers used for real-time quantitative RT-
PCR.
Found at: doi:10.1371/journal.pone.0013169.s010 (0.01 MB
XLS)
Table S2 Gene expression data for 300 influenza virus regulated
genes identified in our experiments. Values are log2 normalized
gene expression intensities (see Experimental Procedures).
Found at: doi:10.1371/journal.pone.0013169.s011 (0.28 MB
XLS)
Table S3 Approved indications of the eight potential antivirals.
Found at: doi:10.1371/journal.pone.0013169.s012 (0.01 MB
XLS)
Table S4 Potency of the positively correlated drugs against A/
Moscow/10/99 (H3N2). CC50: molecule concentration of 50%
cytotoxicity; EC50: molecule concentration of 50% inhibition of
viral replication; SI: selective index.
Found at: doi:10.1371/journal.pone.0013169.s013 (0.01 MB
XLS)
Table S5 Comparison between the 300 regulated genes in our
experiment and identified factors required for influenza replication
in published human RNAi screens. Genes belonging to the concise
signature used to query connectivity map in our study are
highlighted in grey. Negative regulators of influenza replication
(antiviral) are genes whose depletion enhance viral infection.
Positive regulators (proviral) knock-out decrease viral infection.
Antiviral factors were identified in Shapira et al and Brass et al
studies.
Found at: doi:10.1371/journal.pone.0013169.s014 (0.03 MB
XLS)
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Feuille1
Page 1
Reverse Primer
ICAM1 AGCTTCTCCTGCTCTGCAAC AATCCCTCTCGTCCAGTCG
OAS1 CCAGGAAATTAGGAGACAGC GAGCGAACTCAGTACGAAGC
G1P2 ACTCATCTTTGCCAGTACAGGAG CAGCATCTTCACCGTCAGGTC 
CAPN1 GCCAAAACATTGCCTGTTATCTTAG ATAGGAGGCCGTATCAAAATTCC
NTE GGCAACGTCATTGAGAAAATGC AATCTCTGCCAAGTCAGTGAAGC
DNMT1 GTGGGGGACTGTGTCTCTGT TGAAAGCTGCATGTCCTCAC
GAPD GTGAAGGTCGGAGTCAACG TGAGGTCAATGAAGGGGTC
Gene Symbol Forward Primer 
Table S2. 
Gene expression data for 300 influenza virus regulated genes identified in our experiments. Values 
are log2 normalized gene expression intensities (see Experimental Procedures).
Ce fichier n'est pas reproduit compte tenu du nombre important de pages qu'il 
représente  ﬁtableau  contenant  les  ﬂ eurs  d'ession  au  sein  de  chaque 
échantillon des 300 gènes identifiés).
IndicationsName
2 aminobenzenesulfonamide 2 aminobenzenesulfonamide (or sulfanilamide) have antibacterial effects by inhibiting the production of folic acid inside the bacterial cell.
Brinzolamide Brinzolamide is a carbonic anhydrase II (CA-II) inhibitor used topically to treat ocular hypertension and glaucoma
Calcium Folinate
Calcium folinate (or leucovirin) is a 5 formyl derivative of tetrahydrofolic acid which has vitamin activity equivalent to folic acid without requiring dihydrofolate 
reductase for its conversion. This compound is used as an adjuvant in cancer chemotherapy involving methotrexate.
Harmol
Harmol is one of the β-carboline indoleamine alkaloids in the plants Peganum, Tribulus, Kallstroemia spp. with various pharmacological activities and 
neuromodulator properties.
Merbromin Merbromin (marketed as Mercurochrome) is a topical antiseptic used for minor cuts and scrapes.
Midodrine Midodrine is an alpha1-adrenergic receptor agonist used in the clinical management of patients with orthostatic hypotension.
Ribavirin Ribavirin is an antiviral drug with several proposed mechanisms. It is licensed for treatment of hepatitis C and respiratory syncytial virus.
Rilmenidine Rilmenidine is an imidazoline derivative that appears to lower blood pressure by an interaction with imidazoline (I1) receptors in the brainstem (and kidneys). 
H3N2 moi 2 H3N2 moi 0.2
Substance SI = CC50/EC50 SI = CC50/EC50
> 10 > 10 ND ND
6281.48 (8537.13) 2414.28 (2436.88) 2.60 (3.50) 452.31 (302.77) 13.89 (28.20)
592,77 491,74 1,21 278,95 2,13
6,35 5,60 1,13 4,55 1,40
853,80 1185,82 0,72 ND
4155,67 2180,73 1,91 2101,90 1,98
100.03 (5950.26) 39.31 (1718.95) 2.54 (3.46) ND
CC50 (uM) EC50 (uM) EC50 (uM)
alvespimycin enhance viral production
DL-Thiorphan (in DMSO)
Latamoxef
Methylbenzethoniumchloride
Pyrvinium enhance viral production
Sulfameter
Sulodictil (in DMSO) enhance viral production
Confirmation (A549/WSN) Y2H (H1) H2 U20S/PR8
ETV3 2117 Y
ABTB2 25841 Y
SLC2A2 6514 Y
PPFIBP1 8496 Y
ICAM1 3383 Y 6
MEF2D 4209 Y
HYAL4 23553 Y
LPAR1 1902 Y
OAS1 4938 Y 2
CFD 1675 Y
ALG2 85365 Y
ISG15 9636 Y 2
OASL 8638 2
IRF7 3665 2
IFITM1 8519 2
IFIT3 3437 2
FOSB 2354 Y
KPNA6 23633 Y
HSPG2 3339 Y 11
CAPN1 823 Y
PPP1R14D 54866 Y
PNPLA6 10908 Y
DNMT1 1786 Y
NOP16 51491 Y
CLASP2 23122
MAN2C1 4123
BTBD11 121551
ACTB 60
DECR2 26063
GEMIN4 50628 10
VPREB3 29802
HELB 92797
SUSD1 64420
RRP7A 27341
TGIF1 7050
MRPL48 51642
NCK1 4690
AURKB 9212
RPN2 6185
IFNG 3458
SCUBE2 57758
MAP4 4134
PLCE1 51196
MGAT1 4245
NUCB1 4924 10
CDC20 991
CPSF1 29894
BID 637
MLPH 79083
CTSD 1509
TUBA1A 7846 10
PSMC4 5704
PGD 5226 10
PREX2 80243
TUBA3D 113457
PCNA 5111
SNX17 9784
TPD52L1 7164
CLK2 1196 11
GBA 2629
BLOC1S1 2647
FZR1 51343
NISCH 11188 10
AIFM1 9131
SCRN1 9805 10
SLC22A3 6581
SLC7A7 9056
AGGF1 55109
FSTL3 10272
XAB2 56949
SMARCA1 6594
STRA13 201254
CXXC1 30827
FPGS 2356
HSP90AB3P 3327
EBP 10682
PMEPA1 56937 10
PPP2R5A 5525
ILK 3611
LAMB2 3913
E2F2 1870
ACTB 60
GTF3C1 2975
TLN1 7094
TRIM28 10155
NRD1 4898
SLC24A6 80024
DHX9 1660
SEPHS1 22929
TWF2 11344
TKT 7086
GAA 2548
DNASE2 1777
PTPN3 5774
TRAF6 7189 1 6
GATA1 2623
FADS1 3992
C1QTNF2 114898
DDB2 1643
MTOR 2475
LHB 3972
FLNB 2317
PDIA4 9601
CLU 1191 7
CBY1 25776
CDCA8 55143
ZCCHC9 84240
CANT1 124583
CD36 948
SOX2 6657
ALDH3A1 218
CARS 833
SFPQ 6421
MCM7 4176
PMS2L3 5387
LMNA 4000
SCAMP4 113178
TCF4 6925 4
PCNX 22990
KLF6 1316 5
SARS2 54938
ALDOA 226
SLC37A2 219855
JAG2 3714 10
CD63 967
PTPRF 5792
POLR1B 84172
CDH19 28513
RHBDF2 79651
INSIG1 3638 3
C1QTNF6 114904
FDPS 2224
CYFIP1 23191
PTRF 284119
CASP3 836 1
GPM6B 2824
EXOC3 11336
L3MBTL2 83746
IL13RA1 3597
NDUFS4 4724
PKN2 5586
NTF4 4909
NT5C 30833
ELOVL1 64834
UBA1 7317
SACS 26278 10
RUSC1 23623
G6PD 2539
POMT1 10585
TACC3 10460
TUBGCP6 85378
ABCC2 1244
PFKL 5211
PLXNB2 23654 11
CENPF 1063 10
VAMP5 10791
KRT8 3856
ASPH 444
NPIPL3 23117
CBX1 10951
IGFBP4 3487
CSTF3 1479
STON1 11037
THAP11 57215
MEN1 4221 10
XRN2 22803
SIDT1 54847
MMP14 4323
TUBA1C 84790
VPS29 51699
CDK4 1019 10
SPR 6697
APOBEC3C 27350
ZNF135 7694
TNFRSF10A 8797
MAPK8 5599
AFG3L1 172
MRPL27 51264
TUBB2A 7280
ACSS2 55902
FAM19A2 338811
AKAP1 8165
COL7A1 1294
YEATS4 8089
STIM1 6786
USP11 8237
CCDC80 151887
AP2B1 163 11
XPO6 23214
KRT7 3855
MAP1S 55201
SBSN 374897
G6PD 2539
LOXL1 4016
GCN1L1 10985
ACTN1 87
IGFBP6 3489 1
CYP2S1 29785
SNRPB2 6629
EIF4G3 8672
SEMA4B 10509
PTP4A1 7803 8
TUBA4B 80086
CPB2 1361
SPG7 6687 10
MAP2K5 5607
DARC 2532
PKD1 5310
PAK4 10298
DOK1 1796
LTBR 4055
HSPBP1 23640
MCM5 4174
ELOVL5 60481
SLC9A10 285335
PKM2 5315
VCL 7414
EIF3CL 728689
NPC1 4864
THADA 63892
VCAN 1462 10
FLOT2 2319
UCHL3 7347
EHD1 10938
CDIPT 10423
RBM28 55131 11
HARS2 23438 11
NCLN 56926
PPIE 10450
PSAP 5660
SLC25A11 8402
THRB 7068
DNM1L 10059
TUBB 203068
IFI44L 10964 2
GGT1 2678
SIGIRR 59307
TEX264 51368
LONP1 9361
BCAP31 10134
RANBP10 57610
ALDH1A1 216
POMZP3 22932
FAM127A 8933
CCM2 83605
DCTN2 10540
LRRC16A 55604
IGHMBP2 3508
CXXC5 51523
LAPTM4B 55353
NOP2 4839
TRPV6 55503
PTCD1 26024
NDUFA10 4705
BHLHE41 79365
ACTN4 81
ZNF215 7762
FH 2271
JOSD2 126119
ABCD1 215
MRC2 9902
FOLR1 2348
ATP5C1 509
SLC3A2 6520
MTUS1 57509
PILRB 29990
ZNF76 7629
PCYOX1 51449
VRK1 7443
DKC1 1736
FUS 2521
NR2F6 2063
SST 6750
YWHAH 7533
ZNF133 7692
GLG1 2734
PROK1 84432
CDC73 79577
GLA 2717
SCAF1 58506
CIAPIN1 57019
GRN 2896
TMEM9 252839
DGKQ 1609
PAPSS1 9061
TMEM97 27346
SERPINE2 5270
SYNCRIP 10492
TUBB3 10381
GSTT2 2953
ZNF217 7764 7
PKP3 11187
CYP24A1 1591
POLM 27434
KIDINS220 57498
SLC35C1 55343
NXT2 55916
ATP5B 506
SAMM50 25813
TXNRD1 7296
Karlas et al. 2010 Konig et al 2010 Shapira et al 2009 Brass et al 2009
Symbol GeneID Expression after infection Signature_Connectivity Primary hit (A549/WSN) Confirmed hit (A549/WSN or A/Hamboug/04/2009)  A549/WSN-Ren Expression Cluster (HBEC/PR8) siRNA (HBEC/PR8)
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Discussion
La réponse immunitaire innée à l'encontre des micro-organismes est supposée être 
schématique  et  stéréotypée  [77].  Sommairement,  elle  met  en  jeu  une  réponse 
humorale  innée  (anticorps  naturels,  défensines,  système  du  complément)  et  un 
ensemble de cellules capables de réagir sans éducation préalable (lymphocytes NK, 
granulocytes, macrophages et cellules dendritiques). Les techniques d’analyse à haut 
débit  montrent  que  cette  simplification  est  excessive.  La  réponse  de  l’hôte  à 
l’infection est basée sur des mécanismes différents en fonction de l’agent vulnérant et 
de l’hôte lui-même. L'arrivée d'outils tels que les puces à ADN permet par exemple 
d'explorer la relation hôte-pathogène avec infiniment plus de détails qu'auparavant 
[78].
Les  interactions  entre  un  hôte  et  un  micro-organisme  sont  diverses  et 
choréiformes. Les caractéristiques et le devenir de ces interactions diffèrent selon le 
type de cellule immunitaire recrutée, le sous-type de lymphocyte impliqué ou encore 
le profil de médiateurs produits. Il existe des thèmes communs dans la réponse de 
l’hôte à l’infection (par exemple les PAMPs pour « Pathogen Associated Molecular 
Patterns »).  Parallèlement,  il  existe  des  thèmes  communs  dans  les  facteurs  de 
virulence des micro-organismes (facteurs d'adhérence, toxines, systèmes de sécrétion, 
facteurs  de  régulation de  l'expression du génome microbien)  [79].  La description 
séparée  de  chaque  partenaire  (hôte  et  micro-organisme)  montre  une  certaine 
homogénéité. Pourtant, la description détaillée de toutes les interactions spécifiques 
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entre  un  hôte  et  un  micro-organisme  met  à  jour  une  grande  hétérogénéité  des 
mécanismes. Chaque micro-organisme a construit au cours de son évolution sa propre 
stratégie de manipulation de l'hôte pour optimiser sa survie et sa transmission. Ainsi, 
quand un micro-organisme se retrouve face à un hôte naïf, il entraîne souvent une 
réponse inadaptée de la part de l'hôte [80]. 
Les puces à ADN offrent la possibilité de décrire de manière précise la réponse de 
l'hôte  face à  un micro-organisme.  Elles  examinent  les  composantes de la relation 
hôte-pathogène dans l’ensemble de leur dimension. Nos études ont exploré divers 
aspects de la réponse inflammatoire au niveau du transcriptome de l'hôte. La possible 
dichotomie entre  inflammation d’origine infectieuse ou non sous-tend une grande 
part  de nos recherches.  Le même outil  d'analyse  a  été  utilisé  sur  des  cellules en 
culture, dans des modèles animaux, ou in-vivo en pathologie humaine. 
Jusqu'à récemment, le modèle de choix pour expliquer la morbidité et la mortalité 
liées au sepsis était celui d'une réponse hyperinflammatoire non contrôlée de la part 
de l'hôte [81]. Ce modèle était soutenu par de nombreuses études dans lesquelles les 
animaux recevaient  des  doses  importantes de bactéries  ou de produits  bactériens. 
L'injection de quantités exagérées de bactérie entraîne la libération brusque d'un flot 
de médiateurs inflammatoires entraînant le décès de l’hôte  [82-87].  De nombreux 
essais  cliniques  ont  évalué  le  bénéfice  de  traitements  anti-inflammatoires  sur  la 
mortalité.  Ces  essais  ont  été  des  échecs.  Ces  échecs  ont  conduit  à  reconsidérer 
l'hypothèse  selon  laquelle  seule  la  réponse  pro-inflammatoire  de  l'hôte  était 
responsable de la  mortalité  du sepsis.  De plus,  des modèles pré-cliniques ont  été 
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élaborés mimant de façon plus conforme le sepsis humain [88]. 
La relation entre l'hôte et un micro-organisme semble basée sur une réponse pro-
inflammatoire  précoce  suivie  de  façon  rapprochée  par  une  réponse  anti-
inflammatoire,  conduisant  à  un  état  d'immunosuppression  en  cas  d’évolution 
défavorable [5]. La décortication de la relation hôte-pathogène permet d'avancer dans 
la compréhension des mécanismes physiopathologiques du sepsis.
La première variable à intégrer dans la modulation de la réponse de l'hôte est le 
temps. La réponse de l'hôte au pathogène est un processus dynamique. L'intégration 
du temps est  fondamentale  pour  interpréter  la  pertinence de la  mesure d'un gène 
comme  marqueur  diagnostic  ou  comme  cible  thérapeutique  potentielle.  Dans 
l'analyse,  le  temps  s'intègre  comme « le  temps  qui  s'écoule  à  partir  du  début  de 
l'agression »,  mais  également  comme  « le  moment  de  la  journée  où  survient 
l'agression ».
Nous avons décrit la réponse de l’hôte au cours du temps après injection d'acide 
oléique en intraveineux dans un modèle murin [89]. Un millier de gènes sont modulés 
dans  le  parenchyme pulmonaire  après  l’agression.  Six  points  de  mesures  ont  été 
réalisés (1h, 1h30, 3h, 4h, 18h et 24h). Trois profils d’expression (cluster) ont été 
individualisés :  précoce  (1h-1h30),  intermédiaire  (3h-4h)  et  tardif  (18h-24h).  Ces 
trois clusters de gènes ont été associés à des fonctions différentes. Les gènes modulés 
précocement  sont  impliqués  dans  la  réponse  pro-inflammatoire  (cytokines  pro-
inflammatoires, récepteurs et protéines impliquées dans la transduction du signal). 
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Ceux modulés entre 3 et 4 h sont associés à l'expression de molécules d'adhésions, de 
composants  du  cytosquelette  et  à  la  migration  transendothéliale  des  cellules  du 
système immunitaire. Ceux activés tardivement sont impliqués dans la transcription, 
la synthèse des protéines, et le métabolisme, notamment celui du cholestérol.
Nos résultats sont en accord avec un modèle humain basé sur l’administration 
d’endotoxine à des sujets sains [67]. Ces modèles sont comparables puisque, dans les 
deux  cas,  l’agression  n’était  pas  létale.  L'expression  de  plusieurs  cytokines  et 
chemokines  pro-inflammatoires  (TNF,  IL1A,  IL1B,  CXCL1  (GRO-α),  CXCL2 
(GRO-β), CCL2 (MCP1), CXCL8 (IL8), CXCL10) atteint un pic entre 2 et 4 h après 
l'injection  d'endotoxine.  Les  facteurs  de  transcription  connus  pour  contrôler 
l'expression de ces gènes (NFKB1, NFKB2, RELA, RELB) sont également à leur pic 
d'expression dans cette période. Quatre à 6 h après l'injection de LPS, on observe une 
poursuite  de  l’activation  de  la  réponse  inflammatoire  (par  certains  facteurs  de 
transcription comme STAT et CREB). De façon concomitante, plusieurs mécanismes 
participent  au  contrôle  de  cette  réponse  (SOCS3,  IKBK,  IL1RAP,  IL1R2, 
TNFRSF1A).  Cette  période  de  temps  charnière  est  critique  pour  le  retour  à  un 
phénotype normal. Nos données histologiques montraient un retour à un phénotype 
pulmonaire normal après 4 h. Il faut noter que cette temporalité de la réponse semble 
être dose-dépendante [90].
La  traduction  clinique  de  cette  approche  a  été  faite  dans  le  projet  intitulé 
SepsiChip. L’objectif primaire était de déterminer une signature transcriptionnelle de 
la  pneumonie  chez  des  patients  traumatisés.  Les  patients  traumatisés  avaient  été 
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choisis pour avoir un fonds inflammatoire commun dans l’ensemble de notre cohorte, 
permettant  ainsi  d’identifier des marqueurs spécifiques d’infection en éliminant le 
bruit de fond (inflammation). Aucune signature transcriptionnelle spécifique n’a été 
mise en évidence chez les patients développant une pneumonie. Les différences entre 
les  patients  au  moment  de  l’admission et  au  moment  du  début  de  la  pneumonie 
étaient liées au facteur temps, puisque les mêmes variations étaient retrouvées chez 
des sujets  contrôles.  Les seules variations retrouvées dans cette  étude étaient  une 
diminution de la production de médiateurs pro-inflammatoires lors du diagnostic de 
pneumonie.  Ces  données,  en  accord  avec  une  étude  précédemment  publiée  [70], 
démontrent que le facteur temps est essentiel dans l’analyse du transcriptome. Cette 
composante  doit  donc  être  prise  en  compte  pour  toute  analyse  de  données  de 
transcriptome. 
Après  infection  par  Coxiella  burnetii, nous  avons  montré  que  l'expression 
hépatique des gènes impliqués dans le  contrôle  de l'horloge biologique (ARNTL, 
CLOCK, PER2) au niveau moléculaire est modifiée  [91]. L'horloge circadienne est 
perturbée précocement, puis l’expression des gènes revient à un niveau d'expression 
basal. Parallèlement, on observe un pic d'expression d'IFN-γ et d'IL-6 à J4, alors que 
l'expression d'IL10 et de son effecteur (STAT3) augmente constamment durant les 
sept jours de l’étude. Les modulations du rythme circadien ne sont retrouvées que 
chez les souris femelles. Ceci souligne l'interaction des différentes variables (temps et 
sexe) dans la modulation de la réponse de l'hôte.
La littérature montre que le rythme circadien interfère avec la réponse de l'hôte. 
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La variation circadienne de l'expression des gènes qui composent l'horloge biologique 
au  niveau  moléculaire  (comme  CLOCK  ou  ARNTL)  influe  sur  l'expression  de 
cytokines  [92] ou  l'activité  des  cellules  NK  [93].  La  réponse  à  une  stimulation 
antigénique  est  différente  selon  le  moment  de  la  journée  [94].  Après  injection 
d'oxazolone (allergène utilisé pour tester l'hypersensibilité de type retardée) en sous-
cutanée,  le  nombre  de  cellules  immunitaires  et  l'inflammation  (mesurée  par 
l'épaisseur cutanée) diffèrent selon que l'injection est réalisée le jour ou la nuit. Une 
inversion du cycle jour/nuit alterne le profil de réponse par rapport à une heure fixe 
d'injection (à 10 h ou 22 h). De même, la susceptibilité de drosophiles infectées par 
Pseudomonas aeruginosa est maximale quand l’infection survient en milieu de nuit 
[95]. Ces données confirment l’interaction entre le rythme circadien et la réponse de 
l’hôte. 
L’'influence du sexe dans la réponse de l'hôte a été largement décrite mais reste 
difficile à apprécier. Actuellement, la prise en charge des patients en sepsis grave ne 
diffère  pas  en  fonction  du  sexe.  Dans  d’autres  champs  d’application,  comme  la 
traumatologie crânienne ou l’arrêt cardiaque, des essais cliniques en cours évaluent 
l’effet de traitements par de la progestérone sur le pronostic des patients (Clinical 
Trials NCT00822900, NCT01143064, NCT00048646). Les femmes ont généralement 
une production accrue d’anticorps. Elles développent d’ailleurs plus de maladies de 
système  que  les  hommes  [96].  Par  rapport  aux  hommes,  elles  ont  une  moindre 
susceptibilité  au  sepsis  [76,97],  nécessitent  moins  souvent  d’être  hospitalisées  en 
réanimation  [98] et  développent  moins  de  complications  [98,99].  Par  contre,  les 
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données épidémiologiques montrent que la mortalité est équivalente entre les deux 
sexes.  Ces  différences  sont  supportées  par  des  données  in-vitro où  des  cellules 
immunitaires exposées  ex-vivo à du LPS produisent plus de cytokines lorsqu'elles 
proviennent  d'un  homme  que  d'une  femme  [100,101].  Ceci  explique  la  réaction 
inflammatoire plus soutenue chez les hommes.
Des  données  épidémiologiques  ont  montré  que  le  sexe  ratio  des  patients 
développant une fièvre Q est d’environ deux hommes pour une femme [102].  Le rôle 
des hormones sexuelles  a  été  confirmé dans un modèle  murin d’infection par  C. 
burnetii. On dénombrait moins de bactéries et de granulomes dans le foie et la rate 
des souris  femelles que chez les  souris mâles  [103]. Pour expliquer avec plus de 
précisions ces observations, nous avons élaboré une approche transcriptionnelle. En 
fait,  86 % des  2 777 gènes  modulés  par  l'infection sont  sous  l'influence  du sexe. 
Brièvement,  chez  les  mâles,  les  gènes  étaient  rattachés  à  l'adhésion  cellulaire,  la 
production de défensines, la transduction du signal et l'activation de la voie Jak/Stat. 
Ceux modulés chez les femelles étaient associés au rythme circadien. Pour affiner le 
modèle, nous avons soumis les souris à une castration chirurgicale. Cela a entraîné 
une réduction de 60 % des gènes modulés. Ce résultat confirme donc un dimorphisme 
sexuel au niveau de la réponse transcriptionnelle et le rôle prépondérant joué par les 
hormones  sexuelles.  Ces  résultats  posent  également  les  bases  pour  expliquer  le 
dimorphisme sexuel observé dans les données épidémiologiques.
Dans  l'analyse  de  la  réponse  à  l'infection  par  le  virus  Influenza [104],  cinq 
souches virales ont été utilisées. Ces souches variaient par leur caractère antigénique 
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(hémaglutinine et neuraminidase) et leur virulence [105]. Des modèles in vitro [106] 
ou in vivo [107,108] ont mis en évidence une forte augmentation de l'expression des 
gènes de réponse à l'IFN après infection par la souche H5N1. Cette induction est 
probablement  liée  à  la  virulence  de  cette  souche  [107,108].  Dans  notre  étude, 
l'infection  par  H5N1  entraîne  une  expression  supérieure  en  nombre  et  en  valeur 
absolue des gènes de la réponse inflammatoire par rapport à l'infection par les autres 
souches. Pour les gènes de réponse à l'IFN (OAS1, OASL, IFITM1, IRF7, ICAM1, 
G1P2,  et  IFIT3),  on observait  un ratio  d'expression de 2 à  4  fois  supérieur  pour 
l'infection par H5N1, par rapport aux autres souches. Au contraire, l'infection par la 
souche  A/New  Caledonia/20/99  (H1N1)  entraîne  des  modifications 
transcriptionnelles modestes.  Ainsi,  sur  plus de 8 500 gènes testés,  l'infection par 
H1N1 modulait 36 gènes, alors que les autres souches modulaient de 1 455 (H5N1) à 
3 020 gènes (H7N1). Ces modifications obtenues avec H1N1 étaient corrélées à la 
faible efficacité de réplication de cette souche dans les cellules. 
Le virus de la  grippe est  un exemple caricatural  de la variabilité  des facteurs 
impliqués  dans  la  relation  hôte-pathogène.  Toutefois,  bien  que  des  déterminants 
intrinsèques contribuent fortement à la virulence d’un agent infectieux [109-111], la 
naïveté de l'hôte face à cet agent joue également un rôle dans la gravité du tableau 
clinique [112]. La complexité des déterminants génétiques de la virulence des micro-
organismes a été bien décrite ailleurs [35]. Le rôle des facteurs de virulence dans la 
variabilité de la réponse de l’hôte est également rapporté dans l’infection bactérienne. 
Les souches pathogènes d'une espèce bactérienne diffèrent des souches commensales 
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par l'acquisition et l'expression de gènes de virulence particuliers [113]. Les toxines 
bactériennes participent pleinement aux lésions infligées à l'hôte. Le tableau le plus 
connu est celui du  toxic-shock-syndrome lié aux infections à staphylocoque doré et 
streptocoque [114,115]. Ces toxines sont fréquemment codées par des gènes localisés 
dans  des  îlots  génomiques  de  structure  particulière  et  regroupant  des  gènes  de 
virulence. Certains de ces îlots génomiques sont communs à de nombreuses bactéries 
[116]. La présence de ces îlots distingue souvent les souches pathogènes des souches 
non virulentes [117]. 
L'ensemble des travaux présentés dans cette thèse utilise la même technologie 
d'analyse du transcriptome par puces à ADN. Bien que les résultats d'expression des 
principaux gènes modulés aient été confirmés par une technologie alternative, cette 
approche présente plusieurs limitations importantes. Tout d'abord, les types de puces 
à ADN employés dans ces travaux ne permettent pas d'explorer les variants alternatifs 
exprimés  à  partir  d'un  même  gène,  variable  importante  de  la  régulation  de 
l'expression  des  gènes.  La  rétro-transcription  à  l'aide  d'amorces  poly-dT  élimine 
également de l'analyse les modulations possibles des ARN non-codants. D'autre part, 
la corrélation entre  la modulation de la  transcription et  de la traduction n'est  pas 
toujours évidente. En plus d'être traduite, de nombreuses protéines dépendent pour 
être  fonctionnelles  de  modifications  post-traductionnelles  spécifiques  et  de  leur 
transport dans des compartiments sub-cellulaires particuliers. Ces différentes étapes 
de la régulation de l'expression des gènes sont complètement ignorées par l'analyse 
présentée ici. Ces limitations sont importantes à considérer lorsque des hypothèses 
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physiopathologiques sont élaborées à partir d'une simple analyse du transcriptome. 
Le développement  de  technologies  comme le  RNA-seq (pour  étudier  les  variants 
alternatifs des ARNm), l'intégration de l'analyse de l'expression des ARN non codants 
et  le  développement  des  technologies  d'analyses  du  protéome  permettent  de 
compléter théoriquement ces limitations.
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Conclusion et perspectives
Le transcriptome est un outil de choix pour analyser la réponse de l’hôte. Nous 
avons  montré  dans  ces  différentes  études  l’influence  de  facteurs  liés  à 
l’environnement (le temps), à l’hôte (le sexe) et au micro-organisme (la virulence) 
dans  la  relation  hôte-pathogène.  La  prise  en  compte  du  temps  est  capitale  dans 
l’interprétation des données transcriptionnelles. La réponse de l’hôte est variable en 
fonction du délai écoulé entre le début de l’infection et celui de la prise en charge. 
L’intérêt  d’une  antibiothérapie  très  précoce  dans  le  sepsis  grave  s’inscrit 
probablement dans cette approche. De plus, la réponse du système immunitaire est 
modulée  par  le  rythme  circadien.  Ceci  ouvre  des  perspectives  de  recherche 
intéressantes,  notamment  en  réanimation  où  les  agents  de  la  sédation,  l’absence 
d’alternance  lumière  /  obscurité  et  l’activité  constante  perturbent  l’horloge 
biologique.  Le  premier  facteur  de  variation  interindividuelle  est  probablement  le 
sexe.  Plus  de  80 %  des  gènes  modulés  dans  l’infection  par  C.  burnetii sont 
dépendants  du  sexe.  Ces  données  expérimentales  éclairent  les  observations 
épidémiologiques. En perspective, nous élaborons une étude similaire en utilisant un 
modèle murin d’infection plurimicrobiennes intra-abdominale. Ce modèle ferait ainsi 
le lien avec notre pratique clinique. La prise en compte du sexe est probablement une 
des premières étapes d’une prise en charge individualisée. Par ailleurs, des approches 
basées sur des traitements hormonaux sont en cours de développement dans diverses 
pathologies  et  mériteraient  d’être  évaluées  dans  le  sepsis.  Enfin,  la  virulence  du 
micro-organisme a un rôle propre. Nous avons démontré qu’il existe une variabilité 
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de réponse en fonction des souches du virus de la grippe. Les deux partenaires de la 
relation  hôte-pathogène  ont  donc  un  rôle  dans  cette  interaction.  En  utilisant  des 
logiciels  comme  « TranscriptomeBrowser»,  les  données  transcriptionnelles 
provenant de différents modèles pourront être analysées afin de déterminer à large 
échelle l’impact des facteurs de virulence des micro-organismes sur la réponse de 
l’hôte.
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1 – Abstract
In this work, we describe a global overview of critical events occurring in blood 
during lung inflammation using a transcriptional approach in a murine model. By 
comparing  transcriptional  data  in  lung  and  blood,  we  show  that  response  to 
inflammation is compartmentalized in these organs. Female C57BL6/J mice received 
an  intravenous  oleic  acid  injection  (OA)  to  induce  an  acute  lung  injury  (ALI). 
Peripheral Blood Mononuclear Cell (PBMC) expression patterns were analyzed using 
a 9900 cDNA mouse microarray (MUSV29K). Our analysis revealed marked changes 
in pathways involving the immune and inflammatory responses and lipid metabolism. 
First,  the pro-inflammatory phase is activated, showing a high expression level of 
genes involved in stress response, DNA damage, protein synthesis, inflammation and 
immune  response.  The  second  phase  was  related  to  the  tissular  spreading  of 
inflammation. This phase was associated with high expression of genes involved in 
metabolism and transcription. At the last stage of inflammation, lipid metabolism was 
disturbed and DNA repair was reactivated. We compared the transcriptional responses 
to inflammation in peripheral blood and lung. Several pathways including immune 
response,  inflammatory  response  and  disruption  of  lipid  metabolism  were 
simultaneously activated in PBMCs and lung. Other pathways, such as DNA repair 
and  autophagy,  were  specifically  activated  in  PBMCs.  Finally,  transcription  was 
activated earlier in PBMCs (3h to 4h after OA injection) than in lungs (18h to 24h 
after OA injection). These findings, taken together with our previous transcriptional 
study in lungs, show that the inflammatory response is compartmentalized.
2 – Introduction
Acute lung injury (ALI) and its most severe manifestation, the acute respiratory 
distress syndrome (ARDS), is a clinical syndrome defined by an acute hypoxemic 
respiratory  failure  accompanied  by  bilateral  pulmonary  infiltrates  consistent  with 
edema  and  normal  cardiac  filling  pressures  [1-2].  ALI  has  many  etiologies, 
suggesting  that  numerous  genetic,  environmental,  and  developmental  factors  are 
involved in its progression. Human studies have provided important and descriptive 
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information about the evolution of the physiological and inflammatory changes in the 
lungs during ALI. This information has led to hypotheses about mechanisms of injury 
[1-2]. However, these hypotheses have been difficult to test in humans because of too 
many clinical variables and confounding factors. 
Animal models provide a bridge between patients and the laboratory bench [3]. 
Indeed, despite some limitations, studies using animal models of ALI/ARDS remain 
essential  because,  to  date,  there  is  no  substitute  for  animal  models  as  a  tool  to 
generate  information  about  the  pathophysiology  of  lung  injury  and  to  test  novel 
therapeutic interventions in complex biological systems. The oleic acid model (OA) 
was  successfully  used  in  mouse  to  reproduce  ALI  and  set  up  a  model  of  lung 
inflammation [4]. The OA model produces the basic characteristics of ALI: early and 
rapidly reversible patchy inflammatory lung injury with permeability changes and 
impairment in gas exchange and lung mechanics [3].  Oleic acid has a direct toxicity to 
endothelial  cells.  Endothelial  injury  is  followed  by  epithelial  injury.  Injection  of  OA leads  to 
membrane damage and necrosis [3]. A major advantage of this model is its reproducibility; 
the administration of the same dose of OA by the same route to different animals is 
followed by a reproducible pulmonary injury [3].
Following OA injection, the pathophysiological events differ from organ to organ, 
and between organs and peripheral blood. This leads to compartmentalization, which 
can be seen as a way for the entire organism to limit the inflammation to its initial 
site.  When the  organism is  unable  to  prevent  the  spreading  of  inflammation,  the 
inflammation becomes systemic. The cellular compositions of each compartment, the 
micro-environment, and the leukocyte recruitment rate have an important influence 
on local inflammation and response [5]. During inflammation, a subtle balance exists 
between pro- and anti-inflammatory mediators both locally and at the systemic level. 
This time-dependent balance is the consequence of a complex network of up- and 
down-regulating signals. Specific surrounding cells that differ from compartment-to-
compartment  play  a  key role  in  this  modulation.  Similarly,  distance  between  the 
initial site of inflammation and distal anatomic compartments influences the timing 
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and amplitude of the inflammatory response [5-8]. We can distinguish the local site of 
inflammation, the systemic circulation and distant compartments. The most striking 
differences are between tissues and the blood compartment [5]. Blood components 
have a uniform distribution, wherever they are found within the organism. In contrast, 
in  the  lungs,  each cellular  type  has  a  specific  localization.  This  means that  cells 
cannot be simultaneously at the same inflammatory stage throughout the organ. 
Similarly, at the organism level, the same compartmentalization process leads to 
an overwhelming inflammation across the whole organism. The inflammation process 
is  associated  with  a  cascade  of  events.  During  de-compartmentalization,  which 
correspond to the spreading of inflammation from the initial site of inflammation to 
other compartments, high levels of pro-inflammatory mediators produced locally and 
released into the bloodstream initiate remote organ injury as a consequence of organ 
cross-talk.  Injured organs are a site of synthesis of inflammatory mediators and the 
associated  increase  in  vascular  and  epithelial  permeability  favors  the  leaking  of 
mediators from one compartment to another [9, 10].
While  the  high  concentrations  of  anti-inflammatory  mediators  present  in  the 
bloodstream prevent  the ignition of  new inflammatory foci,  their  presence within 
tissues  may  not  always  be  sufficient  to  prevent  the  initiation  of  a  deleterious 
inflammatory response in the different compartments. For example, in multiple organ 
failure  patients  with  ARDS,  Douzinas et  al. reported  higher  IL-1β  levels  in 
pulmonary capillary blood than in peripheral vein blood [11]. These results strongly 
suggest  the  production  of  this  cytokine  within  the  tissue  and their  release  in  the 
downstream vein.
It has been previously shown that the gene expression patterns were significantly 
different when studied simultaneously in two different organs during inflammation. A 
previous study compared Peripheral Blood Mononuclear Cells (PBMC) and spleen 
immune cell functions in a murine burn model [12].  This study shows the need to 
consider  gene  expression  in  blood  and  organs  simultaneously.  Indeed,  the 
inflammation status observed at the PBMC level alone in organisms undergoing lung 
inflammation does not allow for correct assessment of the inflammatory status of 
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each organs of the whole organism. The actual immune status at the tissue level has 
to be taken into consideration.
We have previously characterized changes in gene expression over time following 
OA-induced lung inflammation [4]. Gene expression patterns in lung were analyzed 
using a 9900 cDNA mouse microarray (MUSV29K) and a set of 1000 genes whose 
expression  level  significantly  changed  during  a  24h  time-course  was  identified. 
Subsequent functional  annotation allowed us to find pathways related to pro- and 
anti-inflammatory stages.
In the present study, our first objective was to use the OA-induced ALI model 
previously  described  [4]  to  characterize  lung  and  blood  inflammation,  using  a 
transcriptional approach. In doing so, we provided an important database for future 
transcriptional studies of diseases associating inflammation. Since transcriptional studies 
about sepsis do not discriminate between the expression profiles due to infection associated with 
inflammation  from  the  expression  profile  only  due  to  inflammation,  next  experiments  should 
specify the differences between inflammation due to an infectious process and that due to a non-
infectious process. The second objective was to identify which pathways are commonly 
activated or repressed in blood compared with lung and to compare the timing of this 
activation/repression.  Third,  we  show  that  the  response  to  lung  inflammation  is 
compartmentalized in these two organs.
 Results
a- Response Outcome of the mice 
After intravenous OA administration, we noticed a transitional prostration of the 
mice, occurring 1h30 after injection and lasting for several hours. The mice came to a 
standstill in one corner of the cage and started shivering.  The survival rate was 100% after 
24h incubation.
b- Yield of PBMC and RNA isolation
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For each mouse, we collected 200 to 900 µL of blood. Isolation of PBMC using 
Ficoll 1.084 allowed us to recover an average quantity of 1.9x106 PBMC for 600 µl 
of blood. On average, we extracted 1.92 µg of total RNA for each sample (figure S1). 
RNA amplification was necessary since at least 3 µg of total RNA are required for 
microarray hybridization. On average, we amplified each of the RNA samples 15 
times resulting in 28 µg of amplified RNA (aRNA).
c-  Microarray  analysis  identified  a  set  of  genes  significantly  differentially 
expressed in blood during lung inflammation
Since we used the same protocol as previously set up in the OA-induced ALI model described 
in [4], we can confirm that we induced ALI in mice considered in this study.  In order to study 
transcriptional changes associated with the lung inflammatory process in blood, we 
searched  for  a  set  of  genes  differentially  expressed  in  this  tissue  at  different 
incubation times. To this purpose, we used the multi-class Significant Analysis of 
Microarrays (SAM) procedure [13], applying a false discovery rate of 5% (figure 1). 
The analysis yielded a set of 1,534 significantly differentially expressed genes (table 
S2). We performed unsupervised hierarchical clustering to group these genes based 
on the similarities of their expression profiles over the time-course (figure 2). The 
Cluster software [14] classified the 1,534 genes previously identified based on their 
expression profile and we organized them into 4 clusters (figure 2). 
Genes extracted from cluster A (409 genes) were transiently down-regulated 3h to 
4h after OA injection. Their expression level was high at 1h-1h30 and 18h–24h time-
points. Relative to their expression levels at the earlier time-points (1h-1h30), genes 
from cluster B (257 genes) showed increased expression between 3h and 4h and at 
18h–24h. This timing may correspond to the transitional phase between the pro- and 
anti-inflammatory responses to OA injection that we have previously demonstrated 
for this model [4]. At the earliest time-points of the experiment (1h-1h30), genes from 
cluster C (314 genes) were over-expressed. After the early inflammatory phase, genes 
from cluster D (554 genes) were highly over-expressed between 3h and 24h (figure 
2).
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d-  Identification  of  time-dependent  pathways  in  blood  during  lung 
inflammation
Gene Ontology (GO) terms related to DNA damage such as « Response to stress » 
(p=1.8x10-2),  « Response  to  DNA  damage  stimulus »  (p=3.9x10-2)  and  « DNA 
repair » (p=3.4x10-2) were overrepresented in cluster A (table 1). These terms were 
grouped together by the Functional Annotation Clustering tool from the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) in a single annotation 
cluster with an enrichment score of 1.45. In cluster A, we also found genes involved 
in aminoacid metabolism. Indeed, GO terms such as « Nitrogen compound metabolic 
process »  (p=1.7x10-2),  « Amine  metabolic  process »  (p=3x10-2)  and  «Aminoacid 
metabolic process » (p=5.2x10-2) clustered together with an enrichment score of 1.14 
(table 1).
“Regulation of metabolism” and “Transcription” terms were strongly represented 
in cluster B (table 2). GO terms such as «Regulation of cellular metabolic process» 
(p=7.5x10-4), « RNA metabolic process » (p= 7.1x10-3) and «Biopolymer metabolic 
process»  (p=2.2x10-3)  clustered  together  with  genes  involved  in  « Transcription » 
(p=5.7x10-3),  « Regulation  of  transcription »  (p=6.6x10-3)  and  « DNA-dependent 
transcription » (p=8.6x10-3) in the first functional annotation cluster identified by the 
Functional Annotation Clustering tool from DAVID (enrichment score: 1.9) (table 2). 
We found, in the fourth annotation cluster (enrichment score: 1.09), several pathways 
involved in the spreading of inflammation such as the « Il17 signaling pathway » 
Biocarta  pathway  (p=1.7x10-2),  the  « Cell  adhesion  molecules  (CAM) »  Kegg 
pathway (p=9.9x10-2) and GO terms such as « Biological adhesion » (p=9.8x10-2) and 
« External side of plasma membrane » (p=1.8x10-2) (table 2).
Genes  grouped  in  cluster  C  are  involved  in  pathways  related  to  « Immune 
responses » (p=1.5x10-2) such as « Chemokine activity » (p=2x10-2) and « Cytokine-
cytokine  receptor  interaction »  (p=3.1x10-2)  as  well  as  pathways  related  to  the 
« Inflammatory  response »  (p=1.7x10-2).  Once  again,  the  Functional  Annotation 
Clustering tool from DAVID clustered these terms in a  single group with a  high 
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enrichment score (1.63) (table 3). GO terms related to « Autophagy » (p=1.6x10-2) 
clustered together in the third annotation cluster with a 1.55 enrichment score (table 
3). As expected in inflammation response, immune and pro-inflammatory responses 
were  quickly  activated.  These  findings  validate  our  previously  published 
experimental model of inflammation [4].
Functional annotation analysis of genes belonging to cluster D showed an over-
representation  of  GO  terms  related  to  lipid  metabolism,  such  as  « Cholesterol 
metabolic  process »  (p=1.2x10-3),  « Steroid  metabolic  process »  (p=1.1x10-2)  and 
« Cellular  lipid  metabolic  process »  (p=6.5x10-2).  These  pathways  were  clustered 
together by the Functional Annotation Clustering tool from DAVID in a single cluster 
with an enrichment score of 1.55 (table 4, figure 3).
Overall,  our  gene  expression  analysis  revealed  marked  sequential  changes  in 
pathways: i) first, the pro-inflammatory phase is activated with high expression levels 
of genes involved in stress response, DNA damage, protein synthesis, inflammation 
and immune response; ii) then, inflammation is spreading into tissues marked by high 
expression of genes involved in metabolism and transcription; iii) at the last stage of 
inflammation, we observe that lipid metabolism is highly disturbed concomitant with 
the reactivation of DNA repair.
"	 Discussion
This study made it possible to: i) identify a set of 1,534 significantly differentially expressed 
genes which correspond to the response to ALI in PBMC at the transcriptional level and ii) identify 
time-dependent functional pathways. By comparing these results with the response to ALI in the 
lung [4],  we showed that  the response to  lung inflammation is  compartmentalized in lung and 
blood.
a- Transcriptional response to ALI in PBMC
In blood, the injection of OA significantly altered the expression levels of 1,534 
genes that are organized into four clusters based on their expression profiles over 
time.
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The  expression  levels  of  genes  involved  in  defensive  processes  such  as 
inflammatory and immune responses was affected 1h to 1h30 after  OA injection. 
Among them, the transcription of several chemokine genes such as  Cxcr3, Cxcl15,  
Ccr1,  Ccl22,  Ccl25,  Ccl3,  Ccl6 and  Ccl8 was  rapidly activated.  This  mechanism 
probably causes the recruitment of specific leukocyte subpopulations to sites of tissue 
damage  (table  S3)  [15].  We  found  significant  activation  of  the  common  pro-
inflammatory cytokine Il1 as well as members of the Il1 receptor family (Il1r1, Il1r2). 
The transcription of genes involved in DNA damage and DNA repair is activated 
at  early  time-points  (1h-1h30)  and  reactivated  at  late  points  (18h–24h)  of  our 
experiments. This bimodal activation may be linked to cytokines' activity such as Il1 
and Tnf which, in pro- and anti- inflammatory conditions, has been shown to induce 
nitric  oxide  synthase  via  the  endothelial  cells  [16].  The  nitric  oxide  that  is  then 
produced has been postulated to cause DNA damage by direct oxidization, resulting 
in mutations [17]. Genes involved in the Il17 signaling pathway, such as  Cd2 and 
Cd34, activated 3h to 4h after OA injection [18], may also be responsible for the re-
activation  of  genes  involved  in  DNA repair.  Indeed,  fibroblasts  and  other  cells 
stimulated  by  Il17  are  themselves  induced  to  produce  inflammatory  and 
hematopoietic  cytokines.  Several  distinct  DNA  repair  proteins  are  involved  in 
selective  repair  pathways.  Oxidative  DNA damage  is  predominantly  repaired  by 
nucleotide excision repair proteins such as Ercc3 and Rad23b. Other repair pathways, 
however,  are  also  activated:  the  expression  levels  of  Neil3,  Mre11a,  Wrnip1 and 
Mus81 increased;  Fanca, Ube2a and  Ube2b,  which belong to the post-replication 
repair pathway, were highly expressed; and, similarly, transcription levels of genes, 
such as Msh3, involved in the DNA mismatch repair pathway was activated at early 
and late time-points.
We also found several genes involved in autophagy, such as Map1lc3a, Wipi1, 
Atg5 and Atg4b, highly expressed soon after OA injection (1h-1h30). Autophagy is 
an adaptive response to stress, a regulating process used by cells in order to recycle 
non-essential,  redundant,  or  inefficient components.  Simultaneously,  it  enables the 
stressed cell  to  gain vital  nutrients.  Autophagy is  also  involved in  elimination of 
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intracellular microorganisms, tumor suppression, and antigen presentation [19].
Over  all,  at  the  early  and  later  times  points  after  injection,  the  physiological 
activity is focused on an adaptive response to the stress.
The transition phase, 3h to 4h after OA injection, is marked by genes involved in 
the spreading inflammation. Usually,  the visualization of  this process is not well-
depicted because it occurs in a very short time between activation of the pro- and the 
anti-inflammatory immune responses. The relatively late activation of genes involved 
in the spreading of inflammation compared with genes involved in inflammation and 
immune processes is probably due to the fact that the vascular endothelium is the 
target  of  pro-inflammatory  cytokines  [20].  Once  the  vascular  endothelium  is 
activated,  genes  involved  in  cell  adhesion  are  expressed  and  leukocytes  are 
transferred  from  circulating  blood  to  the  site  of  inflammation.  In  our  data,  we 
observed the transitional activation of genes involved in leukocyte transendothelial 
migration  and  cell  adhesion  molecules  (CAM),  such  as  Cd34,  Cd2,  Cx3cl1  and 
Pecam1 (table  S3).  These  molecules  have  been  previously  shown to  be  strongly 
involved  in  the  inflammatory  process  since  they  modulate  leukocyte  trafficking 
allowing the circulation of inflammatory signals between organs [21-23]. 
The transitional phase is also associated with the activation of genes involved in 
primary  metabolism  and  transcription.  This  is  due  to  the  cytokines,  which  were 
highly expressed at the early time-points, and which activated these pathways. 
Finally, we found a late disruption of gene expression level related to the lipid 
metabolism. We identified 26 genes annotated to “lipid metabolic process” whose 
expression level increased from 3h to 4h after OA injection and reached a maximum 
level  after  18h  to  24h  OA incubation  (figure  3).  Previous  studies  showed  the 
disturbance of lipid metabolism soon after the initiation of inflammation or associated 
with inflammation and infection [4, 24-25]. Most of the changes in genes related to 
lipid  metabolism  that  are  induced  by  inflammation  are  attributable  to  the  high 
transcription level of pro-inflammatory cytokines early after OA injection [24, 26-28] 
(table 1).  Our findings on the timing of the effect of cytokines on lipid metabolism 
are in line with those obtained by Feingold et al. [29] .
171 / 192
We  expected  a  massive  release  of  inflammatory  mediators  soon  after  OA 
injection, followed by the release of anti-inflammatory mediators [28]. This sequence 
of events has been previously reported in models of sepsis [30]. 
Overall, at this complex stage (between 3h-4h) we observed elements links to the 
inflammation spreading, the activation of the primary metabolism and transcription, 
and lipid metabolism modulation, the lipid metabolism being mainly modulated at the 
latest time points. In this study, we confirmed the findings of our previous study [4]. 
We identified pathways activated simultaneously or delayed in either lungs or PBMC. 
Even in the same OA-induced ALI model in mouse, transcriptional profiles differ 
from one compartment to another at the same time-points. We show here that the 
response to inflammation is compartmentalized in mouse in a least two organs: lung 
and blood.
b- Compartmentalization of transcriptional response to ALI in lung and blood
We previously used the same mouse inflammation model to analyze the transcriptional profile 
in inflamed lung following OA injection [4]. However, lung and PBMC studies were not performed 
on the same mice. Given the robustness of this model, this limitation does not prevent to compare 
the  response  to  lung  inflammation  in  lung  and  PBMC  (figure  4). We  identified  several 
pathways simultaneously activated in lung and PBMC, whereas other pathways are 
specifically activated in either one or the other organ. When the same pathways were 
activated in both lung and PBMC, their activation was not necessarily simultaneous. 
These differences imply that inflammation is compartmentalized in these two organs. 
Of the 1,534 genes whose expression changed significantly over time in PBMC, 720 
(47%)  are  also  significantly  differentially  expressed  over  time  in  the  lung.  The 
expression level variations of these 720 genes, which represent 72% of the 1,000 
genes whose expression levels changed over the time-course in lung, are similar in 
both organs. 
Among  the  similarities  between  the  lung  and  PBMC  responses,  we  found  a 
simultaneous activation of the inflammation and immune responses. The expression 
levels of numerous chemokines increased early after OA injection, corresponding to 
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the pro-inflammatory response to ALI. Right after the pro-inflammatory phase, the 
activation of pathways involved in the spreading of inflammation such as the CAM 
proteins  occurred simultaneously  in  PBMC  and  lung  cells.  This  activation  is 
concomitant with the high transcriptional rate of genes involved in the hematopoietic 
cell  lineage pathway. Finally,  we noted the simultaneous late disruption of  genes, 
with a slight shift, related to lipid metabolism in both blood and the lung (18h to 24h 
after  OA injection).  Besides  their  role  in  lipid  transport,  lipoproteins  seem  to 
participate in innate immunity [4,24-25]. 
The shift  in  response  to  inflammation between lung and PBMC signed a  de-
compartmentalization  process.  Indeed,  the  PBMC response  to  lung  inflammation 
shows  several  differences  to  that  in  the  lung.  First,  more  than  53%  genes  were 
significantly differentially expressed in PBMC over the time-course compared with 
lung  (1,534  vs.  1,000).  This  suggests  that  the  response  to  inflammation  is  more 
general in the PBMCs compared with lung. Out of the 1,534 genes, we identified 814 
genes specifically differentially expressed in PBMC over time-course (i.e. 53%). In 
contrast, only 280 (28%) genes identified in the lung are differentially expressed only 
in this organ.
Among genes specifically overexpressed in PBMC, we identified genes involved 
in DNA damage and DNA repair at early (1h-1h30) and late time-points (18h-24h). 
Similarly, the activation of autophagy seems to be blood-specific. We suggest that the 
activations  of  the  DNA repair  and  autophagy  pathways  are  limited  to  the  blood 
compartment because anti-inflammatory mediators already prevented the activation 
of these pathways at the lung level.
Finally, we showed that activation of transcription occurred earlier (3h to 4h after 
OA injection) in blood than in lung (18h to 24h after OA injection). This delay may 
be explained by the time required for the circulating inflammatory mediators to cross 
the lung border and by the fact that blood is the first organ in contact with OA.
Studies  have  demonstrated  that  under  non-pathological  conditions  the 
microenvironment  and  tissue  compartment  (blood,  liver,  gut,  spleen...)  markedly 
influence  immune  cell  functional  capabilities,  thereby  creating  diversity  and 
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heterogeneity within the immune system [31-32]. Two previous studies compared the 
response of immune cells from various tissues after thermal injury and inflammation 
(spleen,  blood, mesenteric lymph nodes,  Peyer's  patches)  [12, 33].  They observed 
significant  compartmental  differences  in  the  kinetics  of  immunosuppression. 
Likewise, the ability of PBMC to generate a pro-inflammatory response to endotoxin 
differs from that of splenic macrophages. Splenic macrophages from burned mice 
produced significantly higher levels of nitric oxide, PGE2, TNFα and Il6 as compared 
with  macrophages  from  control  animals  [12].  In  contrast,  PBMC  isolated  from 
injured mice only produced significantly elevated levels of PGE2 as compared with 
those  isolated  from control  mice  [12].  Moreover,  PBMC productive  capacity  for 
TNFα and Il6 was significantly suppressed at post-burn. This confirms that the timing 
of  the  pre-existing  inflammation  (pro-  or  anti-inflammatory  stage)  influences  the 
outcome of the organism undergoing infection as well. 
&
 Conclusion
In this study, we  assessed gene expression profiles in mouse PBMC associated 
with a lung inflammation during a 24h time-course. By comparing similarities and 
differences between the transcriptional profiles in lung and PBMC, we pointed out 
significant  compartmental  differences  in  the  kinetics  of  the  lung inflammation in 
mice as well as the consequences of de-compartmentalization for distant organs.
Overall,  our  microarray analysis  provides a  global  overview of  critical  events 
occurring  in  blood  within  lung  inflammation.  We  confirm  that,  in  blood,  gene-
expression profile discriminates between pro- and anti-inflammatory phases during 
this inflammatory process. The analysis of gene functional annotation reveals several 
major  features.  As  expected,  it  indicates  that  the  pro-inflammatory  stage  is 
characterized  by  the  activation  of  the  immune  response  and  inflammatory 
mechanisms.  The ultimate  severity  of  the  inflammation  depends  on  the  interplay 
between  pro-  and  anti-inflammatory  mediators  and  repair  mechanisms,  beginning 
after  the initiation of  injury.  Later,  the immune cells migrate into tissues through 
interaction with vascular endothelial cells,  metabolism regulation and transcription 
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are then activated. At the late stage of inflammation, metabolism is deeply disturbed. 
We showed here that inflammation is associated with marked changes in lipid and 
lipoprotein metabolism. 
Our findings suggest that, because of the compartmentalization of the response to 
lung inflammation in blood and lung, changes of cell transcription profiles depend on 
the targeted organ. Thus, changes induced by lung inflammation in lung and PBMC 
compartments should be considered together.  The timing of inflammation and the 
interaction between pro- and anti-inflammatory phases depend of each organ. The 
structure of each organ constitutes a barrier to the propagation of inflammation. It is 
responsible for the heterogeneity of the inflammatory response at the level of each 
organ.  We show that the assessment of PBMC function alone in patients with lung 
inflammation may not  accurately  reflect  their  actual  immune status.  Nonetheless, 
future animal studies of lung inflammation should compare the analysis of PBMC 
and  fixed  tissue  immune  cell  function  at  multiple  time-points.  Multi-parameter 
experimental analysis should improve the potential extrapolation of the experimental 
findings to the clinical arena.
  Materials and Methods
a – Experimental groups
Wild-type female C57Bl/6J mice, 7 weeks old, were obtained from Janvier and 
housed  in  a  specific  pathogen-free  animal  facility. C57BL/6J  mice  have  been  chosen 
because it is the most widely used inbred strain.  It has been used  in a wide variety of research 
areas, especially in studies related to transcriptional response to pathogens. However, strain of mice 
may affect the transcriptomic response, as shown by Cavarra  et al. [34].  We studied 37 mice 
divided  into  6  groups  (figure  5).  Each  group  included  one  or  two  mice  given 
physiological serum and 4 to 6 mice given OA. Each group was identified according 
to the incubation time: 1h, 1h30, 3h, 4h, 18h and 24h. During our previous work on 
lung expression profiles during inflammation, we performed real-time PCR on TNFα, 
Il10, Il4 and Il6 to identify the OA incubation time corresponding to the pro- and the 
anti-inflammatory  stages  [4].  We found that,  in  this  model,  the pro-inflammatory 
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stage occurred 1h to 1h30 after OA injection and the anti-inflammatory stage reached 
a maximum level 18h to 24h after OA injection. This work explains how we defined 
our time-points. All experimental procedures involving animals were approved by the 
veterinary office of the Ministry of Agriculture, France (authorization number: 13-
27). 
b- Injections
Female C57Bl/6J  mice  were anesthetized  with 5% Xylazine  – 20% Ketamine 
(0,1ml/10g). We injected 200 µl of physiological serum in the control mouse at each 
time-point and 200 µl of OA (1,2 µl/g body weight, sigma #27728-1L-R) in the other 
26  mice  of  our  study.  Administration  of  physiological  serum and  OA was  done 
through the tail vein with a 0.3-ml insulin syringe (BD #320837).
c- Blood sampling and PBMC isolation
Each group of mice was sacrificed 1h, 1h30, 3h, 4h, 18h or 24h after injection of 
OA or physiological serum by exsanguination through the eye vein. 200 to 900 µL of 
whole  blood was  collected  in  tubes  containing 100µL EDTA 0.5M.  PBMC were 
isolated using a ficoll gradient 1.084 (Ficoll-Paque Premium 1.084, GE Healthcare 
#17-5446-02). Cells were resuspended in 500 µL PBS and counted.
d- RNA extraction and amplification
Total  RNA from PBMC was  isolated  using  the  Mouse  RiboPure-Blood RNA 
isolation kit (Ambion, #AM1951). The quality of RNA was confirmed on the Agilent 
2100 Bioanalyzer (Agilent,  #G2938C) using the RNA 6000 Nano chips (Agilent, 
#5067-1511), and the concentration of RNA was determined by reading absorbance at 
260/280 nm. RNA was amplified using the MessageAmp II aRNA amplification Kit 
(Ambion, #AM1751). For up to 5 µg RNA amplification, we used a 20 µl reverse transcription 
(RT) reaction with 1µl T7 Oligo(dT) Primer, 4µl dNTP, 1µl Ribonuclease inhibitor and 1µl Reverse 
transcriptase in 1× first-strand buffer with a 42°C incubation for 2 hours. Second-strand synthesis 
was carried out in 100 µl with 2µl DNA polymerase, 1µl RNase H, and 4µl dNTP in 1× second-
strand buffer simply by adding 80 µl of an ice-cold second-strand premix to the ice-cold 20 µl RT 
176 / 192
reaction and incubating at 16°C for 2 h. cDNA was purified on cDNA Filter Cartridge and was 
transcribed in 40 µl  [37°C, 14 h,  4µl T7 RNA enzyme Mix, 7.5mM T7-GTP, 7.5mM T7-ATP, 
7.5mM T7-UTP, 7.5mM T7-CTP, T7 1× buffer]. Amplified antisense RNA (aRNA) was purified on 
aDNA Filter Cartridge.
e- Microarray design
We used the GPL9478 Nylon platform described in the Gene Expression Omnibus 
(GEO)  public  repository  [35-36].  This  microarray  contains  1Kb  PCR  fragments 
representing 7,771 bacterial clones matching 6622 mouse genes. 73% (4833) of the 
genes are represented by a single cDNA clone and about 27% (1789) of the genes 
included in this  gene set  are  represented by two or more different cDNA clones, 
providing  internal  controls  to  assess  the  reproducibility  of  gene  expression 
measurements. MUSV29K contains 8 positive controls (poly-A LBP2S and Cot1, a 
mix of DNA fragments containing repeated sequences) and 2,205 negative controls 
(empty spots and CG03, an Arabidopsis thaliana cDNA sequence). In summary, the 
MUSV29K mouse microarray contains 9,984 spots, identifying 6,622 mouse genes.
f- Microarray data acquisition and analysis
Twenty-five mRNA samples (one per mouse) were run on a single microarray. In 
addition, 12 samples were run on two microarrays, and were considered as technical 
replicates. This corresponds to a total of 49 microarrays (i.e. 37 mice). All microarray 
procedures were done at our microarray core facility [37]. cDNAs were designed and 
prepared as described in Puthier  et al. [38], using 5µg of amplified mRNA in the 
presence of α-dCTP 33P.
After  image  acquisition,  data  were  processed  as  described  in  figure  1. 
Hybridization signals were quantified using the Bzscan2 software [39]. All images 
were  carefully  inspected  and  spots  with  overestimated  intensities  due  to 
neighborhood effects were manually excluded. We used the NylonArray library for R 
locally developed by A. Bergon and D. Puthier [40]. This package contains functions 
to  perform  diagnosis  and  normalization  of  nylon  microarray  data.  For  each 
microarray,  we  obtained  two  datasets:  the  first  was  obtained  by  hybridizing  the 
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microarray with a probe, whose oligonucleotide sequence is common to all spotted 
PCR products (vector) and the second was obtained by hybridizing the microarray 
with PBMC cDNA (sample). The sample datasets were corrected for neighborhood 
effects  and  local  background  as  described  by  F.  Lopez  et  al. [39].  Quantile 
normalization  was  applied  to  sample  data  to  correct  for  global  intensity  and 
dispersion. 
Microarray  data  were  statistically  analyzed  using  the  TIGR  MeV 
(MultiExperiment  Viewer)  V4.3.01  software  [41].  Significant  Analysis  of 
Microarrays (SAM) procedure was applied to look for time specific variation in gene 
expression  in  the  dataset  [13].  At  each  time-point,  gene  expressions  in  control 
samples (physiological  serum injection) were subtracted from gene expressions in 
OA samples. Before partitioning the genes, we performed a hierarchical clustering of 
the samples in TMEV V4.3.01 using average linkage clustering metrics and Pearson 
correlation for the distance. This analysis partitioned the samples into three groups: 
group 1 (1h, 1h30), group 2 (3h, 4h) and group 3 (18h, 24h). Hierarchical clustering 
(average linkage clustering metrics and Pearson correlation for the distance) was then 
applied to the genes using the Cluster software and results were visualized with the 
Treeview software [14]. We identified biological annotations for the clusters using 
DAVID [42-43] and interaction networks using the Kegg pathways [44]. To interpret 
our data, we used two functionalities in DAVID: the « Functional annotation Chart» 
and the « Functional annotation clustering » tools. The first associates a gene ID with 
a biological term, which belongs to one of the 40 annotation categories available in 
DAVID,  including  GO  terms,  protein-protein  interactions,  protein  functional 
domains,  disease  association  and  sequence  features.  This  extended  annotation 
coverage increases analytic power by allowing investigators to analyze their genes 
from  many  different  biological  aspects  at  once.  DAVID  functional  annotation 
clustering measures relationships between annotation terms based on the number of 
genes  sharing  these  terms.  This  type  of  grouping  of  functional  annotations  can 
provide greater insight into the relationships between annotation categories and terms 
than the traditional linear list of enriched terms, as it is not confounded by highly 
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related or semantically redundant terms. Each cluster of functional annotations was 
associated  with  an  enrichment  score,  which  depended  on  the  distribution  of  the 
enrichment (p-values) of each member. A good enrichment score was obtained when 
most members of a cluster had significant p-values. This is a relative score and not a 
statistical  probability,  and has  no minimum or  maximum limits.  This  means that 
enrichment scores could be considered only together, by comparing them.
All data are contain the Minimum Information About a Microarray Experiment, 
meaning they are MIAME compliant and have been submitted to the GEO database 
[36]  (accession number GSE19030). 
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9- Figure Legends
Figure 1. Schematic outline of data analysis.
a We compared gene expression between three groups: 1h-1h30 / 3h-4h / 18h-24h.
b HCL: Hierarchical Clustering
We considered the full  dataset  (n=6,622 genes)  to  identify genes  significantly 
differentially expressed  between the three classes previously described.  The 1,534 
genes  identified  with  the  Significant  Analysis  of  Microarrays  (SAM)  tool  were 
clustered using the Cluster software and each cluster was independently functionally 
annotated using the Database for Annotation, Visualization and Integrated Discovery 
tool (DAVID).
Figure 2.  Hierarchical classification of 1,534 significant  genes differentially 
expressed during the time-course of inflammation. 
This  set  of  genes  was  extracted  from  the  full  dataset  (n=  9,984)  using  a 
Significant Analysis of Microarrays (SAM) procedure and a false discovery rate of 
5%. Each row represents a gene and each column represents a sample. Red and green 
indicate  expression  levels  above  and  below  the  median  respectively.  Before 
partitioning  the  genes,  we  performed  a  hierarchical  clustering  of  the  samples  in 
TMEV V4.3.01.  Average linkage  clustering  metrics  and Pearson correlation  were 
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used for the distance. This analysis partitioned the samples into 3 groups based on the 
Oleic Acid (OA) incubation time (1h-1h30, 3h-4h, 18h-24h). Hierarchical clustering 
(average linkage clustering metrics and Pearson correlation for the distance) was then 
applied to the genes using the Cluster software and results were visualized with the 
Treeview software. 4 clusters were identified: A, B, C and D. Genes of cluster A (409 
genes - blue) were transitively down-regulated 3h to 4h after OA injection.  Their 
expression level was high at early time-points (1h-1h30) and late time-points (18h–
24h). Genes of cluster B (257 genes - pink) were over-expressed between 3h and 4h 
relative  to  their  expression level  at  the earlier  time-points  (1h-1h30)  and the  late 
measurements (18h–24h). At the earliest  time-points of  the experiment (1h-1h30), 
genes from cluster C (314 genes - green) were over-expressed. Following the early 
inflammatory phase, genes from cluster D (554 genes - yellow) were highly over-
expressed between 3h and 24h. The dendrogram of genes, to the left of the matrix 
represents overall similarities in gene expression profiles. 
C
igure 3. Functional annotation of genes involved in lipid metabolism.
Of the genes in cluster D whose expression level increased 3h to 4h after Oleic 
Acid (OA) injection and reached a maximum level after 18h to 24h, 26 belong to the 
lipid metabolic process. These genes can be assigned to one or several of 4 Gene 
Ontology  (GO)  categories  related  to  Lipid  metabolism.  “Grey”  means  the  gene 
belongs to the pathway and “White” means that the gene does not.
Figure  4.  Representative  variation  of  gene  expression  level  in  lung  and 
Peripheral Blood Mononuclear Cells (PBMCs) for the main pathways involved 
in  the  response  to  OA-lung  inflammation  across  our  24  hours  time-course 
experiment.
We compared the timing and the amplitude of the functional pathways activated 
in lung and in Peripheral Blood Mononuclear Cell (PBMC) 1h to 24h after Oleic 
Acid (OA) injection. The X axis represents time-points of the experiment. Numerical 
values indicate the mean expression level of genes involved in a pathway at a given 
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time-point.
igure 5. Experimental design of the experiment.
We studied 37 mice C57BL6/J, female, 7 weeks old. We divided these mice into 6 
groups based on the incubation time (1h, 1h30, 3h, 4h, 18h, 24h). In each group, mice 
are  divided  into  2  subgroups  depending  on  the  injection:  Oleic  Acid  (OA)  or 
physiological serum. 25 samples have been hybridized on 2 microarrays consisting in 
technical replicates and 12 samples have been hybridized once.  We performed 49 
hybridizations.
10- Supplemental data
S1:  RNA_Agilent_electropherograms.pdf  -  The  quality  of  total  RNA from PBMC isolated 
using the Mouse RiboPure-Blood RNA isolation kit (Ambion, #AM1951) was confirmed on the 
Agilent 2100 Bioanalyzer (Agilent, #G2938C) using the RNA 6000 Nano chips (Agilent, #5067-
1511).  After  1H  (A),  1H30  (B),  3H  (C),  4H  (D),  18H  (E)  and  24H  (F)  OA incubation,  the 
electropherograms show that the RNA is neither degraded, nor contaminated with genomic DNA. 
The X-axis represents the time in seconds and the Y-axis represents the fluorescence intensity (i.e. 
the RNA amount). Peaks at 41.5s and 47s represent 18S and 28S ribosomal RNA respectively.
S2:  1534_differentially_expressed_genes.txt  -  A set  of  1534  differentially  expressed  genes 
between across time-course has been identified by SAM with FDR 5%. Each gene is associated 
with its expression values in OA samples. Each expression value has been normalized by quantile 
and adjusted with its physiological serum value at the same time point.
S3: inflammatory_process_pathways.txt - Genes differentially expressed across time-course and 
involved in inflammatory process pathways are grouped into 5 sub-categories: Inflammatory and 
immune response, DNA damage and DNA repair, Autophagy, Cell adhesion molecules (CAM) and 
Lipid metabolism. Each gene is associated with its mean expression value at each time point after  
OA incubation.  Data have been normalized using quantile and adjusted on physiological serum 
expression level at each time point.
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%% tables
Table 1. Functional enrichment of genes belonging to cluster A.
Annotation Cluster 2 Enrichment Score: 1.45
Database Term Coun
t
P-Value
Gene Ontology Response to stress 37 1.8E-02
Gene Ontology Response to endogenous stimulus 18 2.4E-02
Gene Ontology DNA repair 14 3.4E-02
Gene Ontology Response to DNA damage stimulus 16 3.9E-02
Gene Ontology DNA metabolic process 27 9.3E-02
Annotation Cluster 5 Enrichment Score: 1.14
Database Term Coun
t
P-Value
Gene Ontology Nitrogen compound metabolic process 21 1.7E-02
Gene Ontology Nitrogen compound biosynthetic process 8 2.4E-02
Gene Ontology Amine metabolic process 19 3.0E-02
Table 2. Functional enrichment of genes belonging to cluster B.
Annotation Cluster 1 Enrichment Score: 1.9
Database Term Coun
t
P-Value
Gene Ontology Regulation of cellular metabolic process 53 7.5E-04
Gene Ontology Biopolymer metabolic process 89 2.2E-03
Gene Ontology Transcription 46 5.7E-03
Gene Ontology Regulation of transcription 44 6.6E-03
Gene Ontology Transcription DNA-dependent 42 7.0E-03
Gene Ontology RNA metabolic process 51 7.1E-03
Annotation Cluster 4 Enrichment Score: 1.09
Database Term Coun
t
P-Value
Biocarta IL17 signaling pathway 4 1.7E-02
Gene Ontology External side of plasma membrane 8 1.8E-02
Gene Ontology Cell surface 8 9.5E-02
Gene Ontology Biological adhesion 14 9.8E-02
Gene Ontology Cell adhesion 14 9.8E-02
KEGG pathway Cell adhesion molecules (CAMs) 6 9.9E-02
Gene Ontology Cell-cell adhesion 6 1.7E-01
KEGG pathway Hematopoietic cell lineage 4 4.2E-01
Table 3. Functional enrichment of genes belonging to cluster C.
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nnotation Cluster 2 Enrichment score: 1.63
Database Term Count P-Value
Gene ontology Immune response 18 1.5E-02
Gene ontology Inflammatory response 11 1.7E-02
Gene ontology Chemokine activity 6 2.0E-02
KEGG pathway Cytokine-cytokine receptor interaction 12 3.1E-02
Annotation Cluster 3 Enrichment score: 1.55
Database Term Count P-Value
Gene ontology Autophagy 4 1.6E-02
Gene ontology Autophagic vacuole formation 3 2.8E-02
Gene ontology Macroautophagy 3 5.0E-02
Table 4. Functional enrichment of genes belonging to cluster D.
Annotation Cluster 2 Enrichment score: 1.55
Database Term Count P-Value
Gene ontology Cholesterol metabolic process 10 1.2E-03
Gene ontology Sterol metabolic process 10 1.6E-03
Gene ontology Steroid metabolic process 12 1.1E-02
Gene ontology Cellular lipid metabolic process 27 6.50E-
002
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Figure 1 : Relations schématiques entre les différents états inflammatoires et 
infectieux
Le  syndrome  inflammatoire  de  réponse  systémique  est  le  reflet  d'une  réponse 
inflammatoire  généralisée,  dont  les  étiologies  sont  variées.  Ainsi,  la  chirurgie,  un 
traumatisme grave, une brûlure étendue ou une pancréatite aiguë induisent une réponse 
de  l'organisme  sans  qu'il  y  ait  d'infection  associée.  Le  sepsis  est  une  réponse 
inflammatoire survenant du fait d’une infection. Le sepsis grave associe un sepsis et une 
défaillance  d’organe.  Le  choc  septique  est  un  sepsis  grave  avec  une  défaillance 
hémodynamique nécessitant l’introduction de vasopresseurs.
Figure 2 : Relations entre les cellules du système immunitaire en réponse à 
l'agression
Les  macrophages  et  les  cellules  dendritiques  sont  activés  par  la  phagocytose  des 
bactéries et par les médiateurs (IFN-γ par exemple) sécrétés par les lymphocytes T CD4+. 
Au contraire, les lymphocytes T qui ont un profil anti-inflammatoire (Th2) sécrètent de l'IL-
10  qui  module  l'activation  macrophagique.  Les  lymphocytes  T  CD4+  sont  également 
activés (type Th1, inflammatoires) via la production d'IL-12 par les macrophages et les 
cellules  dendritiques,  et  sécrètent  en  réponse  des  cytokines  pro-inflammatoires.  Le 
dialogue  entre  les  différentes  cellules  conduit  à  la  modulation  de  la  réponse,  soit 
inflammatoire, soit anti-inflammatoire, voire l'évolution vers un état d'anergie. Les flèches 
bleues  indiquent  une  activation  de  type  pro-inflammatoire.  Les  flèches  rouges  une 
activation de type anti-inflammatoire. Les signes « + » et « - » symbolisent respectivement 
« activation »  ou  « inhibition ».  Th1/2 :  Lymphocyte  T  de  type  helper  1  /  2.  Figure 
reproduite à partir de [3] avec la permission de l'auteur.
Figure 3 : Evolution de la réponse inflammatoire et de ses conséquences lors du 
choc septique
Bien  que  les  deux  types  de  réponses  (pro-  et  anti-inflammatoire)  soient  activées 
précocement  dans  le  sepsis,  la  réponse  pro-inflammatoire  prédomine  initialement.  Au 
cours de l'évolution, la réponse anti-inflammatoire devient prépondérante et c'est durant 
cette  phase  tardive  que  surviennent  des  infections  secondaires  (bactériennes  ou 
réactivations virales). Figure reproduite à partir de [5] avec la permission de l'auteur.
Figure 4 : Construction d'une banque soustractive
Deux transcriptomes A et  B sont  extraits  de deux conditions expérimentales  ou de deux tissus 
différents.  L'un  des  deux  transcriptomes  est  marqué  par  de  la  biotine  lors  de  l'étape  de  rétro-
transcription (ici le transcriptome B). Les ADN complémentaires issus de A et B sont mélangés et 
mis en condition d'hybridation. Les ADNc marqués sont éliminés (les double-brins d'ADNc de B, 
ou les ADNc hybrides pour les gènes communs à A et B). Les ADNc spécifiques du transcriptome A 
sont alors clonés dans des vecteurs d'expression. Figure reproduite avec la permission de l'auteur 
(Christine Dole, Université de Strasbourg).
Figure 5 : Principe de la méthode « Serial Analysis of Gene Expression » (SAGE)
1.
2.
3.
4.
5.
1. Rétrotranscription des ARNm à partir  d'une amorce poly-dT couplée à de la  biotine.  Les ADNc sont  
purifiés à l'aide de streptavidine, et soumis à une digestion par NlaIII (« anghoring enzyme » (AE)). Tous les 
fragments possèdent ainsi  une extrémité 5'-CATG. 2. Ligation avec un premier adaptateur ("linker")  A à 
l'extrémité  CATG.  Pour  l'autre  moitié  du  prélèvement,  ligation  avec  l'adaptateur  B.  Ces  adaptateurs 
contiennent des sites de fixation uniques (5'-GGGAC) pour l'enzyme d'étiquetage ("tagging enzyme" TE) 
BsmFI, et une extrémité compatible avec l'enzyme de restriction NlaIII. 3. Digestion par l'enzyme BsmFI : 
cette enzyme génère les étiquettes (fragments des ADNc initiaux qui seront séquencés) en coupant 10  
nucléotides  en  3'  de  sa  séquence  de  reconnaissance.  Les  fragments  d'ADNc  (libérés  des  billes 
magnétiques) portent tous la séquence de l'adaptateur à leur extrémité 5'. En revanche, ils diffèrent tous à 
leur extrémité 3' par les 10 à 14 nucléotides spécifiques de leur étiquette. 4. Ligation des étiquettes par leur 
extrémité 3' ("ditags"). Les « ditags » sont amplifiées par PCR avec 2 amorces spécifique des adaptateurs A 
et B. 5. Digestion par NlaIII  qui libère les adaptateurs.On isole alors les « ditags » qui  sont concaténés 
(jusqu'à une cinquantaine), clonés et séquencés. Le compte des étiquettes, une fois que celles-ci ont été 
alignées sur un génome de référence, permet d'avoir une évaluation quantitative de l'expression du gène 
identifié. Figure reproduite à partir de [18] avec la permission de l'auteur.
Figure 6 : Principe de l'analyse par puces à ADN
La figure présente deux approches classiques d'analyse du transcriptome par  puce à 
ADN. De manière générale, les ARNm sont rétro-transcrits en ADNc. Au cours de cette 
étape, les ADNc sont marqués à l'aide d'un fluorochrome ou d'un isotope radioactif. Les 
ADNc sont hybridés sur les puces, et après un lavage, une image de la puce est générée 
par un scanner adapté. L'intensité de chaque point de la puce reflète la quantité d'ARNm 
de chaque gène dans le prélèvement initial.  Dans la partie de gauche, on réalise une 
analyse comparative de deux transcriptomes A et  B marqués par  deux fluorochromes 
différents. Cette méthode ne permet d'obtenir que des « ratios d’expression » entre les 
deux  conditions  A  et  B  étudiées.  Au  contraire,  dans  la  partie  de  droite,  un  seul 
transcriptome est hybridé par puce. Cette technique demande deux fois plus de puces à 
ADN, mais permet de ré-analyser et de comparer des jeux de données différents. Figure 
reproduite à partir de [19].
Figure 7 : Principe de l'analyse par séquençage haut-débit (RNA-seq)
Brièvement, les ARN sont dans un premier temps convertis en une librairie de fragments 
d'ADNc, soit par fragmentation initiale des ARN, ou fragmentation secondaire des ADNc. 
Des adaptateurs de séquençage (bleu) sont alors ajoutés aux fragments. La séquence 
des  fragments  est  alors  obtenue  par  séquençage  haut-débit.  Les  courtes  séquences 
obtenues (« reads ») sont alignées sur le génome ou le transcriptome de référence et 
classés en séquences exoniques, jonctionnelles ou poly-(A). Comme cela est représenté 
dans le bas de la figure, ces données d'alignement sont utilisées pour générer un profil  
d'expression pour chaque gène. Figure reproduite à partir de [29].
Figure  8 :  Spécificité  des  signatures  en  fonction  de  l'origine  de  la  réponse 
inflammatoire
Le  diagramme  de  Venn  ci-dessus  montre  la  forte  spécificité  des  signatures 
transcriptionnelles obtenues lors de l'analyse d'un modèle d'infection et d'inflammation. 
Les signatures ont été obtenues en comparant deux à deux les modèles inflammatoire 
(pancréatite), infectieux (infection intra-abdominale) et contrôle. Seuls 15 (5%) gènes sont  
communs aux signatures spécifiques de l'inflammation d'origine infectieuse ou non. Figure 
reproduite à partir de [49].
Figure 9 : Evolution du transcriptome après injection de lipopolysaccharide chez 
des volontaires sains.
Représentation  schématique  des  gènes  et  voies  métaboliques  activées  (rouge)  ou 
inhibées (bleu)  lors de l'injection de lipopolysaccharide chez des volontaires sains.  La 
représentation principale (a)  est reproduite afin de montrer le rôle fondamental du temps 
dans la modulation de l'expression des gènes (b). Figure reproduite à partir de [67].
Figure 10 : Riboleukogramme
Représentation schématique d'un « Riboleukogramme ». Cette représentation est issue 
d'une analyse en composante  principale  de l'expression  d'un groupe de 85 gènes au 
cours  du  temps.  L'expression  des  gènes  était  analysée  par  puce à  ADN,  à  partir  de 
prélèvements sanguins effectués tous les deux jours chez des patients de réanimation 
soumis  à  une  ventilation  mécanique.  La  construction  du  riboleukogramme permet  de 
suivre  l'évolution  des  patients  (prélèvement  initial  =  rond  vert),  avec  un  diagnostic 
moléculaire précédant le diagnostic clinique (flèche rouge), et une inversion de la variation 
au  moment  de  la  rémission  (rond  rouge).  Figure  reproduite  à  partir  de  [70]  avec  la 
permission de l'auteur.
Tableau 1 : Caractéristiques comparées des différentes techniques de séquençage 
haut-débit
454 sequencing Ilumina SOLID
Chimie Pyroséquençage Polymerase-based Ligase-based
Méthode 
d'amplification
Emulsion Bridge Emulsion
Taille des fragments 3kb 200bp 3kb
Mb séquencés par 
analyse
100Mb 1 300Mb 3 000Mb
Durée d'une analyse 7 heures 4 jours 5 jours
Coût par analyse 8 500 $ 9 000 $ 17 500 $
Coût par Mb 85 $ 6 $ 6 $
